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1 Bone infections
Bacterial infections occur when harmful bacteria invade and reproduce 
in the human body [1]. Bone tissue, for instance, can be infected when 
complex bone fractures are exposed to bacteria [2]. Such infections 
can develop into serious and even life-threatening conditions such as 
osteomyelitis [2, 3], which is associated with a high morbidity [4]. 
In addition to bone tissue, artificial bone implants can also be infected. 
Orthopedic and dental implants are increasingly used for treatment of 
bone fractures, fixation of non-unions, joint replacement, spinal revision 
surgery as well as oral and maxillofacial surgery [5]. These implants improve 
the quality of life by restoring mobility and function and alleviating pain 
[5-7]. Even though modern implantology has made significant progress 
during the past decades, infections following invasive surgery remain a 
major clinical challenge without satisfactory clinical treatment [8, 9]. These 
infections may lead to implant failure as well as acute and often chronic 
complications. 
The incidence of osteomyelitis varies between individuals and regions, 
and this type of infection is difficult to treat. The incidence rate of bone 
implant-associated infections depends on the surgical site and procedure 
[10]. Typical incidence rates can be as high as 13% for infections related to 
bone allografts [11], 2% to 5% for spinal infections [5, 10, 12], 2% to 30% 
for transcutaneous fracture fixation pins [10, 13], and 0.2% to 2.2% for 
primary total hip replacement [5, 14]. The treatment of these infections 
places a huge burden on healthcare and cause pain and suffering of the 
patients [15]. 
2 Therapeutic strategies for the treatment of bone 
infections
Traditional modalities for treatment of bone infections involve systemic 
administration of high amounts of antibiotics for extended periods of time 
[1, 5]. Systemic delivery of antibiotics is, however, often associated with 
systemic toxicity [16, 17], antibiotic resistance and recurrence of infections 
[1, 9, 18]. The surface of bone implants is rapidly coated with serum proteins 
after implantation in the human body, which promotes cell recruitment 
and tissue repair by the host [10]. Unfortunately, these serum proteins 
also facilitate adhesion and invasion of bacteria [19-21]. Subsequently, the 
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bacteria colonize implant surfaces followed by formation of a biofilm [22, 
23], which protects bacteria from antibiotic activity and host immune cell 
surveillance [10, 23, 24]. These problems impose a major challenge for 
traditional treatment modalities against infection. 
A powerful alternative strategy to reduce the complications and side-effects 
related to the systemic delivery of antibiotics involves local and sustained 
delivery of high amounts of antibacterial drugs at the site of infection. In 
addition, the development of new methods to prevent (instead of treat) 
infections is gaining interest since infection prevention may avoid revision 
surgery, reduce the suffering of the patients and decrease the medical costs. 
Therefore, active antibacterial drug release systems should be developed 
which can deliver antibacterial agents locally in a sustained manner at 
sufficiently high concentrations to treat or prevent bone infections.
3 Nanocarriers for drug delivery
The design and fabrication of drug delivery systems is crucial to improve 
the efficacy of antibacterial therapy [3, 25]. These delivery systems should 
release antibacterial drugs at the local site in a spatiotemporally controlled 
manner while retaining their bioactivity to optimize their therapeutic 
efficacy and reduce their side effects [26]. Recently, nanotechnology has 
provided several tools to develop novel nanosized pharmaceutical carriers 
(nanocarriers) [27] that facilitate controlled release of a wide range of 
antibacterial molecules [3, 25, 28, 29]. 
Nanoparticles (nanospheres) and nanofibers are among the most 
commonly investigated nanocarriers. Nanoparticles exhibit a considerably 
higher surface area as compared to traditional microparticles, which can 
allow higher drug loading efficiencies and more sustained release profiles 
[30, 31]. The nano-scale dimensions of nanoparticles also provide the 
possibility for targeted or intracellular delivery of antibiotics [32, 33]. Besides 
nanoparticles, electrospun nanofibers have also been widely explored for 
drug delivery purposes due to their high drug loading and encapsulation 
efficiency, ability to modulate biomolecule release, cost-effectiveness, and 
ease of processing into e.g. fibrous membranes or sheets [34, 35]. 
4 Objectives of this study
Gelatin and gelatin-based materials have been widely used in regenerative 
medicine [36-39] due to their biodegradability, biocompatibility, and 
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cost-effectiveness. Gelatin nanospheres (GNs) are particularly interesting 
since they have exceptional physiochemical characteristics for tissue 
regeneration and biomolecule delivery [31, 40, 41]. The charged nature 
of GNs renders them suitable for the controlled delivery of oppositely 
charged bioactive macromolecules such as growth factors [31, 42, 43] 
and nucleic acids [44, 45]. These macromolecules were shown to bind 
to oppositely charged GNs through the formation of polyion complexes 
between macromolecules and GNs [46]. However, it is still not yet known if 
small biomolecules of low molecular weight (< 1.5 kDa), such as antibiotics, 
can be released from GNs in a sustained manner. Therefore, detailed 
studies on the interactions between various antibiotics and gelatin carriers 
are necessary to understand their mutual interaction and pave the way for 
development of nanocarrier-based drug delivery systems for local delivery 
of antibiotics.
In addition to the direct use of GNs as drug delivery vehicles, GNs can also 
be incorporated into various matrices including coatings and (fibrous) 
membranes to modify the release characteristics of various biomolecules. 
Although several local delivery systems have been developed recently 
including chitosan implant coatings [17, 47, 48] and silk fibroin nanofibrous 
membranes [49, 50], control over the release of biomolecules from these 
carriers is still poor due to the lack of interactions between the drugs and 
carriers. The incorporation of GNs into these delivery systems can be 
used to modulate their delivery characteristics as well as mechanical and 
biological performance.
Before the clinical use of GNs can be considered, it is of utmost importance 
to evaluate the biological properties of GNs thoroughly due to concerns 
related to the safety of gelatin-derived biomaterials [40, 51]. Consequently, 
suitable animal models that can provide the requested insight on the 
biological safety and efficacy of GNs should be developed.
Although local delivery of antibiotics is frequently studied, antibiotics 
are effective against bacteria only and can induce the development of 
antibacterial resistance [9, 52]. In fact, the development rate of antimicrobial 
resistance is exceeding the development rate of new drugs by far [53]. 
Therefore, local delivery of antiseptics instead of antibiotics can be an 
effective alternative to kill bacteria without inducing antibacterial resistance.
Chapter 1
16
To address the challenges mentioned above, the current thesis focused on 
the following scientific questions:
1. What is the current state-of-the-art with respect to the use of gelatin or 
gelatin-based materials for bone tissue engineering? (Chapter 2)
2. Can gelatin nanospheres be used as carriers for the sustained delivery 
of small biomolecules such as antibiotics, and what is the mechanism 
of interaction between antibiotics and gelatin nanospheres? (Chapter 
3)
3. Can gelatin nanospheres be deposited inside chitosan coatings applied 
on the surface of metallic implants to tune the release profile of loaded 
antibiotics? (Chapter 4)
4. Can gelatin nanospheres be incorporated into electrospun silk fibroin 
nanofibers to form a novel nano-in-nano fibrous membrane to 
facilitate sustained delivery of antibiotics and modulate cell adhesion 
and growth? (Chapter 5)
5. Can zebrafish be used as a preclinical animal model for evaluation of 
the spatial distribution and immune response of gelatin nanospheres? 
(Chapter 6) 
6. Can antiseptics such as chlorhexidine and silver be loaded onto 
electrospun chitosan nanofibers to achieve fast release of chlorhexidine 
and sustained release of silver to induce bactericidal effects without 
causing antibacterial resistance? (Chapter 7)
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17
1
References
1. Song, J., et al., Influence of the molecular weight and charge of antibiotics on their release 
kinetics from gelatin nanospheres. Macromol Biosci, 2015. 15(7): p. 901-11.
2. Yun, H.C., J.G. Branstetter, and C.K. Murray, Osteomyelitis in military personnel wounded 
in Iraq and Afghanistan. J Trauma, 2008. 64(2 Suppl): p. S163-8; discussion S168.
3. Xiong, M.-H., et al., Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev, 
2014. 78: p. 63-76.
4. Marriott, I., Apoptosis-associated uncoupling of bone formation and resorption in 
osteomyelitis. Front Cell Infect Microbiol, 2013. 3: p. 101.
5. Goodman, S.B., et al., The future of biologic coatings for orthopaedic implants. 
Biomaterials, 2013. 34(13): p. 3174-83.
6. Borse, V., et al., Nanobiotechnology Perspectives on Prevention and Treatment of 
Orthopaedic Implant Associated Infection. Curr Drug Deliv, 2015.
7. Shah, S.R., F.K. Kasper, and A.G. Mikos, Perspectives on the prevention and treatment 
of infection for orthopedic tissue engineering applications. Chin Sci Bull, 2013. 58(35): 
p. 4342-4348.
8. Chen, Q., et al., Electrophoretic deposition of antibiotic loaded PHBV microsphere-alginate 
composite coating with controlled delivery potential. Colloids Surf B Biointerfaces, 2015. 
130: p. 199-206.
9. Gilchrist, S.E., et al., Fusidic acid and rifampicin co-loaded PLGA nanofibers for the 
prevention of orthopedic implant associated infections. J Control Release, 2013. 170(1): 
p. 64-73.
10. Hickok, N.J. and I.M. Shapiro, Immobilized antibiotics to prevent orthopaedic implant 
infections. Adv Drug Deliv Rev, 2012. 64(12): p. 1165-1176.
11. Mankin, H.J., F.J. Hornicek, and K.A. Raskin, Infection in massive bone allografts. Clin 
Orthop Relat Res, 2005(432): p. 210-6.
12. Collins, I., et al., The diagnosis and management of infection following instrumented 
spinal fusion. Eur Spine J, 2008. 17(3): p. 445-450.
13. Masse, A., et al., Prevention of pin track infection in external fixation with silver coated 
pins: clinical and microbiological results. J Biomed Mater Res, 2000. 53(5): p. 600-4.
14. Namba, R.S., M.C.S. Inacio, and E.W. Paxton, Risk factors associated with surgical site 
infection in 30 491 primary total hip replacements. J Bone Joint Surg Br, 2012. 94-B(10): 
p. 1330-1338.
15. Necula, B.S., et al., In vitro antibacterial activity of porous TiO2–Ag composite layers 
against methicillin-resistant Staphylococcus aureus. Acta Biomater, 2009. 5(9): p. 3573-
3580.
16. Hanssen, A.D. and M.J. Spangehl, Practical applications of antibiotic-loaded bone cement 
for treatment of infected joint replacements. Clin Orthop Relat Res, 2004(427): p. 79-85.
17. Beenken, K.E., et al., Chitosan coating to enhance the therapeutic efficacy of calcium 
sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis. J Biomater 
Appl, 2014. 29(4): p. 514-23.
18. Zhang, L., et al., Electrospun vancomycin-loaded coating on titanium implants for the 
prevention of implant-associated infections. Int J Nanomedicine, 2014. 9: p. 3027-36.
19. Ahmed, S., et al., Staphylococcus aureus Fibronectin Binding Proteins Are Essential for 
Internalization by Osteoblasts but Do Not Account for Differences in Intracellular Levels 
Chapter 1
18
of Bacteria. Infect Immun, 2001. 69(5): p. 2872-2877.
20. Hauck, C.R. and K. Ohlsen, Sticky connections: extracellular matrix protein recognition 
and integrin-mediated cellular invasion by Staphylococcus aureus. Curr Opin Microbiol, 
2006. 9(1): p. 5-11.
21. Piroth, L., et al., The fibrinogen- and fibronectin-binding domains of Staphylococcus 
aureus fibronectin-binding protein A synergistically promote endothelial invasion and 
experimental endocarditis. Infect Immun, 2008. 76(8): p. 3824-31.
22. Elek, S.D. and P.E. Conen, The virulence of Staphylococcus pyogenes for man; a study of 
the problems of wound infection. Br J Exp Pathol, 1957. 38(6): p. 573-86.
23. Boelens, J.J., et al., Biomaterial-associated persistence of Staphylococcus epidermidis in 
pericatheter macrophages. J Infect Dis, 2000. 181(4): p. 1337-49.
24. Qu, H., et al., Percutaneous external fixator pins with bactericidal micron-thin sol-gel films 
for the prevention of pin tract infection. Biomaterials, 2015. 62: p. 95-105.
25. Stebbins, N.D., M.A. Ouimet, and K.E. Uhrich, Antibiotic-containing polymers for localized, 
sustained drug delivery. Adv Drug Deliv Rev, 2014. 78: p. 77-87.
26. Mottaghitalab, F., et al., Silk fibroin nanoparticle as a novel drug delivery system. J Control 
Release, 2015. 206: p. 161-76.
27. Torchilin, V.P., Multifunctional nanocarriers. Adv Drug Deliv Rev, 2012. 64, Supplement: 
p. 302-315.
28. Brooks, B.D. and A.E. Brooks, Therapeutic strategies to combat antibiotic resistance. Adv 
Drug Deliv Rev, 2014. 78: p. 14-27.
29. Forier, K., et al., Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J 
Control Release, 2014. 190: p. 607-623.
30. Wang, H., et al., Oppositely charged gelatin nanospheres as building blocks for injectable 
and biodegradable gels. Adv Mater, 2011. 23(12): p. H119-24.
31. Wang, H., et al., Comparison of micro- vs. nanostructured colloidal gelatin gels for 
sustained delivery of osteogenic proteins: Bone morphogenetic protein-2 and alkaline 
phosphatase. Biomaterials, 2012. 33(33): p. 8695-703.
32. Abed, N., et al., An efficient system for intracellular delivery of beta-lactam antibiotics to 
overcome bacterial resistance. Sci Rep, 2015. 5: p. 13500.
33. Lehar, S.M., et al., Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. 
Nature, 2015. 527(7578): p. 323-8.
34. Chou, S.F., D. Carson, and K.A. Woodrow, Current strategies for sustaining drug release 
from electrospun nanofibers. J Control Release, 2015. 220(Pt B): p. 584-91.
35. Song, J., et al., Antibacterial effects of electrospun chitosan/poly(ethylene oxide) 
nanofibrous membranes loaded with chlorhexidine and silver. Nanomedicine, 2016.
36. Santoro, M., A.M. Tatara, and A.G. Mikos, Gelatin carriers for drug and cell delivery in 
tissue engineering. J Control Release, 2014. 190: p. 210-8.
37. Song, J. and S.C. Leeuwenburgh, Sustained delivery of biomolecules from gelatin carriers 
for applications in bone regeneration. Ther Deliv, 2014. 5(8): p. 943-58.
38. Foox, M. and M. Zilberman, Drug delivery from gelatin-based systems. Expert Opin Drug 
Deliv, 2015. 12(9): p. 1547-63.
39. Su, K. and C. Wang, Recent advances in the use of gelatin in biomedical research. 
Biotechnol Lett, 2015. 37(11): p. 2139-45.
40. Elzoghby, A.O., Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing 
three decades of research. J Control Release, 2013. 172(3): p. 1075-1091.
General Introduction
19
1
41. Sahoo, N., et al., Recent advancement of gelatin nanoparticles in drug and vaccine 
delivery. Int J Biol Macromol, 2015. 81: p. 317-31.
42. van der Stok, J., et al., Enhanced bone regeneration of cortical segmental bone defects 
using porous titanium scaffolds incorporated with colloidal gelatin gels for time- and 
dose-controlled delivery of dual growth factors. Tissue Eng Part A, 2013. 19(23-24): p. 
2605-14.
43. Wang, H., et al., Combined delivery of BMP-2 and bFGF from nanostructured colloidal 
gelatin gels and its effect on bone regeneration in vivo. J Control Release, 2013. 166(2): 
p. 172-81.
44. Doi, N., J.I. Jo, and Y. Tabata, Preparation of Biodegradable Gelatin Nanospheres with a 
Narrow Size Distribution for Carrier of Cellular Internalization of Plasmid DNA. J Biomater 
Sci Polym Ed, 2012;23(8):991-1004
45. Ishikawa, H., et al., Gelatin nanospheres incorporating siRNA for controlled intracellular 
release. Biomaterials, 2012. 33(35): p. 9097-9104.
46. Young, S., et al., Gelatin as a delivery vehicle for the controlled release of bioactive 
molecules. J Control Release, 2005. 109(1-3): p. 256-74.
47. Bernkop-Schnurch, A. and S. Dunnhaupt, Chitosan-based drug delivery systems. Eur J 
Pharm Biopharm, 2012. 81(3): p. 463-9.
48. Hu, L., Y. Sun, and Y. Wu, Advances in chitosan-based drug delivery vehicles. Nanoscale, 
2013. 5(8): p. 3103-11.
49. Numata, K. and D.L. Kaplan, Silk-based delivery systems of bioactive molecules. Adv Drug 
Deliv Rev, 2010. 62(15): p. 1497-1508.
50. Yucel, T., M.L. Lovett, and D.L. Kaplan, Silk-Based Biomaterials for Sustained Drug Delivery. 
J Control Release, 2014. 0: p. 381-397.
51. Bayer, O., et al., Renal effects of synthetic colloids and crystalloids in patients with severe 
sepsis: a prospective sequential comparison. Crit Care Med, 2011. 39(6): p. 1335-42.
52. Zhang, L., et al., Electrospun vancomycin-loaded coating on titanium implants for the 
prevention of implant-associated infections. International journal of nanomedicine, 
2014. 9: p. 3027-36.
53. Brooks, B.D. and A.E. Brooks, Therapeutic strategies to combat antibiotic resistance. Adv 
Drug Deliv Rev, 2014. 78C: p. 14-27.

Sustained delivery of biomolecules from gelatin 
carriers for applications in bone regeneration
 Jiankang Song
Sander C.G. Leeuwenburgh
Department of Biomaterials, Radboud 
University Medical Centre
Therapeutic Delivery, 2014, 5(8):943-58
Chapter 2

Delivery of Biomolecules from Gelatin Carriers for Bone Regeneration
23
2
1 Introduction
Healthy bone tissue is a dynamic tissue that is continuously remodeled 
by the interdependent processes of bone resorption and bone formation. 
However, bone defects caused by trauma, tumor resection and congenital 
abnormalities are common clinical problems. Usually, bone tissue has 
ability to regenerate itself, but large defects that exceed a certain critical 
size cannot be healed by themselves [1]. 
Autologous bone transplantation is the most effective method for bone 
restoration, because it provides three essential elements: osteoconduction, 
osteoinduction, and osteogenic cells [2]. Autologous grafts facilitate 
bone growth along their surface or into their pores (osteoconduction) 
and stimulate osteoprogenitor cells to differentiate into osteoblasts 
(osteoinduction) [3]. However, shortage of donors, donor site morbidity, 
the persistence of pain, risk of infection, risk of hemorrhage, and other 
disadvantages reduce the attractiveness of this technique [2, 4].  Although 
these problems can be circumvented by using allografting, clinical risks 
related to immunological reactions and disease transmission still persist 
[5]. Consequently, engineered biomaterials that present bioactive cues, 
such as growth factors (GFs) (osteogenic and angiogenic factors), to the 
surrounding tissue have recently emerged as a new therapeutic modality 
for applications in bone regeneration [6]. Such GFs are exposed to cells 
during bone healing under tight spatial and temporal control. To mimic 
this highly sophisticated presentation of biomolecules, therapeutic factors 
such as GFs should be released at optimal doses to target tissue for pre-
defined periods of time [7]. To meet this challenge, novel carrier materials 
are urgently needed to allow for spatiotemporal control over delivery of 
therapeutic biomolecules [8, 9].
Besides delivery of angio- and osteogenic biomolecules, gelatin carriers can 
also be used to deliver biomolecules locally for treatment of bone tissue 
of compromised health due to, for example, ageing, diseases like cancer 
and osteoporosis, or infection. For instance, osteomyelitis may occur when 
severe fractures are exposed to environmental bacteria [10]. To combat 
this phenomenon, systemic administration of antibiotics is the standard 
treatment modality, but high and frequent doses are needed to achieve 
the desired antibacterial effect, resulting into, for example, systemic toxicity 
as well as drug resistance. Moreover, the efficacy of systemic delivery of 
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antibiotics is often limited by the local low concentrations of antibiotics 
and the poor blood supply of the bone tissue [11]. Therefore, a local drug 
delivery system is advantageous because it decreases the systemic toxicity 
and side effects of systematically delivered antibiotics, while improving 
the efficacy by delivering higher and sufficient drug concentrations to the 
infected bone. 
Developments in the field of biomaterials research have been applied 
in the field of pharmaceutical research during the past decades by 
designing advanced carriers for the sustained release of a wide variety of 
biomolecules. Since the approval of INFUSE® (a collagen sponge loaded 
with rhBMP-2) for clinical use in 2002 by the US FDA, biomaterials for local 
delivery of osteogenic biomolecules have also entered the commercial 
market [12]. The main strategy for delivering biomolecules during bone 
regeneration involves encapsulating of  biomolecules to a polymer or 
polymer-based carrier followed by in vivo release mediated through either 
carrier degradation or boimolecule desorption. To this end, numerous 
biodegradable and biocompatible synthetic and natural polymers have 
been used to design carriers for controlled release of biomolecules [13, 
14]. Among them, gelatin-based carriers have received specific attention 
due to their superior biocompatibility, biodegradability, biosafety and 
cost-effectiveness, even though the animal origin, broad molecular weight 
distribution and need for additional cross-linking need to be considered 
when using gelatin as carrier [15, 16].
The current study has reviewed the application of gelatin (in form of bulk 
hydrogel foams or sheets, microspheres, nanospheres, colloidal gels 
and composites) as carrier for the controlled delivery of commonly used 
biomolecules for application in bone regeneration. General properties of 
gelatin and the preparation methods for gelatin carriers are discussed, 
Figure 1. (A) Relative number of papers using gelatin as carrier for biomolecule delivery, (B) Con-
cept for the use of gelatin as carrier for biomolecule delivery (DNA = desoxyribonucleic acid, 
PRP = platelet rich plasma). 
BiomoleculesGelatin molecular chain Collagenase
Polyion complex formation Biomolecules release controlled by carrier degradation
Onset of enzymatic degradation
of gelatin carrier
BA
Growth factors
Antibiotics
DNA
PRP
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followed by a general overview of the processes relevant for the loading 
and release of biomolecules. Gelatin has been used as carrier for delivery 
of a wide variety of biomolecules, but GFs are by far the most extensively 
studied type of biomolecule. Figure 1A shows the relative number of 
papers per type of biomolecule corresponding to a PubMed search 
using keywords “gelatin”, “bone”, “bone regeneration” and “release” which 
yielded 59 references. Of these, 44, 7, 5 and 3 studies were devoted to the 
release of GFs, antibiotics, DNA and platelet-rich plasma (PRP), respectively. 
Therefore, the controlled release of GFs  is discussed in detail by focusing 
on the most commonly studied osteo- and angiogenic GFs: BMPs, bFGF, 
TGF-β1, VEGF and PRP which contains several GFs. Additionally, the 
use of gelatin carriers for local and sustained delivery of miscellaneous 
biomolecules such as nucleic acids (plasmid DNA encoding for BMP-2), and 
antibiotics is reviewed. 
2 Gelatin as a reservoir for biomolecules
2.1 Properties of gelatin 
Gelatin is a denatured protein that is prepared through hydrolysis of 
collagen, which is the main organic component of hard, mineralized tissues. 
There are two types of commercially available gelatin: cationic gelatin 
prepared by acid hydrolysis of pig skin type I collagen; and anionic gelatin 
prepared by alkaline hydrolysis of bovine skin [17]. At neutral pH, cationic 
gelatin is positively charged (isoelectric point [IEP] of 7-9) while anionic 
gelatin is negatively charged (IEP of 4.8-5). This charged nature of gelatin 
renders this biopolymer suitable for controlled delivery of oppositely 
charged biomolecules. 
In addition to its charged nature, gelatin is inexpensive and can be prepared 
in various shapes and forms using facile and controllable preparation 
methods. Reversely, the biodegradation of gelatin can be tailored by 
controlling the cross-linking density. Moreover, gelatin exhibits a beneficial 
cell compatibility due to the presence of cell recognition peptide sequences, 
and its pharmaceutical and medical safety is confirmed by long clinical 
usage [18]. Furthermore, gelatin does not produce harmful byproducts 
upon enzymatic degradation since it is derived from collagen, which is the 
most abundant protein in animals [19]. These properties emphasize the 
strong potential of gelatin as carrier for controlled release of biomolecules 
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for bone regeneration. 
2.2 Preparation of gelatin carriers
Gelatin can be processed into hydrogels, porous foams as well as micro- 
or nanoparticles, and cross-linking can be either physical or chemical 
to increase the thermal and mechanical stability under physiological 
conditions [20]. Gelatin hydrogels are generally prepared by cross-linking 
of gelatin solutions containing glutaraldehyde (GA) or a water-soluble 
carbodiimide (WSC) as the most commonly used cross-linkers [21, 22]. 
Gelatin porous foams are usually fabricated by lyophilization of gelatin 
solutions [23], whereas gelatin microspheres are generally prepared using 
water-in-oil emulsions [24-27]. Gelatin nanospheres can be prepared 
using two-step disolvation [17, 27], coacervation-phase separation [28], 
emulsification-solvent evaporation [29] or nanoprecipitation [30, 31]. A 
detailed description of the fabrication details of gelatin carriers as well as a 
description of the cross-linking process of gelatin carriers can be found in 
reviews of Young et al. [20] and Elzoghby [19]. 
2.3 Loading and release of biomolecules
Figure 1B shows how gelatin matrices can be used as the carrier for the 
controlled release of biomolecules. Typically, biomolecules are loaded onto 
gelatin matrices through polyion complex formation and released upon 
degradation of gelatin. 
2.3.1 Biomolecule loading
The mechanism of loading therapeutic agents onto gelatin carriers to 
obtain biomolecule immobilization is most frequently based on polyion 
complexation [20]. Polyion complexation relates to a type of electrostatic 
interaction formed between positively or negatively charged electrolytes 
and their oppositely charged counterparts. Herein, polyion complexes 
formed between biomolecules and gelatin macromers are described. 
Polyion complexation can be used for controlled release of a wide variety 
of therapeutic agents such as GFs, polysaccharides, polynucleotides and 
antibiotics [19, 20]. Many biomolecules are positively charged at neutral pH 
since their IEPs are higher than physiological pH values of 7 (IEP of bFGF = 
9.6, VEGF = 8.6, BMP-2 = 8.5, and TGF-β = 9.5 [18]). Positively charged GFs 
are electrostatically complexed with negatively charged gelatin macromers. 
Using this strategy, biomolecules are impregnated into gelatin carriers by 
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simply dripping aqueous biomolecule solutions onto  freeze-dried gelatin 
carriers, which is defined as diffusional postloading [32]. This procedure 
effectively facilitates sorption of biomolecules to the carrier matrix and 
preserves biomolecule bioactivity. Compared to other loading methods, 
for instance covalent binding through enzymatic cross-linking [33] or 
loading during carrier preparation, biomolecules are not harmed by harsh 
processing conditions or organic solvents during diffusional postloading, 
which is highly beneficial from an applied perspective. 
2.3.2 Biomolecule release 
Two possible mechanisms of biomolecule release from a biodegradable, 
charged polymeric carrier have been described by Tabata et al. [34], 
who indicated that biomolecules can be released from carriers by either 
environmental changes (such as a change in ionic strength) or degradation 
of the carrier itself. It is known that gelatin does not degrade by simple 
hydrolysis but by proteolysis, and the degradation of gelatin depends on its 
water content and degree of cross-linking [35], where a lower water content 
or higher cross-linking density results into lower rates of gelatin degradation. 
In that way, charged biomolecules such as GFs, once complexed with an 
oppositely charged gelatin carrier, cannot be released from the gelatin 
matrix unless gelatin degradation occurs. As a consequence, degradation 
of gelatin matrices that containing GFs with lower water content or higher 
cross-linking density will be slow, resulting into slow sustained release of 
GFs over longer periods of time. In that way, the release of biomolecules 
from gelatin matrices can be regulated by controlling the rate of gelatin 
degradation. On the other hand, gelatin itself has no active ability to induce 
bone formation [36, 37]. When the rate of gelatin degradation is slower 
than the rate of bone regeneration, the gelatin remaining in the defect sites 
will physically impair bone regeneration even though long-term release of 
TGF-β1 is achievable [36]. Thus, a gelatin hydrogel with a suitable in vivo 
degradability functions not only as a matrix for GFs release at the bone 
defect site, but also as a space provider to prevent ingrowth of soft tissues 
into the defect. Therefore, an optimal balance between the rates of GF 
release and new bone formation is pivotal for successful bone regeneration 
induced by GFs incorporated into gelatin matrices. Based on these 
mechanisms, gelatin-based materials have been widely studied to obtain 
controlled and sustained delivery of biomolecules for bone regeneration.
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3 Release of GFs
Recombinant DNA technology has enabled mass production of GFs [38, 
39]. Nevertheless, when GFs are applied locally without carriers, their 
bone-formation capacity was markedly limited because of its short in vivo 
biological half-life and/or loss of bioactivity [40-42]. One common strategy 
to circumvent this problem and enhance the in vivo efficacy of GFs is to 
release the GFs from locally applied carriers over a long period of time 
[43]. Therefore, several biomaterials have been investigated to provide 
controlled and sustained delivery of biologically active GFs at the defect 
site to mimic its temporal profile during natural bone healing in vivo and 
maximize its bone-inductive ability. As mentioned above, gelatin (in form of 
bulk hydrogels, microspheres, nanospheres, colloidal gels and composites) 
is one of the most frequently investigated carrier materials to this end. 
3.1 Bone morphogenetic proteins
BMPs are members of the TGF-β superfamily. Generally, their gene 
expression is upregulated at sites of bone fracture, which shows that 
BMPs play an important role in bone regeneration [44]. They mainly act 
as differentiation factors for precursor cells [45] and are present during 
various stages of bone healing, both in the initial phases of fracture repair 
[46] and in the later stages involving chondrogenesis and osteogenesis [47]. 
Among them, BMP-2/4 and BMP-6/7 were confirmed to be osteoinductive 
although the induction pathways for osteoblastic differentiation of primary 
human mesenchymal stem cells (hMSCs) are different [48]. Specifically, 
BMP-2/4 used predominantly BMPR1A and BMPR2 for signaling, whereas 
ACVR1A and ACVR2A were more sensitive to signaling by BMP-6/7. In 
addition, BMP-2 can also recruit bone progenitor cells and promote the 
osteogenic differentiation of these cells [22]. Previous studies showed that 
these factors elicited new bone formation in animal models [40, 49-51]. 
3.1.1 BMP-2 release from gelatin bulk hydrogels
Gelatin bulk hydrogels prepared by chemical cross-linking of gelatin 
solutions followed by freeze-drying have been widely used in bone 
regeneration since these scaffolds facilitate sustained release of BMP-
2, both during ectopic bone formation and orthoptopic regeneration of 
critical-sized bone defects. Table 1 summarizes in vivo studies using gelatin 
bulk hydrogels (foams/sheets) for the controlled release of BMP-2. 
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A study conducted by Yamamoto et al. [40] was shown using an ectopic 
implantation mode that the in vivo retention period of BMP-2 prolonged 
with decreased water content of gelatin bulk hydrogels, resulting into bone 
formation around the hydrogel incorporating BMP-2. Additionally, Kimura 
et al. [22] proved that recruitment of bone marrow-derived osteoblast 
progenitor cells from the blood circulation was determined by the local 
concentration of BMP-2 upon release from gelatin bulk hydrogel, resulting 
into controllable volumes of de novo formed bone tissue around the 
hydrogels. Consequently, it can be concluded that gelatin bulk hydrogels 
are highly suitable for controlled and sustained delivery of BMPs to obtain 
bone regeneration.
Besides the above mentioned ectopic bone formation using gelatin bulk 
hydrogels containing BMP-2, several successful critical bone regeneration 
studies have been listed in Table 1. Although complete bone healing was 
obtained for each of these studies, direct comparison between these 
studies is complicated by the differences in animal type, defect location 
and size, dose of BMP-2 and implantation period. Therefore, systematic 
studies should be performed under identical experimental conditions 
with respect to the type of animal, defect site and water content of gelatin 
hydrogels before unambiguous conclusions can be drawn on the optimal 
conditions for bone regeneration. 
3.1.2 BMP release from gelatin microspheres 
The association between BMP-2 and gelatin is largely based on electrostatic 
interactions [53]. When BMP-2 (with IEP of 8.5) was loaded through 
diffusional postloading onto negatively or positively charged gelatin 
microspheres (exhibiting an IEP of 5 and 9, respectively and cross-linked by 
Animal Implantation site Defect size (mm)
Loading 
amount (μg)
Implaation 
time (weeks) Ref.
Mice Subcutaneous — 0.5, 1 and 5 4 [40]
Mice Subcutaneous — 3 7 [22]
Rabbits Ulna defect 20 17 6 [52]
Monkeys Skull defect 6 in diameter 5, 50 and 200 12 [49]
Rabbits Alveolar clefts defect 6 × 6 17 4 [50]
Dogs Orbital floor fracture 10 × 10 10 5 [44]
Rabbits Ulna defect 20 17 12 [51]
Table1. In vivo studies using gelatin bulk hydrogels for controlled release of BMP-2 
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40 mM glutaraldehyde), the burst release was minimal followed by linear in 
vitro release kinetics, while slower release was observed from the negatively 
charged gelatin microspheres compared to the positively charged gelatin 
microspheres [54]. However, when the gelatin microspheres were cross-
linked by 10 mM glutaraldehyde, the release of BMP-2 was controlled by 
gelatin degradation and did not depend on the type of gelatin [54]. This 
suggested that controlled release of BMP-2 can be achieved using gelatin 
microspheres as carrier. In addition, when gelatin microspheres were 
dispersed through oligo (poly(ethylene glycol) fumarate) (OPF) matrices, 
the burst release of BMP-2 from the resulting composite hydrogel was 
reduced and the retention of BMP-2 was improved upon loading BMP-2 
onto gelatin microspheres instead of the OPF matrix phase [55]. However, 
this formulation did not induce bone augmentation in a rat model [56].  In 
contrast, a study conducted by Li et al. [57] showed that bone defect healing 
in osteoporotic goats was accelerated due to the controlled release of 
rhBMP-2 from composites consisting of gelatin microspheres and calcium 
phosphate cements. This difference may be due to the dense geometry of 
the hydrogel and insufficient degradation of the hydrogel composites [56], 
which inhibited the formation of an interconnected pore network structure 
that would allow for bone ingrowth. 
3.1.3 BMP-2 release from gelatin-based composites 
Gelatin-based composites containing BMP-2 were also used for bone 
regeneration. Weinand et al. [58] observed the formation of bone tissue 
after seeding human bone marrow-derived mesenchymal stem cells 
(hBMSCs) and adipose-derived stem cells (ASCs) onto gelatin/β-tricalcium 
phosphate (β-TCP) composite scaffolds containing BMP-2-loaded gelatin 
microspheres. Besides, successful bone regeneration using gelatin/β-TCP 
scaffolds loaded with BMPs has also been reported both in vitro and in vivo. 
Yang et al. [59] prepared gelatin/β-TCP scaffolds and then soaked these 
scaffolds in BMP-4 solution to form a BMP-containing 3D porous scaffold, 
showed improved cell attachment and osteoblast differentiation compared 
to scaffolds without loading of BMP-4. Takahashi et al. [60] investigated the 
in vivo release profile of BMP-2 from gelatin sponges containing 5 μg BMP-2 
and various contents of β-TCP followed by evaluation of the in vivo ectopic 
osteoinduction activity of these composite sponges. In vivo release of BMP-
2 was shown to be independent of the β-TCP content, but the extent of 
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ectopic bone formation increased with decreasing β-TCP content. A study 
conducted by Matsumoto et al. [61], however, showed that bone defects of 
5 mm diameter in rat mandibles were almost entirely regenerated after 8 
weeks of implantation of gelatin sponges containing 50 wt% of β-TCP and 5 
μg BMP-2. Similarly, Tsuzuki et al. [42] obtained significantly higher amounts 
of bone regeneration after 16 weeks of implantation of gelatin sponges 
containing 50 wt% of β-TCP and 3 μg BMP-2 into the third metacarpal 
bones of horses. These results seems to indicate that the incorporation of 
degradable β-TCP bioceramics only stimulated bone formation in orthotic 
sites as studied by Matsumoto et al. and Tsuzuki et al. [42, 61], but not in 
ectopic implantation sites as investigated by Takahashi et al. [60]. No solid 
explanation was given to account for these differences between ectopic 
and orthotopic implantations. 
3.1.4 Factors influencing BMP-2-induced bone formation
From the above-mentioned in vivo studies, it can be clearly concluded 
that gelatin is a suitable carrier for the controlled delivery of BMPs during 
bone regeneration. Nevertheless, the results from several in vivo studies 
are often controversial irrespective of the form of the gelatin carrier, in 
other words, bulk hydrogel, micro- or nanosphere or composite. It should 
be realized that bone regeneration is a complex and multifactorial process 
regulated by BMP dose, carrier properties, animal type and implantation 
site. 
BMP dosing is crucial for successful bone regeneration since low doses are 
ineffective, whereas high doses of BMP in commercially available products 
(typically in the milligram range [62]) were shown to cause complications 
such as excessive bone growth, back/leg pain, ectopic bone formation, risk 
of cancer, as well as osteolysis [12]. Although it is obvious that pre-clinical 
studies cannot be correlated to human clinical studies, side effects of high 
dose of BMP-2 were also observed in animal studies. For instance, a BMP-2 
dose of more than 150 µg caused detrimental side effects such as cyst-like 
bone formation and significant inflammation in a rat femoral segmental 
defect model [63]. These complications stress the need for carrier materials 
that allow for delivery of BMPs at lower effective doses. The BMP-2 doses in 
the studies listed in Table 1 were much lower and typically in the microgram 
range. Although bone regeneration was successfully achieved in most of 
the above-mentioned in vivo studies, the BMP dosing was different among 
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these studies and no consensus has been reached yet about the optimal 
BMP dose. Additionally, several studies even reported controversial results 
for the same type of gelatin carrier, in other words, for gelatin microspheres 
[56, 57]. Comparing all the in vivo studies, it can be concluded that the 
BMP dose is not the only key factor regulating the regeneration of bone 
defects. Instead, it has become evident that the release profile of BMPs 
determines the bone healing process. For instance, in the study conducted 
by Takahashi et al. [49], bone regeneration in monkey skull defects was 
significantly enhanced even at a low BMP-2 dose of 5 μg per site with BMP-
2 release for 12 weeks. Yamamoto et al. and Takahashi et al. found that 
gelatin bulk hydrogels with a water content of 97.8% exhibited optimal 
BMP-2 release profiles for effective induction of bone formation [49, 52], 
which was mainly controlled by the degradability of the gelatin carrier.
Consequently, optimization of the release profile of BMP-2 by the material 
design is pivotal to promote bone regeneration and to reduce the BMP-2 
dose, so as to shorten the period and lower the amount of BMP required 
for bone regeneration.
3.2 Basic fibroblast growth factor 
In bone tissues, bFGF is produced by cells of the osteoblastic lineage and 
stored in the bone matrix, and it acts as an autocrine/paracrine factor 
[64, 65]. bFGF links to acidic polysaccharides such as heparan sulfate and 
heparin located in the extracellular matrix, where bFGF is protected from 
in vivo deactivation and can be released through enzymatic degradation of 
the polysaccharides [66]. 
Although the mechanism of bFGF on bone formation has not been 
completely elucidated, bFGF is reported to exhibit anabolic effects in the 
early stages of fracture healing through its potent mitogenic action on 
immature mesenchymal cells [67]. Moreover, this GF stimulates proliferation 
of osteoblasts in the late differentiation stages and enriches the population 
of cells competent for osteogenic differentiation and maturation [68]. 
Besides, it stimulates local production of other factors such as TGF-β [69] 
and BMPs [68]. Furthermore, bFGF accelerates callus remodeling resulting 
from both osteoblastic callus formation and osteoclastic callus resorption 
[70, 71]. 
3.2.1 bFGF release from gelatin in vitro
Anionic gelatin (IEP = 5) was selected as the carrier for bFGF (IEP = 9.6) 
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because of the formation of polyion complexes with cationic bFGF, which 
was beneficial for the controlled release of bFGF. On the contrary, almost 
100% of bFGF released from cationic bulk gelatin initially by simple 
desorption since complexes between bFGF and cationic gelatin could not 
be formed [66]. Another strategy to influence the release rate of bFGF from 
anionic gelatin carriers was pursued by Leeuwenburgh et al. who reduced 
the release rate of bFGF from gelatin microspheres by adding calcium 
phosphate nanocrystals [18], thereby slowing down the degradation rate 
of gelatin microspheres. 
3.2.2 bFGF release from gelatin bulk hydrogel in vivo
Gelatin bulk hydrogels have frequently been used to obtain the sustained 
release of bioactive bFGF during bone regeneration. Yamada et al. [72] 
implanted anionic gelatin hydrogel impregnated with 100 μg bFGF into 6 
mm defects in rabbit skulls, resulting into complete closure of the defects 
within 12 weeks. This accelerating effect of bFGF on bone formation at the 
skull defect was also observed at the same dose of bFGF (i.e. 100 μg) in 
rabbits [43] and monkeys [73] preclinical models. Gelatin hydrogel sheets 
loaded with 100 μg bFGF accelerated devascularized sternum healing after 
bilateral removal of the internal thoracic artery in normal [74] and diabetic 
[75] rats as well as in dogs [70], due to the angiogenic and osteogenic 
effects of bFGF. The same amount of bFGF also induced faster recovery and 
lower demineralization of transverse fractures in proximal sesamoid bone 
in horse upon incorporation into gelatin hydrogel sheets as compared to 
screw fixation only [76]. 
3.2.3 bFGF release from gelatin microspheres in vivo
For applications in bone regeneration, anionic gelatin microspheres were 
used as carrier for release of bFGF to treat femoral head osteonecrosis in 
rabbits [26] and alveolar bone defect in dogs [77]. Both studies showed 
positive effects on bone formation. Moreover, gelatin microspheres loaded 
with bFGF were used in combination with bone marrow mononuclear cells 
to treat the medial femoral condyle bone defects in rabbits. This therapy 
enhanced neovascularization and new bone formation [78]. Furthermore, 
Ichinohe et al. [79] combined bFGF-loaded gelatin microspheres with 
hydroxyapatite (HA)-coated titanium nonwoven fabrics for the treatment of 
skull defects in rabbits. Compared to bFGF-free titanium nonwoven fabrics, 
titanium fabrics coated with HA with/without free bFGF, this combination 
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significantly enhanced bone regeneration by enhancing the local bFGF 
concentration at the bone site for prolonged time periods. 
3.2.4 Dosing of b-FGF
From the above-mentioned studies on the use of bFGF for bone regeneration, 
it is obvious that controlled and sustained release of biologically active bFGF 
from gelatin microspheres and hydrogels accelerated bone regeneration. 
The amount of bFGF used, however, was different among these studies. 
Kawaguchi et al. [80] suggested that a threshold amount of bFGF (ranging 
between 100-1000 μg per defect site) was needed to effectively stimulate 
bone healing. Consequently, an amount of 200 μg of bFGF per implantation 
site was used for the treatment of ulna fractures in monkeys [80]. The same 
amount of bFGF was used in treating mandibular ridges defects in dogs 
[81]. However, the most frequent dose of bFGF used for bone regeneration 
at different fracture sites in different animal models was 100 μg. Kodama et 
al. [68] proved that even lower doses of 20 μg bFGF per site were already 
sufficient to stimulate new bone formation in maxillae of mice, and the 
amount of bFGF used for effective bone regeneration around fenestrated 
implants in dogs was even as low as 10 μg [82]. These results confirm that 
the optimal dose of bFGF used is strongly dependent on the fracture site 
and type of animal. 
3.3 Transforming growth factor 
TGF-β1 is the most abundant isoform of the three TGF-β isoforms that 
are detected in bone [83]. It is secreted by bone cells in a latent form 
and is stored in the ECM. Although the mechanism of action of TGF-β1 
on the process of bone regeneration is still not fully elucidated, the most 
commonly accepted model involves recruitment of osteoblast progenitors 
and stimulation of their proliferation, which results into the expansion of 
the pool of committed osteoblasts and enhanced differentiation of the 
progenitor cells at the early stages [84]. Nevertheless, this growth factor 
blocks later phases of differentiation and mineralization, which means 
that the osteogenic ability of TGF-β1 is only effective in the early stage of 
fracture healing. Similar to bFGF, TGF-β1 can form polyion complexes with 
anionic gelatin and can be released in vivo upon gelatin degradation. As a 
consequence, several studies aimed to sustain the delivery of TGF-β1 from 
gelatin-based matrices after implantation in rabbit bone defects [36, 37, 
85, 86]. 
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Similar to the release of BMPs and bFGF, the release of TGF-β1 from 
gelatin hydrogel was shown to correlate strongly to the degradation 
rate of gelatin [37]. When gelatin hydrogels containing 0.1 μg TGF-β1 
were implanted into rabbit calvarial defects, gelatin hydrogels with water 
contents of 90 and 95 wt% induced abundant bone regeneration [37]. In 
addition, Hong et al. investigated the osteogenic ability of gelatin hydrogels 
containing TGF-β1 using a rabbit skull defect model [36]. After 6 weeks 
of implantation of a gelatin hydrogel (water content 95%) loaded with at 
least 0.1 μg TGF-β1, significant bone regeneration was observed. The same 
authors also implanted gelatin microspheres containing 0.5 μg TGF-β1 at 
the rabbit skull bone gap between the autologous bone fragment and the 
surrounding intact bone, resulting into significant bone formation after 
3 weeks implantation [85]. Moreover, gelatin microspheres loaded with 
0.25 μg TGF-β1 were added to calcium phosphate cement at 5 wt% to 
allow for the formation of porosity and enhance the bone response [86]. 
However, bone formation was not improved upon release of TGF-β1 from 
gelatin microspheres. On the other hand, release of TGF-β1 from these 
cements accelerated the degradation of these composites after 12 weeks 
of implantation, which was most likely caused by a stimulatory effect on 
osteoclasts.
3.4 Vascular endothelial growth factor
VEGF is a potent angiogenic GF and it induces proliferation and migration 
of endothelial cells. Besides, VEGF promotes new bone formation by 
increasing mesenchymal stem cell chemotaxis and stimulating osteoblast 
differentiation and proliferation due to an indirect effect on osteoprogenitor 
cells [87]. In vitro release of VEGF from gelatin microspheres displayed a 
characteristic burst release on short term followed by sustained release on 
long term based on degradation of gelatin [24]. Control over the delivery of 
VEGF could be achieved by altering the extent of microsphere cross-linking 
[24]. Ozturk et al. fabricated a gelatin/hydroxyapatite cryogel scaffolds 
containing 5 μg VEGF and implanted them into critical-sized defects in the 
proximal tibiae of rabbits [88]. The bone healing rate was better for the 
scaffold containing VEGF compared to the VEGF-free control scaffolds after 
6 weeks, but there was no difference at 12 weeks, which suggested that 
VEGF plays an important role particularly in the early phases of fracture 
healing [88].   
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3.5 Multiple release of growth factors
Bone regeneration using tissue engineering strategies is a highly 
complex process regulated by many factors including the structural 
characteristics of the ECM analogs, the presence and activity of angiogenic 
and osteogenic GFs, and the osteogenic potential of cells [89]. Generally, 
GFs are presented to cells in vivo in a spatially and temporally controlled 
manner. Since bone is a highly vascularized tissue and angiogenesis is 
pivotal for bone regeneration, neovascularization facilitates recruitment 
of mesenchymal stem cells and osteoblasts necessary for bone repair 
[87]. Thus, besides osteogenesis also angiogenesis should be addressed 
to obtain successful bone regeneration. Moreover, recruitment of host 
osteoblast progenitor cells in the circulating blood to the implant site is also 
beneficial for bone formation [22]. Therefore, several in vivo studies were 
performed to investigate potential synergistic effects of delivery of multiple 
signaling factors, for example, BMP-2, VEGF, bFGF and TGF-β from gelatin 
microspheres [25], gelatin bulk hydrogels [89] and colloidal gelatin gels [27, 
32, 90] were performed to mimic the natural bone healing process. 
3.5.1 Dual release of growth factors from gelatin microspheres
Patel et al. [25] investigated the effects of dual delivery of VEGF and BMP-2 
for bone regeneration in a rat cranial critical size defect. They loaded 12 μg 
VEGF and/or 2 μg BMP-2 onto gelatin microparticles and incorporated these 
microparticles into porous polymer scaffold made from poly(propylene 
fumarate). Significantly higher bone volumes were observed following dual 
release of VEGF and BMP-2 compared to single growth factor release after 
4 weeks of implantation, pointing to synergistic effects, in other words, 
VEGF induced promotion of chemotaxis and differentiation of osteoblasts. 
However, differences between single and dual release were not observed 
anymore after 12 weeks, suggesting that dual growth factor release was 
most effective at early stages of bone healing and synergistic effects of dual 
release result in faster healing times. 
3.5.2 Dual release of growth factors from gelatin hydrogels
Stromal cell-derived factor-1 (SDF-1, also known as C-X-C motif chemokine 
12, CXCL12), is critical to induce migration and homing of stem cells to a 
target site [91] and recruits endothelial progenitor cells that are necessary 
for angiogenesis [92], Additionally, it is reported that the SDF-1 plays a 
Delivery of Biomolecules from Gelatin Carriers for Bone Regeneration
37
2
crucial role in the migration of bone marrow stromal cells (BMSCs) to the 
fracture site, where recruited cells actively participated in endochondral 
bone repair in a segmental bone defect model [93]. Therefore, it was 
hypothesized that co-delivery of SDF-1 and BMP-2 would stimulate stem 
cell recruitment, and angiogenesis (by SDF-1) as well as osteogenesis (by 
BMP-2) [89]. To prove this hypothesis, gelatin hydrogel were loaded with 
SDF-1 and BMP-2 to treat critical-sized ulna defects and induce the ectopic 
bone formation in rats [89]. The initial release of SDF-1 was accelerated 
by the combination with BMP-2, whereas the release of BMP-2 was not 
influenced by the co-delivery of SDF-1. Dual release of 5 µg SDF-1 and 
3µg BMP-2 from these gelatin hydrogels induced a significantly greater 
extent of bone formation in both the critical-sized bone defect and the 
subcutaneous implantation site compared to the single release of either 
SDF-1 or BMP-2, which confirms the synergistic effects of both factors. 
3.5.3 Dual release of growth factors from gelatin nanospheres 
colloidal gel
Recently, our laboratory developed a colloidal gel system made of 
oppositely charged gelatin nanospheres. Due to the reversible non-
covalent (i.e. electrostatic and/or hydrophobic) interactions between these 
nanoparticles, cohesive and self-healing colloidal gels were obtained [17]. 
These nanostructured colloidal gelatin gels exhibited superior viscoelastic 
properties over microsphere-based gels with respect to elasticity, 
injectability, structural integrity, and self-healing behavior upon severe 
network destruction [27]. The high specific surface area of the nanospheres 
facilitated stronger polyion complexation of GFs to oppositely charged 
gelatin nanospheres, while the GFs were more effectively entrapped in 
the nanopores between tightly packed nanospheres, which resulted into 
zero-order release kinetics of BMP-2 without any initial burst release [27]. 
Additionally, sustained delivery of GFs from these colloidal gelatin gels was 
controlled by fine-tuning the cross-linking densities of gelatin nanospheres 
[27, 32]. 
These colloidal gelatin gels were also shown to be suitable for dual release 
of angiogenic and osteogenic GFs. Wang et al. [32] monitored the in vitro 
dual release kinetics of osteogenic BMP-2 and angiogenic bFGF from 
colloidal gelatin gels, and compared the effect of single or dual delivery of 
BMP-2 and bFGF on bone regeneration using a rat femoral condyle defect 
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model. Fast release of bFGF and slow release of BMP-2 was achieved by 
loading bFGF onto rapidly degrading cationic gelatin nanospheres of low 
cross-linking density and by loading BMP-2 onto slowly degrading anionic 
gelatin nanospheres of high cross-linking, respectively. The amount of 
new bone formation was highest for BMP-2 loaded gels while lowest for 
gels loaded with both BMP-2 and bFGF. The authors suggested that the 
lack of synergistic effects was caused by overdosing of bFGF relative to 
BMP-2 (bFGF:BMP-2 ratio of 1:1), thereby impeding bone formation. 
Therefore, identical colloidal gelatin gels were loaded with lower doses of 
bFGF relative to BMP-2 (bFGF:BMP-2 ratio of 1:5) and inserted into porous 
titanium scaffolds to treat critical-sized femoral bone defect model in rats 
[90]. Significantly more bone was formed outside the porous titanium 
scaffolds for gels containing two GFs, which points to a synergistic effect of 
dual delivery of bFGF and BMP-2.
3.5.4 Release of platelet-rich plasma from gelatin hydrogels
PRP is blood plasma that is enriched with platelets, which contains and 
releases several types of GFs including a.o. platelet-derived growth 
factors and TGF-β [94, 95]. Local application of PRP from bone grafts has 
been proposed to enhance bone regeneration since 1998 [95] as PRP is 
easily purified from the patient’s own peripheral blood, thereby avoiding 
transmission of diseases. Gelatin hydrogels have also been considered as 
carrier for the local application of PRP during bone regeneration. 
Hokugo et al. [96] prepared gelatin hydrogel containing PRP for application 
in  bone defects in rabbit ulna, resulting into successful healing after 4 
weeks of implantation.  In this study, PRP platelets were activated by 
exposure to gelatin molecules upon impregnation into the hydrogel, 
resulting into the secretion of platelet-derived growth factors and TGF-β1. 
The released PRP GFs were then immobilized onto the carrier through 
electrostatic interaction with gelatin macromers. As described above, the 
immobilized GFs were released upon enzymatic degradation of gelatin and 
subsequently stimulated bone formation. PRP induced bone regeneration 
was also observed in rabbit calvarial defects treated with PRP impregnated 
gelatin hydrogel [97]. 
4 Release of nucleic acids 
GFs are by far the most popular class of biomolecules for use in bone 
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regeneration. Nevertheless, the fragile nature of GFs is still a major 
concern for the long-term efficacy of growth factor-based therapy [98]. To 
circumvent this problem, gene transfection strategies have been proposed, 
which involve the introduction of exogenous genes into cells for therapeutic 
purposes [99]. Specifically, gene delivery therapies in bone regeneration 
aim at effective delivery of plasmid DNA encoding a therapeutic protein 
which stimulates bone formation after secretion by cells. 
To this end, cationized gelatin has been used for the controlled and 
sustained delivery of DNA. DNA, a polyanionic macromolecule, can 
electrostatically bind to cationized gelatin to form electrostatic complexes 
[100]. Thus, the release of plasmid DNA from gelatin carrier is driven 
by the enzymatic degradation of the cationized gelatin, and the release 
kinetics can be controlled through adjusting the cross-linking density of 
the gelatin. Moreover, it was suggested that DNA can remain complexed 
with degradation fragments of the cationized gelatin carriers [101]. In that 
way, degradation of the DNA by nucleases can be reduced, which facilitates 
cellular uptake through interaction of the positively charged complexes 
with negatively charged cell membranes [100]. 
Several studies were performed aiming at delivery of plasmid DNA 
encoding BMP-2 from cationized gelatin microspheres-containing scaffolds 
in vitro [102] and in vivo [103, 104]. Herein, amino groups were introduced 
onto cationic gelatin (IEP-9) through chemical conversion of carboxyl 
groups [100] followed by preparation of cationized gelatin microspheres 
and incorporation into OPF hydrogels. In vitro release of plasmid DNA 
from hydrogels with or without gelatin microspheres was dominated 
by the degradation of the OPF network, and loading of DNA onto the 
cationized gelatin microspheres prolonged the duration of DNA release 
[102]. When plasmid DNA was loaded onto either gelatin microspheres or 
onto OPF hydrogel matrix, the in vivo release kinetics of DNA was similar, 
and the release of DNA from the composites was in accordance with the 
degradation of the microspheres within the OPF [103]. 
When the hydrogel composites loaded with plasmid DNA were implanted 
into a critical-sized rat cranial defect no enhancement of bone formation 
was observed after 30 days of implantation [104]. In another study, 
poly(propylene fumarate) scaffolds were filled with gelatin microspheres 
loaded with plasmid DNA complexed with a biodegradable branched 
triacrylate/amine polycationic polymer to enable controlled release of DNA 
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[105]. Although the release of plasmid DNA could be varied by controlling the 
degradation rates of the TAPPs, release of DNA did not result in enhanced 
bone formation [105]. However, a study conducted by Hosseinkhani et al. 
showed that a scaffold seeded with complexes of cationized gelatin and 
plasmid DNA encoding BMP-2 effectively enhanced in vivo ectopic bone 
formation [99]. In this study, the cationized gelatin-plasmid DNA complexes 
were impregnated into the lyophilized collagen sponges containing 
poly(glycolic acid) (PGA) fibers. The lack of bone formation resulting from 
plasmid DNA delivery as observed by Kasper et al. [104] and Chew et al. 
[105] was related to poor cellular uptake of DNA, which resulted into a low 
transfection efficiency. Generally, it can be concluded that strategies using 
gelatin carriers for in vivo delivery of DNA have not yet been successful 
so far. Nevertheless, recent data indicate that gelatin nanospheres have 
the potential to enter the cell through endocytosis, thereby enhancing 
the transfection efficiency of DNA. In addition, it was recently shown that 
gelatin nanospheres can be used successfully for intracellular delivery of 
small interfering RNA [106]. Based on these preliminary data, intracellular 
delivery of DNA from gelatin nanospheres instead of microspheres will be 
a viable strategy to achieve stimulation of new bone formation.  
5 Release of antibiotics 
Bone defects caused by severe trauma are highly susceptible to infection. 
This type of infection easily develops into osteomyelitis, which is a severe 
bone infection and associated with a high morbidity [107]. Besides, 
osteomyelitis typically lead to complications such as bone resorption, bone 
dysfunction, and progressive inflammatory destruction of bone [108]. 
Traditional treatment of osteomyelitis involves systemic administration 
of antibiotics to eradicate the residual bacteria after the removal of the 
affected tissue [109]. This treatment, however, may lead to systemic toxicity 
and side effects. To circumvent these clinical complications, local delivery 
of antibiotics is a potential alternative treatment option that would increase 
local concentrations and decrease required dosing and corresponding 
side effects. To this end, the beneficial properties of gelatin for local 
delivery have been exploited to facilitate controlled release of antibiotics 
in vitro and in vivo to treat bone infection or osteomyelitis caused by bone 
reconstruction. 
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5.1 Release of antibiotics from gelatin microspheres
Shi et al. [110] loaded colistin sulfate onto gelatin microparticles 
by diffusional postloading, and incorporated the swollen gelatin 
microparticles into polymethylmethacrylate to form antibiotic-releasing 
polymethylmethacrylate/gelatin/antibiotic constructs. In these constructs, 
gelatin microparticles served as both biomolecule carrier and porogen. 
Colistin released continuously during 10 or 14 days with an average release 
rate above 10 µg/ml per day in vitro. After degradation of the gelatin 
microparticles a porous structure was formed, which was suggested to 
favor ingrowth of fibro-vascular and other tissue types. 
5.2 Release of antibiotics from gelatin hydrogels
Wu et al. [111] developed a β-TCP bactericidal scaffold reinforced with a 
gentamicin-doped gelatin/genipin hydrogel. The initial burst release of 
gentamicin from this scaffold was followed by zero-order release kinetics 
which effectively inhibited the growth of Staphylococcus aureus both 
in vitro and in vivo. Using a rat osteomyelitis model, it was shown that 
osteomyelitis could be fully cured within 3 weeks of implantation. Commonly 
used antibiotics (gentamicin or vancomycin) have also been loaded into 
interpenetrating hydrogel networks based on poly(acrylic acid) and gelatin 
by simple diffusional post-loading to treat osteomyelitis in rabbits [112]. 
This scaffold degraded completely and healed the infection within 6 weeks 
after implantation. No differences in healing rate were observed between 
the release of gentamicin or vancomycin. 
5.3 Release of antibiotics from gelatin/bioceramics 
composites
Antibiotics have also been loaded to osteoconductive and osteoinductive 
bioceramics like β-TCP [113, 114] or hydroxyapatite (HA) [115] to prevent 
bone infections during bone repair or implant surgery. Yaylaoğlu et al. [116] 
mixed gelatin, gentamicin and calcium phosphate by means of solution-
casting followed by glutaraldehyde cross-linking of gelatin to prepare 
membrane-like composites. Gentamicin released from the composite in 
a burst manner both in vitro and in vivo, but details on the release kinetics 
were not provided in that article. In another study, Sezer et al. [113] prepared 
β-TCP/gelatin composite microspheres cross-linked with different amounts 
of glutaraldehyde using water-in-oil emulsification, where gentamicin was 
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loaded onto these microspheres by diffusional post-loading. The same 
authors also added these gentamicin-loaded microspheres into poly(ε-
caprolactone) matrices to prepare biodegradable antibiotic-releasing 
composite films for bone regeneration [114]. A minimal initial burst  (20-
30%) followed by sustained release of gentamicin was observed until 5 
days of soaking when 78% of the antibiotic was released upon degradation 
of gelatin microspheres and poly(ε-caprolactone) matrices. Kim et al. [115] 
fabricated porous gelatin-HA nanocomposites loaded with tetracycline 
during cross-linking of the lyophilized scaffold in an acetone-water solvent 
mixture using carbodiimide chemistry. Tetracycline release kinetics were 
studied as a function of HA content and cross-linking density. The majority 
of the tetracycline was released during an initial burst (up to 10 h) followed 
by a more sustained release until 3 days. In this study, however, the amount 
of biomolecule loading was diffusion-limited by the large dimensions of the 
porous gelatin-HA scaffolds. Nevertheless, biomolecule loading by simple 
swelling of gelatin or gelatin composite in drug solution [110, 112-114] can 
increase the loading efficiency up to around 100%.
5.4 Future improvements of gelatin-based carriers for release 
of antibiotics
Generally, it should be emphasized that an objective comparison 
and evaluation of the above-mentioned studies and materials is not 
straightforward by any means due to several complicating factors in the 
study design. Firstly, the majority of the release studies were performed 
in vitro which cannot be correlated to the in vivo conditions. Release 
periods and dosing of antibiotics largely varied among the various studies, 
stressing that consensus on the desired release kinetics and duration is 
still lacking although it is known that the local concentration of antibiotics 
should exceed the minimal inhibitory concentration (MIC) of the respective 
antibiotic. Therefore, studies comparing the loading and release mechanism 
of different types of antibiotics from different forms of gelatin carriers (i.e. 
bulk hydrogels and spheres) are needed to optimize the antibacterial effect 
of local delivery of antibiotics from gelatin-based carriers. 
6 Conclusion
Gelatin has gained considerable interest in the field of bone regeneration 
as carrier for local delivery of biomolecules. These biomolecules bind to 
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gelatin matrices through formation of polyion complexes with gelatin 
macromolecules upon diffusional postloading, thereby retaining their 
biological activity. Upon enzymatic degradation of gelatin carriers, the 
loaded biomolecules are released at rates which can be precisely tuned 
by adjusting the cross-linking density of gelatin. This mechanism has been 
proved for large biomolecules such as the GFs and DNA, whereas the loading 
and release mechanism of small molecules such as antibiotics remain to be 
elucidated. Current challenges for clinical translation and commercialization 
of gelatin-based carriers for bone regeneration and infection include 
upscaling of carrier manufacturing under the strict regulations of good 
manufacturing practice, and selection of proper preclinical animal models 
to correlate in vivo release kinetics with detailed characterization of the 
response of bone tissue to local delivery of biomolecules.
7 Future perspective
Despite two decades of research on the use of gelatin carriers for local 
biomolecule delivery, gelatin carriers have not yet been used for clinical 
treatment of bone defects/infections and/or commercially available 
medical devices. Proof-of-concept for the suitability of gelatin carriers 
for local delivery of biomolecules to bone tissue has been obtained in 
a plethora of pre-clinical animal studies. These studies, however, were 
performed in a wide range of animal models and types of bone, which 
complicates comparison of the obtained data in terms of properties of the 
gelatin carriers (e.g. gelatin type, form and cross-linking) and characteristics 
of the respective biomolecules (e.g. biomolecule type, dosing and loading). 
In order to meet these challenges, development of cost-effective upscaling 
methods to prepare gelatin carriers (as bulk hydrogels, micro- and 
nanoparticles, etc.) under the strict regulations of good GMP will become 
a critical issue. Specific attention should be paid to the physicochemical 
characteristics of the commercially available gelatins in terms of molecular 
weight, isoelectric point and purity to guarantee reproducible industrial 
production of gelatin-based carriers. In addition, clinicians and experts in 
chemistry, materials science, bone biology and pharmaceutical research 
should join forces to optimize biomolecule release from gelatin carriers 
according to clear and pre-defined criteria in terms of dosing, loading and 
in vivo release kinetics. After these optimization studies, the efficacy of 
biomolecule delivery from gelatin carrier should be directly compared to 
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conventional carriers for local delivery of biomolecules such as collagen 
fleeces and sponges. Finally, advanced pre-clinical imaging tools such as 
micro single-photon emission computed tomography (microSPECT) [117] 
should be used to monitor the in vivo release of labeled biomolecules in 
bone tissue both spatially and temporally, and correlate these findings to 
the actual effects of biomolecule release on bone tissue using histology 
and histomorphometry. 
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1 Introduction
Bacterial infections occur when harmful bacteria invade and reproduce 
in the host. This infectious disease can develop into serious, even life-
threatening conditions such as osteomyelitis [1]. This type of infection is 
associated with a high morbidity [2] and occurs when a complicated bone 
fracture is exposed to bacteria [3]. Traditional treatment modalities for 
osteomyelitis involve systemic administration of antibiotics for several 
weeks to months [4], which is often associated with toxicity, antibiotic 
resistance and recurrence of infections [5, 6]. In addition, bone infections 
are frequently caused by more than one type of bacteria [7, 8], which 
requires the delivery of different types of antibiotics from a single carrier 
to avoid ineffective treatment and antibiotic resistance. A powerful strategy 
to reduce the complications and side-effects related to the systemic use of 
antibiotics involves local and sustained delivery of multiple antibiotics at the 
site of infection. In order to facilitate this strategy, a suitable carrier system 
should be developed that is biocompatible, safe, and most importantly, 
biodegradable in a controllable manner [9]. Gelatin, a denatured protein 
prepared by hydrolysis of collagen, is particularly attractive as a drug carrier 
for controlled release due to its non-toxicity, bioactivity, cost-effectiveness, 
tunable charge and degradability [10-13].
Gelatin nanospheres (GNs) have been extensively studied as carriers 
for controlled delivery of therapeutic biomolecules of high molecule 
weight such as growth factors [14-20] and nucleic acids [21-26]. These 
macromolecules were shown to bind to oppositely charged gelatin carriers 
through the formation of polyion complexes [12] between macromolecules 
and gelatin matrices, thereby facilitating sustained delivery of bioactive 
macromolecules. However, it is still unknown if small biomolecules of low 
molecular weight (< 1.5 kDa) such as antibiotics can be released from GNs 
in a sustained manner. Therefore, detailed studies on the interactions 
between various antibiotics and gelatin carriers are necessary to understand 
their mutual interaction upon diffusional post-loading. These studies will 
be useful to become able to adjust the release kinetics of antibiotics from 
GNs and exploit the full potential of gelatin as carrier for local delivery of 
antibiotics. 
Recently, it has been shown that the physicochemical characteristics of 
antibiotics have a strong influence on the release kinetics of antibiotics 
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from synthetic polymers [27]. Shah et al. [27] found that the charge and 
molecular weight of antibiotics influenced the incorporation into and 
release of antibiotics from poly (DL-lactic-co-glycolic acid) microparticles. 
Negatively charged antibiotics were incorporated less efficiently than 
positively charged antibiotics, while antibiotics of higher molecular weight 
revealed a more sustained release. Nevertheless, the mechanisms of 
interaction between antibiotics and polymeric carriers have not been 
studied before, thereby hindering full understanding of the loading and 
release of antibiotics from polymeric carrier materials. 
Therefore, the aim of our study was to investigate the fundamental 
relationship between the physicochemical characteristics of antibiotics 
and the kinetics of their release from GNs, aiming at the development 
of a simple and practical strategy towards local and sustained delivery of 
antibiotics. We hypothesized that sustained release of antibiotics from GNs 
could only be achieved provided that sufficiently strong electrostatic and 
hydrophobic interactions could be established between the antibiotics and 
GNs, which were hypothesized to depend strongly on the molecular weight 
and charge of the antibiotics.
To this end, we selected four commonly used water-soluble antibiotics 
of different molecular weight and charge (i.e. gentamicin, moxifloxacin, 
vancomycin and colistin, see Table 1 and Figure S1 for more detail). Firstly, 
we compared the long-term kinetics of the release of these antibiotics 
from GNs of low and high cross-linking densities in the absence or 
presence of collagenase. Additionally, we studied the short-term release 
of these antibiotics from GNs as a function of pH, ionic strength and 
detergent concentrations without any collagenase present to investigate 
the fundamental interactions between the antibiotics and gelatin carriers. 
Finally, we correlated the release kinetics of the antibiotics with the 
degradation rate of gelatin carriers to unravel the mechanisms of antibiotic 
release from gelatin carriers. 
Antibiotic Molecular weight (g/mol)
Number of NH2 
per μg (× 1015) pKa
Charge 
(pH 7.4)
Gentamicin   477.6 5.05 5.8, 7.4, 8.2, 8.9, 9.5 [33] 6
Moxifloxacin   401.4 0 6.3 and 9.3 [37] 12
Vancomycin 1449.3 0.83 2.6, 7.7, 8.6, 9.6, 10.5, 11.7 [27] 4
Colistin 1155.4 2.61 10.3 and above [27] 12
Table1. Physicochemical properties of gentamicin, moxifloxacin, vancomycin and colistin
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2 Materials and Methods
2.1 Materials
Gelatin type B (from bovine skin, 225 bloom, isoelectric point (IEP) ~ 5), 
Sigma-Aldrich, The Netherlands); gentamicin sulfate (potency ≥ 590 µg/mg), 
moxifloxacin hydrochloride (VETRANAL™, analytical standard), vancomycin 
hydrochloride hydrate (potency ≥ 900 µg/mg) and colistin sulfate (potency 
≥ 15000 U/mg) were purchased from Sigma-Aldrich, all of the antibiotics 
salts are soluble in water. Relevant physicochemical properties of these 
antibiotics are listed in Table 1. Glutaraldehyde (25 wt% solution in water) 
was purchased from Acros Organics while all other chemicals were 
purchased from Sigma-Aldrich.
2.2 Preparation of gelatin nanospheres
Gelatin nanospheres of low and high cross-linking densities (GNLs and 
GNHs) were prepared using a two-step desolvation method [28]. In brief, 
1.25 g gelatin type B was dissolved in 25 ml deionized water to form a 
5 w/v% solution at 50 °C. 25 ml acetone was then added to precipitate 
the high molecular weight gelatin. Gelatin type B was selected to allow 
for complexation with oppositely charged antibiotics. After precipitation, 
the supernatant was discarded and the gelatin was re-dissolved in water 
at 50 °C, followed by adjusting the pH of the gelatin solution to 2.5 using 
hydrochloric acid solution. Thereafter, 80 ml acetone was added dropwise 
(~2 ml/min) into the gelatin solution under vigorous stirring to form GNs. 
Subsequently, the GNs were stabilized by adding different amounts of 
glutaraldehyde into the suspension yielding molar ratios of glutaraldehyde 
relative to the amine content of gelatin of 1:2 (GNL, 74 μl of glutaraldehyde 
per gram of gelatin) and 4:1 (GNH, 592 μl of glutaraldehyde per gram of 
gelatin), respectively. After cross-linking for 16 h, 100 mM glycine solution 
was added to block unreacted aldehyde groups. The suspension was then 
subjected to three cycles of centrifugation (5000 rpm for 60 min) and re-
suspension in deionized water by vortexing, after which the pH of the 
nanosphere suspension was adjusted to pH 7.0 and lyophilized for 24 h. 
The lyophilized GNs were stored at 4 °C for further use.
2.3 Characterization of gelatin nanospheres
The morphology of the GNs was characterized by scanning electron 
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microscopy (SEM, JEOL 6301). Images of the GNs were taken at an 
accelerating voltage of 5 kV. The size and size distribution of GNs were 
measured using dynamic light scattering (DLS, Zetasize Nano-S, Malvern 
Instruments Ltd., Worcestershire, United Kingdom) by dispersing the 
GNs in 5 mM HEPES buffer, at pH 7.0. ζ-potential values of GNs were 
measured by laser doppler electrophoresis with a Zetasizer Nano-Z 
(Malvern Instruments Ltd., Worcestershire, United Kingdom) using a folded 
capillary cell (DTS 1060) in HEPES buffer (5 mM, pH 7.0). The water content 
of GNs was detected according to a previously published method [17] by 
comparing the weight of GNs in dry and fully swollen state in PBS.  
The amount of residual free amine groups as present in the cross-
linked gelatin spheres was quantified using the 2,4,6-trinitrobenzene 
sulfonic acid (TNBS) assay. Specifically, approximately 2 ~ 4 mg GNs were 
dispersed in 2 ml NaHCO3 solution (pH 8.5, 4 w/v%) and reacted with 
0.01M 2,4,6-trinitrobenzenesulfonic acid (TNBS) for 2 h at 40 °C, followed 
by hydrolyzing with 3 ml HCl (1 M) for 1.5 h at 60 °C. After hydrolysis, the 
solution was cooled to room temperature and 5 ml sterile deionized water 
was added. Finally, the absorbance of the solution was measured at λ = 
420 nm with an enzyme-linked immunosorbent assay (ELISA) plate reader 
(EL800, Bio-Tek Instruments. Inc.). The weight percentage of free amine 
groups per milligram of gelatin was calculated according to the standard 
curve prepared by using glycine as the standard reagent. 
2.4 Long-term release of antibiotics from gelatin nanospheres
A diffusional post-loading method was used to load the antibiotics onto 
GNs, which involved direct mixing of the solution containing antibiotics with 
lyophilized GNs. The volume of antibiotic-containing solution was lower 
than required for complete swelling of GNs yielding a colloidal gel with a 
solid content of 20 w/v%, while the amount of antibiotic was fixed at 5 μg 
per gram of GNs. Briefly, 25 μl of 1 mg/ml antibiotic in PBS solution was 
dripped onto 5 mg of GNs in an 1.5 ml Eppendorf® (n = 5). After loading, 
the mixtures were stored at 4 °C overnight to allow for complete swelling 
of gelatin carriers and sorption of antibiotics, followed by centrifugation 
at 13000 rpm for 5 min. 1 ml PBS containing 400 ng collagenase IA and 
0.001 w/v% sodium azide was added into the tubes to start the in vitro 
release study. The tube was then incubated at 37 °C on a rotating plate at a 
speed of 100 rpm. At each time point, the tubes were centrifuged at 13000 
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rpm for 5 min to sediment the gelatin spheres, after which 900 μl of the 
supernatant was obtained for further analysis and refreshed with the same 
amount of medium.  
2.5 Influence of pH, ionic strength and detergent concentration 
on the short-term release of antibiotics
GNHs were used as carriers for an additional release study on the kinetics 
of antibiotic release in media with different i) pH (PBS at pH 7.4 at an ionic 
strength of 154 mM as well as citrate buffers at pH 5 and 3 at a similar 
ionic strength of 154 mM), ii) ionic strength (10 mM, 100 mM and 1000 mM 
NaCl solutions in water) and iii) detergent concentration (0.002 v/v%, 0.01 
v/v% and 0.1 v/v% Tween 20). As described previously, 25 μl of solutions 
containing1 mg/ml antibiotic in PBS were mixed with 5 mg GNs in 1.5 ml 
Eppendorf® tubes and stored at 4 °C overnight to form antibiotic-loaded 
colloidal gels. To start the short-term release studies, 1 ml of the above-
mentioned media were added into each tube separately (n = 3). At each 
time point, the tubes were centrifuged at 13000 rpm for 5 min to sediment 
the gelatin spheres, after which 900 μl of the supernatant was obtained for 
further analysis and refreshed with the same amount of medium. 
2.6 Detection of antibiotics in the supernatants
The concentration of gentamicin was monitored by an indirect ELISA 
method. A gentamicin-bovine serum albumin conjugate was coated 
onto the ELISA-plate as a competitor for the soluble gentamicin in the 
sample. The concentration of gentamicin was determined in relation to a 
gentamicin calibration curve (range: 1 - 1000 ng/ml). The detection was 
performed by a specific anti-gentamicin primary antibody (Abcam, USA) 
and a horseradish peroxidase (HRP) labeled secondary antibody (Dako, 
Denmark) subsequently visualized by 3,3′,5,5′-tetramethylbenzidine (TMB, 
Sigma-Aldrich, USA) and measured at 450 nm in an ELISA reader (MultiSkan 
FC, Thermo Scientific). 
Moxifloxacin [29] and vancomycin [30] concentrations were detected by 
reverse phase high performance liquid chromatography (RP-HPLC) using 
a Hitachi HPLC machine. This system consisted of a Hitachi L-2130 pump, 
a Hitachi L-2400 UV detector and a Hitachi L-2200 auto samper, as well 
as a LiChrospher® RP-18 endcapped HPLC column (125 mm × 4 mm, 
particle size 5 μm). For moxifloxacin, the mobile phase consisted of 50 
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mM phosphate buffer (pH 2.6) and acetonitrile (75:25, v/v). For analysis 
of moxifloxacin concentrations, 50 μl of moxifloxacin-containing samples 
were injected and the effluent was monitored at 296 nm with a flow rate 
of 1 ml/min. Regarding the detection of vancomycin, a mixture of 50 mM 
ammonia phosphate buffer (pH 3, adjusted with H3PO4) and acetonitrile 
(90:10, v/v) was used as the mobile phase, at a flow rate of 1 ml/min 
and an injection volume of 50 μl. The UV detector was set at 240 nm to 
quantify the vancomycin concentrations without any interference from 
gelatin degradation products. Standard calibration curves in the range of 
0.1 to 25 μg/ml and 0.2 to 25 μg/ml were prepared for the quantification 
of moxifloxacin and vancomycin, respectively. Release of colistin was 
monitored using liquid chromatography-mass spectrometry (LC/MS) [31]. 
The liquid chromatography was performed using a Shimadzu system with 
two LC20AD pumps, a SIL20AC autosampler, a CTO20AC oven at 35 °C and 
an RP-C18 column (Phenomenex Gemini NX, 50 mm × 2.0 mm, 3 μm, 110A), 
while the mass spectrometry was conducted using a Thermo® LCQ Fleet® 
electrospray ion-trap mass spectrometer. The mobile phase consisted of 
acetonitrile and water (both containing 0.1% formic acid), with a gradient 
of acetonitrile from 5% to 100% in 10 min at a flow rate of 0.2 ml/min. 100 
μl of sample was injected and the doubly charged ions ([colistin A + 2H]2+ 
at m/z 585.9 and [colistin B + 2H]2+ at m/z 578.8) were analyzed in the 
mass spectra collected in the range of 100 to 2000 in order to determine 
the amount of colistin present in the samples. The amount of colistin was 
quantified with a standard calibration curve in the range of 0.79 to 25 μg/
ml. 
2.7 In vitro degradation of gelatin nanospheres
The degradation behavior of GNs was monitored under the same conditions 
as the release of antibiotics, except for the fact that the GNs were loaded 
with 25 μl deionized water instead of antibiotic-containing PBS. The amount 
of gelatin degradation at various time points was quantified by measuring 
the total protein released in the supernatant using the bicinchoninic acid 
(BCA) assay. Briefly, 25 μl deionized water was loaded onto 5 mg GNs in 1.5 
ml Eppendorf® tubes and stored at 4 °C overnight to allow for the complete 
swelling of GNs (n = 5). 1 ml PBS containing 400 ng/ml collagenase IA 
and 0.001 w/v% sodium azide was then added into the tube, which was 
then incubated at 37 °C on a rotating plate. At each time point, 900 μl of 
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supernatant was collected for the BCA assay after centrifugation at 13000 
rpm for 5 min to sediment the GNs, and the tubes were refreshed with the 
same amount of fresh medium. 
2.8 Statistics
All of the measurements were depicted as average ± standard deviation 
and the statistical analyses were conducted using GraphPad Prism. 
Differences among groups were analyzed by Analysis of Variance (ANOVA) 
followed by a Tukey post-hoc test, and a value of P < 0.05 was considered 
as a statistically significant difference. 
3 Results 
3.1 Long-term release of antibiotics from gelatin nanospheres
In the presence of collagenase, vancomycin and colistin were released from 
GNLs and GNHs in a sustained manner for more than 14 days (Figure 1A 
and 1B). Comparable amounts of colistin and vancomycin were released 
from GNLs (Figure 1A), whereas almost two times more vancomycin was 
released from GNHs as compared to colistin. In the absence of collagenase, 
however, sustained release was only observed for vancomycin, whereas 
the release of colistin stopped after two days (Figure 1C and 1D). In 
Figure 1. Release kinetics of antibiotics from gelatin nanospheres of low (A, C) and high (B, D) 
cross-linking densities in the presence (A, B) or absence of collagenase (C, D). 
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contrast, gentamicin and moxifloxacin were released in a burst-wise 
manner irrespective of the gelatin cross-linking densities or the presence 
of collagenase (Figure 1A-D). 
3.2 Influence of pH, ionic strength and detergent concentration 
on the short-term release of antibiotics
To investigate the interactions between antibiotics and gelatin carriers in 
more detail, antibiotics were released from GNs in media of different pH, 
ionic strength and detergent concentration. The corresponding release 
profiles of the various antibiotics are shown in Figure 2 - 5.
3.2.1 Colistin release 
Figure 2. Release of colistin from gelatin nanospheres of low (GNL) and high cross-linking densi-
ties (GNH) in the presence (GNL-CA and GNH-CA) or absence of collagenase (GNL and GNH) 
(A); release of colistin from gelatin nanospheres of high cross-linking density in media of different 
pH (B), ionic strength (C) and detergent concentrations (D) in the absence of collagenase.
Release of colistin from both GNLs and GNHs revealed two distinct phases 
(Figure 2A). In the presence of collagenase, an initial burst release after 1 
day was followed by a phase of sustained release. Without collagenase, on 
the contrary, no phase of sustained colistin release was observed after the 
initial burst phase. More than two times more colistin was released from 
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GNLs compared to GNHs in the burst release stage, irrespective of the 
presence of collagenase. 
The amount of colistin release after 3 days increased strongly with 
decreasing pH from about 20% at neutral pH (7.4) to almost 80% at 
acidic conditions (pH of 3.0) (Figure 2B). Although the release of colistin 
also increased with increasing ionic strength, the effect of ionic strength 
on colistin release was much less pronounced than the pH (Figure 2C). 
Similarly, the effect of the addition of detergent (Tween 20) was also minor 
compared to the effect of pH (Figure 2D) since colistin was not released at 
low concentrations while less than 15% of colistin was released when the 
concentration of Tween 20 was increased to 0.1 v/v%.  
3.2.2 Vancomycin release 
Release of vancomycin from GNHs did not depend on the presence or 
absence of collagenase. More vancomycin was released from GNLs, 
whereas the presence of collagenase resulted into more vancomycin 
Figure 3. Release of vancomycin from gelatin nanospheres of low (GNL) and high cross-linking 
densities (GNH) in the presence (GNL-CA and GNH-CA) or absence of collagenase (GNL and 
GNH) (A); release of vancomycin from gelatin nanospheres of high cross-linking density in media 
of different pH (B), ionic strength (C) and detergent concentrations (D) in the absence of colla-
genase. 
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release from day 7 onward (Figure 3A). The addition of Tween 20 had the 
most pronounced effect on the rate and amount of vancomycin release 
since vancomycin release was negligible at low detergent concentrations 
but increased dramatically to more than 90% at the highest detergent 
concentration of 0.1 v/v% (Figure 3D). In contrast, the effects of pH and 
ionic strength on the release of vancomycin were less pronounced (Figure 
3B and 3C) although it can be concluded that the release of vancomycin 
increased with increasing ionic strength and decreasing pH. 
3.2.3 Gentamicin and moxifloxacin release
Gentamicin and moxifloxacin displayed a comparable burst-type release 
behavior characterized by more than 70% of cumulative release within 
less than 1 day irrespective of the degree of cross-linking (GNLs vs. GNHs) 
or the presence of collagenase (Figure 4A and Figure 5A). Gentamicin 
release increased considerably with increasing ionic strength (Figure 4C), 
while the addition of detergent stimulated release of gentamicin at the 
Figure 4. Release of gentamicin from gelatin nanospheres of low (GNL) and high cross-linking 
densities (GNH) in the presence (GNL-CA and GNH-CA) or absence of collagenase (GNL and 
GNH) (A); release of  gentamicin from gelatin nanospheres of high cross-linking density in media 
of different pH (B), ionic strength (C) and detergent concentrations (D) in the absence of colla-
genase.
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highest detergent concentration only (i.e. 0.1 v/v%, Figure 4D). The effect 
of pH was negligible since differences between the various pH values were 
statistically insignificant (Figure 4B). Moxifloxacin release was not affected 
by differences in pH (Figure 5B), while moxifloxacin release increased only 
moderately with increasing ionic strength and detergent concentration. 
4 Discussion
The main goal of the current study was to investigate the main interaction 
forces between antibiotics and gelatin matrices in order to unravel the 
different mechanisms of antibiotic release from GNs. To this end, we 
studied the release kinetics of four commonly used antibiotics of different 
molecular weight and charge (Table 1 and Figure S1) from GNLs and GNHs 
(Figure S2). We observed that colistin and vancomycin could be released in 
a sustained manner for more than 14 days in the presence of collagenase, 
whereas gentamicin and moxifloxacin were released in a burst-wise 
Figure 5. Release of moxifloxacin from gelatin nanospheres of low (GNL) and high cross-linking 
densities (GNH) in the presence (GNL-CA and GNH-CA) or absence of collagenase (GNL and 
GNH) (A); release of  moxifloxacin from gelatin nanospheres of high cross-linking density in 
media of different pH (B), ionic strength (C) and detergent concentrations (D) in the absence of 
collagenase.
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manner within less than two days (Figure 1A and 1B). 
Gelatin is a denatured protein which is prepared through the hydrolysis 
of collagen. At neutral pH, gelatin A (IEP of 7-9) is positively charged while 
gelatin B (IEP of 4.8-5) is negatively charged [32]. This charged nature 
of gelatin renders this biopolymer suitable for controlled delivery of 
oppositely charged biomolecules. The most widely accepted mechanism to 
explain release kinetics of bioactive macromolecules (e.g. growth factors) 
from gelatin carriers relies on the formation of polyion complexes between 
charged biomolecules and oppositely charged gelatin carriers, where 
sustained release of biomolecules is enabled by enzymatic degradation of 
gelatin [12]. However, our results showed that the most positively charged 
antibiotic  (i.e. gentamicin [33], see Table 1) was not released in a sustained 
manner from oppositely charged GNs. In contrast, vancomycin had a 
higher molecular weight and was released in a sustained manner although 
this antibiotic contains a much lower amount of positively charged amine 
groups than gentamicin. Finally, most sustained release profiles were 
observed for colistin of high molecular weight and intermediate charge. 
These results indicate that the release of colistin was most likely caused 
by the formation of polyion complexes, whereas the formation of such 
complexes between gelatin carriers and gentamicin or vancomycin was 
unlikely. Therefore, we have explored the interactions between antibiotics 
and gelatin carriers in more detail in order to obtain fundamental insight 
into the release kinetics of the selected antibiotics.
Generally, gelatin macromolecules consist of both positively (~ 13% lysine 
and arginine), negatively (~ 12% glutamic and aspartic acid) and hydrophobic 
amino acids (~ 11% leucine, isoleucine, methionine and valine) [10]. This 
composition facilitates the establishment of electrostatic and hydrophobic 
interactions between antibiotics and gelatin carriers. To investigate the 
formation of electrostatic interactions between antibiotics and gelatin 
nanospheres, the charged nature of gelatin was affected by i) decreasing 
the pH of the release medium (to switch the charge of GNs from negative 
to positive), and ii) increasing the ionic strength of the medium (to screen 
the charge of GNs). Moreover, to examine the formation of hydrophobic 
interactions between antibiotics and gelatin nanospheres, we added 
detergent Tween 20 into the release media since amphiphilic Tween 20 
can disrupt such hydrophobic interactions and accelerate the release of 
antibiotics that are bound to gelatin carriers by hydrophobic forces [34]. 
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The strong increase in colistin release with decreasing pH was a clear 
indication that electrostatic interactions were formed between colistin and 
GNs. At neutral pH, gelatin carriers and colistin were oppositely charged, 
whereas gelatin carriers were uncharged at a pH value of 5.0 which was 
similar to the isoelectric point of gelatin type B [13]. At a lower pH of 3, 
gelatin carriers and colistin were similarly charged due to protonation 
of gelatin’s carboxylate and amine groups [13]. Apparently, electrostatic 
interactions could be formed between gelatin and colistin provided that 
their respective charges were opposite. Subsequent release of colistin 
from GNHs was shown to be pH-responsive (Figure 2B) since the extent of 
gelatin degradation under similarly acidic conditions was negligible (Figure 
S3B). The formation of electrostatic interactions between cationic colistin 
molecules and anionic gelatin macromers was further confirmed by the fact 
that colistin release increased with increasing the ionic strength (Figure 2C). 
Obviously, screening of the charges of carriers resulted into a decreased 
mutual affinity between colistin and gelatin and strongly enhanced colistin 
release. With increasing ionic strength, the electric double layer of the 
gelatin nanospheres became more compressed [28]. As a consequence, 
more positively charged sodium ions entered the Stern layer [35, 36] and 
competed with positively charged colistin molecules to establish stable 
complexes with the negatively charged groups of gelatin. Since only a 
limited amount of colistin (27%) was released after 3 days into solutions 
of highest ionic strength (1000 mM, Figure 2C), it can be concluded that 
the electrostatic interactions between colistin and gelatin carriers were 
strong and not easily disrupted by charge screening. These results are in 
line with the observation that colistin was only released upon enzymatic 
degradation of gelatin after the initial burst (Figure 2A), which stresses that 
diffusional post-loading of colistin onto gelatin carriers resulted into a tight 
interaction between the carriers and antibiotics. In addition, it was shown 
that only 13% of colistin was released into media of very high detergent 
concentration (0.1 v/v% Tween 20) (Figure 2D), which confirms that 
hydrophobic interactions hardly contributed to the formation of bonds 
between colistin and gelatin. Summarizing, our findings provide evidence 
that the interactions between colistin and gelatin nanospheres were strong 
and mainly of electrostatic nature. 
Owing to the high strength of these interactions, the release of colistin from 
GNs was strongly dependent on the enzymatic degradation of GNs (Figure 
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2A, Figure S3A) since colistin was not released anymore after the initial burst 
from both GNLs and GNHs when collagenase was not present. The initial 
burst release of colistin that preceded the linear, sustained release phase 
corresponded weakly bound colistin since gelatin hardly degraded during 
the first 2 days (Figure S3A). Highly cross-linked GNs displayed a lower burst 
release (~ 20%) than GNs of lower cross-linking density (~ 50%) (Figure 2A). 
This observation was attributed to the lower amount of free amine groups 
for GNHs that resulted from cross-linking using glutaraldehyde, which 
rendered these carriers more negatively charged than GNLs (Table S1). 
Electrostatic interactions were also formed between vancomycin and 
gelatin carriers, as the release of vancomycin from GNHs increased 
moderately with increasing pH (Figure 3B) and ionic strength (Figure 3C). 
These electrostatic forces were, however, not the only type of forces that 
contributed to the binding of vancomycin to gelatin. Vancomycin was 
released almost completely in the medium with the highest concentration 
(0.1 v/v%) of  Tween 20 (Figure 3D), thereby confirming that both 
electrostatic and hydrophobic forces contributed to the strong affinity 
between vancomycin and gelatin. Moreover, in the presence of collagenase, 
the degradation rate of GNLs was much faster than that of GNHs from 
day 5 onwards (Figure S3A). Apparently, the release rate of vancomycin 
was affected by the degradation rate of gelatin nanospheres due to the 
formation of strong hydrophobic and electrostatic interactions between 
vancomycin and gelatin. Consequently, the release of vancomycin was 
slightly accelerated after 5 days by the presence of collagenase for GNLs 
only, whereas the presence of collagenase did not affect the kinetics of 
vancomycin release for GNHs of higher cross-linking density (Figure 3A). 
Apparently, vancomycin release was controlled by weak interactions up 
to the fifth day of soaking, while enzymatic degradation of GNLs became 
active after 5 days of soaking. 
Both electrostatic and hydrophobic interactions were formed between 
gentamicin and GNs, since the release of gentamicin increased dramatically 
with increasing ionic strength and concentration of Tween 20 (Figure 4C 
and 4D). However, the combined action of both forces was still too weak to 
bind gentamicin sufficiently strong to gelatin carriers, resulting into a lack 
of bonding strength between gentamicin and gelatin and correspondingly 
a burst-wise release profile. Moxifloxacin, on the other hand, was hardly 
affected by changes in pH or ionic strength, while its release was only 
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slightly affected by increasing the concentration of Tween 20. 
From our findings, it can be concluded that the interactions that are formed 
between antibiotics and gelatin carriers are strongly dependent on the 
inherent physicochemical properties of these antibiotics, thereby directly 
determining antibiotics release kinetics. Specifically, molecular weight and 
charge are two major parameters that contribute to differences in release 
kinetics. In the current study, molecular weight had a stronger effect on 
the release kinetics of antibiotics than antibiotic charge density. Antibiotics 
of higher molecular weight (i.e. colistin and gentamicin) were released in a 
sustained manner irrespective of their charge density, whereas antibiotics 
of low molecular weight were released in a burst-type manner even though 
antibiotics of highly positive charge such as gentamicin were investigated. 
Apparently, the number of non-covalent interactions between gelatin 
carriers and antibiotics is a more important criterion for the formation of a 
tight bonding between antibiotics and gelatin than their charge difference.
Finally, we investigated the relationship between the release of antibiotics 
and the degradation of gelatin carriers by plotting the cumulative release 
of antibiotics vs. the cumulative degradation of GNs (Figure 6). After the 
initial burst release, linear correlations between antibiotic release and 
GNs degradation were observed for both high molecular weight colistin 
and vancomycin (Figure 6), whereas low molecular weight gentamicin and 
moxifloxacin were released from gelatin carriers in a burst-type manner 
without any correlation to the amount of GNs degradation. Summarizing, 
our data suggests that antibiotics of relatively high molecular weight can 
be released in a sustained manner from GNs. These results confirmed that 
the release of antibiotics from gelatin carriers strongly depends on the 
physicochemical characteristics of antibiotics. As a consequence, the data 
Figure 6. Correlations between antibiotics release and degradation of gelatin nanospheres of low 
(A) and high (B) cross-linking densities.
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presented herein are instrumental for the design of novel gelatin-based 
carrier systems for local delivery of antibiotics. 
Although this study provides useful information on the interactions between 
antibiotics and GNs, several stumbling blocks towards clinical translation 
and commercialization of GNs for local delivery of antibiotics need to 
be overcome. Besides the complexity of gelatin-antibiotic interactions, 
the variable physicochemical characteristics of commercially available 
gelatin in terms of molecular weight, isoelectric point and purity remain 
a challenge. This holds particularly true for GNs, since their synthesis is 
sensitive to small variations in e.g. the molecular weight distribution and/
or charge of gelatin. Therefore, it is of utmost importance to reproducible 
industrial production of GNs by securing access to gelatin of controllable 
physicochemical properties. Subsequently, the antibacterial effects of 
gelatin carriers loaded with antibiotics should be investigated in extensive 
in vitro and in vivo studies. In doing so, the efficacy of antibiotics delivery 
from gelatin carrier should be directly compared to conventional carriers 
for local delivery of antibiotics such as collagen fleeces and sponges.
5 Conclusions
The release of antibiotics loaded onto GNs by simple diffusional post-
loading was shown to depend strongly on the physicochemical properties 
of the antibiotics. Antibiotics of high molecular weight (colistin and 
vancomycin) were released in a sustained manner for more than 14 days, 
whereas antibiotics of low molecular weight (gentamicin and moxifloxacin) 
were released in a burst-wise manner. The interactions between antibiotics 
and gelatin carriers were mainly dominated by i) strong electrostatic forces 
for colistin, ii) strong hydrophobic and electrostatic forces for vancomycin, 
iii) weak electrostatic and hydrophobic forces for gentamicin, and iv) weak 
hydrophobic forces for moxifloxacin. The release kinetics of these four 
selected antibiotics strongly correlated to the binding affinity of antibiotics 
to gelatin carriers which decreased in the order colistin (high molecular 
weight and charge) > vancomycin (high molecular weight and neutral) > 
gentamicin (low molecular weight and charge) > moxifloxacin (low molecular 
weight and neutral). 
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Supplementary information
Table S1. Parameters of gelatin nanosphres
Parameters
Nanospheres (swollen state)
  Low CL High CL
Molar ratio of GA/NH2  1/2 4/1
Particle size (nm) 590.5 ± 8.7 397.6 ± 5.0
Water content (%) 90.29 ± 0.9 85.59 ± 3.82
Amout of free amine groups (μg/mg) 289 ± 11.6 32.7 ± 1.3
ζ-potential (mV) -10.2 ± 0.7 -21 ± 1.2
Note: CL = cross-linking density; GA = glutaraldehyde.
Figure S1. Chemical structures of gentamicin (A), moxifloxacin (B), colistin (C) and vancomycin 
(D).
Figure S2. Scanning electron micrographs of gelatin nanospheres of low (A) and high (B) cross-link-
ing densities.
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Figure S3. Degradation of gelatin nanospheres (GNs) of low and high cross-linking densities 
in medium containing 400 ng/ml collagenase (A); degradation of gelatin nanospheres of high 
cross-linking density in medium of different pH without collagenase (B)
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1 Introduction
Orthopedic and dental implants are increasingly used for applications 
such as bone fractures and fixation of nonunions, joint replacement, spinal 
revision surgery, and oral and maxillofacial surgery [1]. These implants 
improve the quality of life by restoring mobility and function and alleviating 
pain [2]. Although modern implantology has made significant progress 
over the past few decades, implant-associated infections following invasive 
surgeries remain a major clinical challenge without satisfactory clinical 
treatment, which may lead to implant failure and acute and often chronic 
complications [3-5]. Therefore, orthopedic implants that have the capacity 
to kill bacteria and facilitate host-tissue integration to prevent implant-
associated infections must be developed [1, 6, 7]. 
To achieve such functional performance, the application of a biologically 
active coating as a local antibacterial drug delivery system to implant 
surfaces is advocated as an effective strategy. Compared to traditional 
systemic delivery by oral or intravenous administration, this local 
delivery can provide a site-specific release of antibacterial drugs at high 
concentrations for a prolonged time period without causing systemic 
toxicity and antibacterial resistance [3, 4, 8]. Consequently, various coating 
techniques, including electrophoretic deposition (EPD) [3, 9, 10], solvent 
casting [11], dip coating [12], and sol-gel coating [13] have been used to 
deposit such biologically active coatings onto implants. These techniques 
enable incorporation of antibacterial drugs into the coatings. 
Among the various coating techniques, EPD is a rapid, cost-effective, 
site-selective, and versatile technique that can produce uniform, stable, 
and mechanically resistant coatings with tunable thickness at room 
temperature [9, 10]. Additionally, the EPD technique allows incorporation 
of drug delivery vehicles into the coating matrix to enhance the control 
over drug delivery [3]. As a coating matrix, chitosan has been widely coated 
on implant surfaces using the EPD technique [3, 14] due to its beneficial 
properties for drug delivery [15-18] and intrinsic antibacterial properties 
[19]. Control over release of the drugs, however, is generally limited due 
to a poor affinity between the drugs and chitosan. Therefore, suitable drug 
delivery carrier vehicles should be incorporated into the EPD coatings. 
More recently, gelatin nanospheres (GNs) have been widely used as drug 
delivery vehicles because of their excellent bioactivity, nontoxicity, cost-
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effectiveness and tunable charge and degradation rate [20]. Previously, it 
was shown that both macromolecules (e.g., growth factors [21, 22] and 
nucleic acids [23]) and small molecules (e.g., vancomycin and colistin [24]) 
could be released from GNs in a sustained manner due to molecular 
interactions between the drugs and GNs, such as hydrophobic and 
electrostatic interactions [24], which offers improved control over drug 
delivery compared to that of traditional diffusional release. 
Therefore, the objective of the current study was to prepare biologically 
active coatings to facilitate sustained release of antibacterial drugs from 
the surface of the implants to prevent implant-associated infections. To this 
end, we deposited chitosan coatings containing GNs loaded with antibiotics 
onto 316L stainless steel plates 
by means of the EPD technique 
(Figure 1). We hypothesized that 
sustained release of vancomycin 
from the EPD coatings would be 
achieved by the strong interactions 
between vancomycin and the GNs 
[24], whereas moxifloxacin would be 
released in a burst-type manner due 
to its weak affinity with GNs [24]. 
We studied the release kinetics of 
vancomycin and moxifloxacin from 
EPD coatings in vitro and examined 
the antibacterial effect of the EPD 
coatings using the zone of inhibition 
test against Staphylococcus aureus. 
2 Materials and Methods
2.1 Materials
Gelatin type B (from bovine skin, 225 bloom, isoelectric point (IEP) ~ 
5) and chitosan (molecular weight in the range of 190-310 kDa with a 
deacetylation degree of 75-80%) were purchased from Sigma-Aldrich. 
Vancomycin hydrochloride hydrate (potency ≥ 900 µg/mg) and moxifloxacin 
hydrochloride (analytical standard) were purchased from Sigma-Aldrich. 
Glutaraldehyde (25 wt% solution in water) was purchased from Acros 
Figure 1. Schematic illustration of electropho-
retic co-deposition. Antibiotic-loaded gela-
tin nanospheres were coated by oppositely 
charged chitosan molecules and deposited 
onto 316L stainless steel plates under the in-
fluence of an applied electrical field. 
Electrophoretic co-deposition 
50ml
-+Gelatin 
nanospheres 
Antibiotic
molecule 
Chitosan
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Organics, while all other chemicals were purchased from Sigma-Aldrich.
2.2 Preparation and characterization of gelatin B nanospheres
GNs were prepared by a two-step desolvation method [25]. Briefly, 25 ml 
of a 5% (w/v) solution of gelatin B in deionized water was prepared at 50 °C, 
and 25 ml acetone was then added to precipitate the gelatin chains of high 
molecular weight. The supernatant was discarded after precipitation, and 
the gelatin was redissolved in water at 50 °C followed by adjustment of the 
pH of the gelatin solution to 2.5. Thereafter, 80 ml of acetone was added to 
the gelatin solution at a constant rate of 4 ml/min under vigorous stirring to 
form GNs. Subsequently, the GNs were stabilized by the addition of 740 μl 
of 25 wt% glutaraldehyde. After 16 h of cross-linking, 105 ml of a 100 mM 
glycine solution was added to block the unreacted aldehyde groups. The 
suspension was then centrifuged at 5000 rpm for 60 min and resuspended 
in deionized water by vortexing. After three cycles of washing, the pH of 
the GNs suspension was adjusted to pH 7.0 and lyophilized for 24 h. The 
lyophilized GNs were stored at 4 °C for further use.
The morphology of the GNs was characterized by scanning electron 
microscopy (SEM, LEO 435 VP, Zeiss, Germany). The size and size distribution 
of GNs in the swollen state were measured in HEPES buffer (5 mM, pH 7.0) 
using dynamic light scattering (DLS, Zetasizer Nano-S, Malvern Instruments 
Ltd., Worcestershire, U.K.). The ζ-potential of the GNs was examined by 
laser doppler electrophoresis with a Zetasizer Nano-Z instrument (Malvern 
Instruments Ltd.) in the same HEPES buffer. 
To investigate the interaction between the GNs and chitosan coatings, the 
ζ-potential of the GNs was also measured after they were thoroughly mixed 
with chitosan solutions. To this end, a suspension containing 2 mg/ml 
GNs and 0.5 mg/ml chitosan was prepared (see Table 1) and magnetically 
stirred overnight to ensure a strong interaction between the GNs and 
Group GNs (mg/ml)
Chitosan 
(mg/ml)
GNs/chitosan ratio 
(wt/wt)
Solvent ratio
(v/v, ethonal/water) pH
1   — 0.5 — 1:1 4.8
2   0.25 0.5 1:2 1:1 4.8
3 0.5 0.5 1:1 1:1 4.8
4 2 0.5 4:1 1:1 4.8
Table1. Composition of antibiotic-free suspensions used for EPD
Note: GNs are gelatin nanospheres; EPD is electrophoretic deposition.
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chitosan. The GNs were then collected by centrifugation and redispersed 
in a citrate buffer (5 mM, pH 4.8, similar to the pH of the suspensions used 
for EPD (see Table 1) by sonication. Subsequently, the size distribution and 
ζ-potential of the chitosan-modified GNs were characterized in the citrate 
buffer as described above. 
2.3 Electrophoretic deposition process
A chitosan solution (1 mg/ml) was prepared when chitosan was dissolved 
into 2% (v/v) acetic acid and magnetically stirred at 200 rpm. Pure ethanol 
of the same volume was added dropwise into the chitosan solution 
under magnetic stirring to minimize electrolysis of the water during the 
EPD process. Different amounts of GNs were then added to the chitosan 
solution. The GNs were dispersed homogeneously inside the chitosan 
solution by sonication for 30 s (cycles of 0.9 s of working time and 0.1 s 
pauses) at 40% amplitude with a Branson digital sonifier (Emerson industrial 
Automation, Branson Europe, Dietzenbach, Germany). The compositions 
of the GNs/chitosan suspensions used for coating deposition using EPD 
are listed in Table 1. 
Two parallel 316L stainless steel plates 12 mm diameters were placed in the 
EPD cell and used as the deposition and counter electrodes. The distance 
between the electrodes was fixed at 10 mm, and the deposition area was 
1 cm2. After optimization of the applied voltage (10-50 V) and deposition 
time (10-300 s), the deposition process was carried out at 15 V over 60 s, 
yielding a homogeneous and crack-free coating with maximal deposit mass. 
Oxidation of the stainless steel substrate during the anodic EPD process 
was negligible due to the excellent corrosion resistance of the stainless 
steel and the gentle conditions employed in the current experiment [26]. 
Group GNs (mg/ml)
Chitosan 
(mg/ml)
GNs/chitosan 
ratio (wt/wt) Antibiotic
Antibiotic concentration 
in  suspension (μg/ml)
V-GNs High 2 0.5 4:1 vancomycin 120
V-GNs Low  2 0.5 4:1 vancomycin 40
V-Control — 0.5 — vancomycin 40
M-GNs 2 0.5 4:1 moxifloxacin 40
M-Control — 0.5 — moxifloxacin 40
GNs-Control 2 0.5 4:1 — —
Table 2. Composition of antibiotic-containing suspensions used for EPD
Note: GNs are gelatin nanospheres, EPD is electrophoretic deposition; V is vancomycin; and M is 
moxifloxacin.
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It should be noted that the proposed coating can be obtained not only on 
316L stainless steel plates but also on other conductive substrates such as 
titanium and titanium alloys using similar EPD parameters. After deposition, 
the deposited cathodes were gently removed from the EPD cell and kept 
in air at room temperature for 20 min followed by drying at 37 °C for 24 h.
To incorporate antibiotics into the EPD coatings, 500 μl of PBS containing 
vancomycin (12 and 4 mg/ml) or moxifloxacin (4 mg/ml) was dropped onto 
100 mg of GNs in a 50 ml centrifuge bottle (Falcon). The GNs were then 
stored at 4 °C overnight to allow for total absorption of the antibiotics 
followed by addition of 50 ml of the chitosan solution. Subsequently, the 
suspension was sonicated as described previously. The compositions of 
the suspensions used for deposition of drug-loaded coatings are listed 
in Table 2. The EPD coatings loaded with antibiotics were then prepared 
under the same conditions as described before.
2.4 Characterization of the electrophoretic deposition coating
The morphology of the EPD coatings was characterized by SEM (Model 
Auriga, Zeiss, Germany). The roughness of the surfaces of the EPD coatings 
was measured using a laser profilometer (UBM, ISC-2). The wettability of 
the EPD coatings was determined by detecting the static water contact 
angles of the surfaces with a DSA30 instrument (Kruess GmbH, Germany). 
The adhesion strength of the composite coatings (GNs/chitosan weight 
ratio of 4:1) to the substrates was measured before and after incubation in 
phosphate buffered saline (PBS) for 3 weeks by means of a scratch tester 
(CSM instruments, Revetest, Switzerland) (n = 7). In this test, a diamond 
indenter with a tip radius of 22 µm was drawn across the composite-coated 
surfaces with a linearly increasing load. A scratch length of 5 mm, a load 
range of 0.09-20 N, and a scratch speed of 10 mm/min were used for the 
measurement. Because the acoustic emission response was too weak, the 
load force which corresponded to the first failure by detachment (observed 
using an optical microscope) was interpreted as the critical load.  
2.5 Release of antibiotics
The coated circular stainless steel plates were placed into glass bottles (n = 
5), followed by addition of 1 ml of PBS. The glass bottles were then placed 
on a shaking plate with a shaking rate of 90 rpm at 37 °C to perform the 
release study. At t = 6 h and 1, 2, 3, 5, 7, 10, and 14 days, 900 μl of the 
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supernatant was collected and refreshed with the same amount of PBS. 
The collected supernatant was stored at 4 °C until the concentrations of 
the antibiotics were determined using reverse phase high-performance 
liquid chromatography (RP-HPLC). 
2.6 Detection of vancomycin and moxifloxacin
Concentrations of vancomycin and moxifloxacin in the supernatants of the 
release study were detected by RP-HPLC using a Hitachi HPLC machine 
which consisted of a Hitachi L-2130 pump, a Hitachi L-2400 UV detector, a 
Hitachi L-2200 auto sampler, and a LiChrospher RP-18 end-capped HPLC 
column (125 mm × 4 mm, particle size 5 μm). Standard calibration curves 
in the ranges of 0.1 to 25 μg/ml and 0.2 to 25 μg/ml were prepared for the 
quantification of moxifloxacin and vancomycin, respectively.
The mobile phase consisted of 50 mM ammonia phosphate buffer (pH 3, 
adjusted with H3PO4) and acetonitrile (90/10 v/v) was used for detection 
of vancomycin, and 50 mM phosphate buffer (pH 2.6) and acetonitrile 
(75/25 v/v) was used for detection of moxifloxacin. Thirty microliters of 
supernatant containing vancomycin or moxifloxacin was injected with a 
flow rate of 1 ml/min. The concentrations of the antibiotics were quantified 
at 196 and 296 nm for vancomycin and moxifloxacin, respectively, using 
standard calibration curves in the concentration range between 0.2 and 
200 μg/ml.
2.7 Cytotoxicity
The lactate dehydrogenase (LDH) activity assay was used to evaluate the 
cytotoxicity of the EPD coatings by following the manufacturer’s standard 
protocol (Thermo Fisher Scientific). Briefly, human foreskin fibroblasts 
(HFFs, isolated from foreskin specimens of a healthy donor by following 
national guidelines for working with human materials) were cultured in an 
αMEM medium (Gibco, Invitrogen Corp., Paisley, Scotland). The cells were 
trypsinized and reseeded into a 24-well plate containing the EPD-coated 
substrates (n = 5) listed in Table 2 at a cell density of 2 × 104 cells/cm2. 
Thermonox coverslides (Thermo Fisher Scientific) and 5% DMSO were used 
as positive and negative controls, respectively. In addition, wells containing 
2% (v/v) Triton - X100 and only culture medium were used as the high 
and low controls, respectively. After 24 h of incubation, 100 µl aliquots of 
metabolized medium from each well were transferred to a 96-well plate 
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in duplicate, and 100 µl of freshly prepared reaction medium was added 
followed by incubation at room temperature for 30 min. The activity of 
the LDH released from the cytosol of damaged cells was determined by 
measurement the absorbance of the suspension at a wavelength of 590 
nm in a Bio-Tek FL600 microplate fluorescence reader (Biotek, Winooski, 
VT). The cytotoxicity was calculated with the following equation: 
                                        (experimental value-low control)
               Cytotoxicity=                                                            × 100%
                                              (high control-low control)  
The final results are listed as cytocompatibility. 
2.8 Antibacterial effects
A zone of inhibition test was used to examine the antibacterial effect of the 
EPD coatings against S. aureus (ATCC 25923TM, Manassas, VA) according to 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
disc diffusion method [27]. Briefly, the isolated bacterial colonies were 
dispersed in sterile saline (0.85% w/v NaCl in water) to reach a density of 
the McFarland 0.5 standard. The bacterial suspension was then diluted 
to a concentration of approximately 1.5 × 107 colony-forming units (CFU) 
per milliliter. After dilution, the bacterial suspension was inoculated on the 
entire surface of a Mueller-Hinton agar plate (Thermo Fisher Scientific). The 
coated discs were then placed on the bacterium-inoculated agar plate. The 
inhibition zone was measured after incubation at 36 °C for 20 h.
Moreover, the morphology of the bacteria on the surface of the EPD coating 
discs was examined by SEM (Zeiss Sigma-300, Germany). In brief, bacterial 
cells were washed with PBS and then fixed with 2 wt% glutaraldehyde in 
a 0.1 M sodium cacodylate solution for 5 min followed by washing with 
the 0.1 M sodium cacodylate solution. Subsequently, the bacterial cells 
were dehydrated in a graded series of ethanol (70, 80, 90, 96 and 100 % 
ethanol and 100 % water-free ethanol) for 5 min and then dried in air in 
tetramethylsilane. The samples were sputter-coated with 10 nm chromium 
and then examined using SEM. 
2.9 Statistics
All measurements were depicted as average ± standard deviation, and the 
statistical analyses were conducted using GraphPad Prism. Differences 
among groups were analyzed by analysis of variance (ANOVA) followed by a 
Tukey post-hoc test, and a value of p < 0.05 was considered as a statistically 
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significant difference.
3 Results 
3.1 Electrophoretic deposition coating
GNs (Figure 2A) with a diameter of approximately 593 nm in the swollen 
state (Table 3, HEPES buffer result) and a ζ-potential of -28.9 mV were 
successfully deposited on the surface of 316L stainless steel plates using 
the EPD technique (Figure 2). The bare chitosan coating (Figure 2B) was 
smooth, while randomly distributed GNs were observed when they were 
added (Figure 2C). With an increase in the amount of GNs in suspension, the 
surface of the coating was highly packed with homogeneously distributed 
GNs (Figures 2D and 2F). The GNs were mostly visible only at the surface of 
Figure 2. Scanning electronic micrographs of the gelatin nanospheres (A) and electrophoretically 
deposited gelatin nanosphere/chitosan coatings at ratios of 0:1(B), 1:2 (C), 1:1 (D and E) and 4:1 
(F and G); (E) and (G) are the cross-sections of (D) and (F), respectively. Arrows in E and G indicate 
the gelatin nanospheres distributed in the coating.
500 nm 5 μm 2 μm
2 μm 500 nm
2 μm 2 μm
A B C
D E
F G
2 μm 2 μm 2 μm
2 μm
A C
2 cm 2 cm 2 cm
B D
F GE
2 μm
H
A BCritical load: 8.3 ± 0.1 N Critical load: 10 ± 0.3 N
Table 3. Parameters of gelatin nanospheres in the swollen state
Parameters
HEPES buffer (pH 7) Citrate buffer (pH 4.8)
Without chitosan   Without chitosan With chitosan
Particle size (nm) 593 ± 5 1291 ± 67 1389 ± 24
ζ-potential ( V) -28.90 ± 0.67 -5.48 ± 0.32 11.10 ± 0.35
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the EPD coatings at GNs/chitosan ratios lower than or equal to 1 (Figures 2C 
and 2E), while a homogeneous distribution of GNs throughout the coating 
was observed when the weight ratio between the GNs and chitosan was 
increased to 4:1 (Figure 2G).
The topography and wettability of the deposited coatings with different 
compositions were determined by roughness and contact angle 
measurements, respectively. The roughness of the EPD coatings was 
correlated to the weight ratio between the GNs and chitosan. Coatings with 
a GNs:chitosan ratio of 1:2 displayed a roughness higher than those of 
experimental groups (Figure 3A). The contact angles of the coated samples 
decreased when the amount of GNs increased (Figure 3B).
The results of the scratch test used to evaluate the adhesion strength of 
the GNs/chitosan coatings to the substrate are shown in Figure 4. The cross 
Figure 3. Roughness (A) and contact angles (B) of electrophoretically deposited coatings with 
different ratios between the gelatin nanospheres and chitosan. p < 0.05 (*). 
Figure 4. Typical scratch track on a GNs and chitosan coating (4:1 weight ratio) before (A) and 
after (B) incubation in PBS for 3 weeks. The arrows show the scratch direction, and the crosses 
show the first coating detachment to determine the critical load.
500 nm 5 μm 2 μm
2 μm 500 nm
2 μm 2 μm
A B C
D E
F G
2 μm 2 μm 2 μm
2 μm
A C
2 cm 2 cm 2 cm
B D
F GE
2 μm
H
A BCritical load: 8.3 ± 0.1 N Critical load: 10 ± 0.3 N
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on the scratch line, which stands for the position of the first detachment 
under the linearly increasing load, was used to determine the critical load 
in the present study. The critical load force of the raw GNs/chitosan coating 
was measured to be 8.1 ± 0.3 N (Figure 4A). An appreciable increase in the 
critical load force to 10 ± 0.3 N was observed after degradation in PBS for 
3 weeks (Figure 4B). 
3.2 Release of antibiotics from EPD coatings
Sustained release of vancomycin 
was observed only from EPD 
coatings containing GNs loaded with 
high amounts of vancomycin (Figure 
5A). An amount of vancomycin (p 
< 0.0001) was released from the 
experimental group containing a 
high amount of vancomycin (V-GNs 
High groups) was significantly higher 
compared to those of the other 
two vancomycin-loaded groups. In 
contrast, moxifloxacin was released 
in a burst-type manner regardless 
of the presence of GNs inside the 
coatings (Figure 5B). Moreover, burst 
release of vancomycin from coatings 
containing only vancomycin without 
GNs was observed (Figure 5A).
3.3 Cytocompatibility
Figure 6 shows the cytocompatibility of the EPD coatings measured using 
the LDH activity assay. None of the EPD coatings were cytotoxic. Further, 
no significant difference was observed among the groups with various 
compositions. 
3.4 Antibacterial efficacy
An inhibition zone diameter for S. aureus was measured to examine the 
antibacterial efficacy of the EPD coatings (Figures 7A-C). The samples that 
Figure 5. Cumulative release kinetics of van-
comycin (A) and moxifloxacin (B) from elec-
trophoretically deposited GNs/chitosan coat-
ings. The labels V-GNs low and high represent 
coatings containing gelatin nanospheres load-
ed with low and high amount of vancomycin, 
respectively; the label M-GNs represents sam-
ples containing GNs loaded with moxifloxacin, and the labels V-control and M-control represent 
pure chitosan coatings containing vancomycin and moxifloxacin, respectively. 
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contained moxifloxacin with or 
without GNs displayed an obvious 
inhibition zone (Figures 7A and 7B), 
whereas none of the groups with 
or without vancomycin induced 
the formation of an inhibition zone 
(Figure 7C and Figure S1). SEM was 
used to observe the morphology 
of S. aureus on the surface of 
the coatings with and without 
vancomycin. Bacteria were clearly 
observed on all of these coatings 
(Figure 7D-F) except for those that 
contained GNs loaded with a high amount of vancomycin (Figures 7G and 
7H).
4 Discussion
The aim of the present study was to develop a method to apply an 
antibacterial coating to the surface of metallic implants to prevent implant-
associated infections. To this end, we used the EPD technique to deposit 
positively charged chitosan containing negatively charged GNs onto the 
surface of 316L stainless steel plates. In these EPD coatings, GNs served as 
delivery vehicles which facilitated improved control over the antibacterial 
Figure 7. Optical images of the inhibition zone of samples containing moxifloxacin with (A) or 
without (B) GNs as well as samples containing GNs loaded with a high amount of vancomycin (C) 
against S. aureus. Scanning electron micrographs of S. aureus growth on the coatings containing 
GNs without antibiotics (D), vancomycin without GNs (E), and GNs loaded with low (F) and high 
(G and H) amounts of vancomycin. H is a cross-sectional image of G. S.aureus cells were fixed 
after 20 h of culture on an agar plate at 36°C.
500 nm 5 μm 2 μm
2 μm 500 nm
2 μm 2 μm
A B C
D E
F G
2 μm 2 μm 2 μm
2 μm
A C
2 cm 2 cm 2 cm
B D
F GE
2 μm
H
A BCritical load: 8.3 ± 0.1 N Critical load: 10 ± 0.3 N
Figure 6. Cytocompatibility of the EPD coat-
ings. V stands for vancomycin, and M stands 
for moxifloxacin. p < 0.001 (***). 
Chapter 4
92
efficacy of the coatings. 
The GNs were successfully incorporated into the EPD coatings as indicated 
by a homogeneous distribution of the spheres throughout the coatings 
(Figures 2F and 2G). During the EPD process, water around the cathode 
was electrolyzed, resulting in a locally increased pH [14]. Meanwhile, the 
protonated chitosan macromolecules migrated to the cathode under 
the influence of the electric field, neutralized their charge by electron 
uptake, and adhered to the electrode at an alkaline pH [14]. To explore the 
possible interaction between GNs and chitosan during the EPD process, 
we measured the size and ζ-potential of the GNs with and without chitosan 
in a citrate buffer, which had a pH similar to that of the suspension used for 
EPD. The pure GNs in the acidic citrate buffer were less negatively charged 
and larger in size than those in the neutral HEPES buffer, which may be 
caused by moderate degrees of aggregation at reduced ζ-potential values. 
After being thoroughly mixed with chitosan macromolecules, the negatively 
charged GNs became positively charged, as indicated by a shift in ζ-potential 
from -5.48 to 11.1 mV (Table 3). This change, in addition to an increase in 
the diameters of the GNs from 1291 to 1389 nm, indicated that the GNs 
were covered by a thin chitosan layer with a thickness of approximately 
50 nm (Table 3). Consequently, the formation of homogeneous and 
intimately mixed GNs/chitosan coatings at the cathode was realized by a 
two-step process: (i) electrostatic adsorption of positively charged chitosan 
molecules onto negatively charged GNs and (ii) co-deposition of free 
chitosan molecules and chitosan-coated GNs onto the working electrode 
driven by the applied electric field [9, 10, 28]. Thus, we assume that the 
amount of deposited GNs was directly controlled by the original weight 
ratio between the GNs and chitosan in the EPD suspension (Figures 2B-G), 
as confirmed by our previous investigation of EPD-deposited composite 
coatings [3, 26]. 
The weight ratio between GNs and chitosan not only influenced the amount 
of GNs inside the EPD coatings but also affected the topography and 
hydrophobicity of the EPD coatings (Figure 3). The highest roughness values 
were observed for the EPD coatings at a GNs and chitosan weight ratio of 
1:2 (Figure 3A) due to the presence of discontinuous GNs (Figure 2C). At 
GNs and chitosan ratios higher than 1:1, the surfaces of the EPD coatings 
were highly packed with a confluent layer of GNs (Figure 2D) which lowered 
the roughness value. Generally, we showed that the surface roughness and 
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wettability of the coatings could be tuned by a simple adjustment of the 
weight ratio between GNs and chitosan.
In addition to the surface roughness, the wettability of metallic implant 
surfaces is crucial for processes such as protein adsorption and cell 
attachment [29-31], which ultimately control the extent of osseointegration 
[3]. Recently, it was reported that chitosan-coated surfaces with a contact 
angle of 76 ± 5° induced higher amounts of albumin and fibronectin 
adsorption as well as enhanced osteoblast cell attachment compared to 
more hydrophilic Ti surfaces (contact angle 32 ± 6°) [29]. These results 
suggest that the high contact angles as observed for our composite coatings 
can be considered beneficial for the process of osseointegration (Figure 
3B). Our composite coatings became more hydrophilic with increasing 
amounts of GNs, which can be explained by the hydrophilicity of water-
swollen GNs [22, 24]. Consequently, the wettability of the chitosan/gelatin 
coatings can be fine-tuned by a simple adjustment of the amount of GNs 
inside the coatings. 
Furthermore, coatings applied to orthopedic and dental implants should 
display sufficient adhesion strength to survive implant installation. In the 
present study, the critical load force (as a measure of the adhesion strength 
of the EPD coatings to the stainless steel plates) increased from 8.1 ± 0.3 
N for as-prepared coatings to 10 ± 0.3 N for coatings after incubation 
in PBS for 3 weeks (Figure 4). This increase suggests that the composite 
coatings remain stable during the incubation process. The slight increase 
in adhesion strength could be attributed to the detachment of weakly 
bonded components while strongly bonded components remained tightly 
adhered to the stainless steel plate. The adhesion strength as observed in 
the current study was similar to or higher than the adhesion strength in the 
range from 6 to 13 N there were reported previously for electrophoretically 
deposited cellulose nanocrystal/bioactive glass [32], electrodeposited 
calcium phosphate/chitosan [33], plasma sprayed hydroxyapatite [34] and 
biomimetic-assembled hydroxyapatite [35]. Consequently, we assume 
that the adhesion strength of the deposited GNs/chitosan coatings was 
sufficient to justify their application as a biodegradable antibacterial 
coating on orthopedic and dental implants. After implantation, bodily fluids 
that contain enzymes such as lysozyme and collagenase may penetrate the 
coatings and thereafter degrade chitosan and the GNs [21, 36], respectively, 
thereby facilitating the osseointegration of the implant. 
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To render the electrophoretically deposited chitosan/gelatin coatings 
biologically active, we loaded two types of antibiotics (i.e., vancomycin 
and moxifloxacin) onto the GNs and then deposited them together with 
chitosan onto the stainless steel plates. As such, the release of antibiotics 
from these novel coatings would be proceeded by desorption from the 
GNs carriers and subsequent diffusion through the chitosan barrier matrix.
To test our hypothesis that antibiotics can be released from these EPD 
coatings in a sustained manner provided that strong interactions exist 
between the antibiotics and GNs, we compared the release kinetics 
of vancomycin and moxifloxacin from the EPD coatings. We observed 
that vancomycin was released in a sustained manner for up to 2 weeks 
(Figure 5A), which is consistent with the fact that vancomycin can establish 
relatively strong hydrophobic and electrostatic interactions with GNs [24]. 
In contrast, moxifloxacin was released in a burst-type manner (Figure 5B), 
which is in line with the weak interaction between moxifloxacin and GNs, as 
reported previously [24]. In addition, we observed that sustained release of 
vancomycin from electrophoretically deposited coatings could be obtained 
only when GNs were incorporated into the coatings (Figure 5A), which 
confirmed the added value of the incorporation of GNs into the chitosan 
coatings. These results are an improvement compared to a recent report 
where chitosan/gelatin hybrid nanospheres were formed through a one-
step EPD process [37]. In this study, the antibiotic was released within 2 h, 
which does not yet meet clinical requirements. 
The cytotoxicity test confirmed the excellent cytocompatibility of the 
coatings. Although chitosan has been recognized as an antibacterial 
material [15, 19], the coatings without antibiotics did not form an inhibition 
zone (Figure S1), and growth of bacteria on the surface of these coatings 
was observed (Figure 7D). These results indicate that chitosan was not 
effective against S. aureus in the present study. Therefore, it was necessary 
to incorporate antibiotics inside the coatings to render them antibacterial. 
The antibacterial efficacy of the coatings loaded with moxifloxacin was 
confirmed because the burst release of moxifloxacin resulted in an obvious 
inhibition zone (Figures 7A and 7B). Although coatings that contained GNs 
loaded with a high amount of vancomycin did not induce the formation 
of an inhibition zone (Figure 7C), it was found that bacteria did not grow 
on the surface of these coatings (Figures 7G and 7H), which indicates that 
these coatings had the ability to kill the contact bacteria. These results 
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suggeste that the released vancomycin did not diffuse on the agar plate 
due to its high affinity with the GNs. Therefore, the antibacterial effects 
of these novel EPD-processed coatings might be improved by increasing 
the amount of vancomycin in the EPD coatings. These results suggest that 
the antibacterial efficacy of electrophoretically deposited gelatin/chitosan 
coatings can be further improved by simultaneous incorporation of GNs 
loaded with either moxifloxain (to achieve an initial burst release, killing 
invaded bacteria) or vancomycin ( to guarantee a long-term antibacterial 
effect, killing latent bacteria).
5 Conclusion
A novel antibacterial implant coating was developed by electrophoretic 
deposition of chitosan coatings containing gelatin nanospheres to improve 
control over the delivery of antibiotics and prevent implant-associated 
infections. The coatings adhered tightly to the stainless steel substrates, 
and gelatin nanospheres were distributed homogeneously throughout the 
chitosan matrix of the coatings. The surface roughness and hydrophobicity 
of the coatings can be fine tuned by a simple adjustment of the weight 
ratio between the gelatin nanospheres and chitosan in the suspensions. 
Vancomycin and moxifloxacin were released in a sustained and burst-
type manner, respectively, while the coatings were highly cytocompatible 
and exhibited sufficient antibacterial effects. These results suggest that 
the antibacterial capacity of metallic implants can be tuned by orthogonal 
control over the release of (multiple) antibiotics from electrophoretically 
deposited chitosan/gelatin nanosphere coatings, which offers a new 
strategy to prevent implant-associated infections. 
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Supplementary information
Figure S1. Optical image of the inhibition zone of coatings containing GNs without antibiotics.
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1 Introduction
The design and fabrication of an effective and efficient drug delivery 
system is of vital importance in the fields of tissue regeneration [1-3] 
and antibacterial therapy [4, 5]. An ideal delivery systems should release 
drug molecules at the required local site in a spatiotemporally controlled 
manner while retaining their bioactivity, thereby optimizing their efficacy 
and reducing their side effects [6, 7]. To this purpose, numerous 
nanostructured carriers including liposomes [8-10], dendrimers [10-12], 
micelles [10, 13], nanoparticles [14, 15] and electrospun nanofibers [16, 
17] have been developed. 
Among these nanocarriers, electrospun nanofibers have been explored for 
drug delivery purposes due to their high drug loading and encapsulation 
efficiency, ability to modulate the release of biomolecules, cost-effectiveness, 
and ease of processing [17, 18]. More recently, silk fibroin (SF) has gained 
interest as a biomaterial due to several beneficial properties such as its 
biocompatibility, biodegradability, and its processability into multiple 
shapes including nanofibers [19-23]. Such nanofibers can be further 
cross-linked by water annealing to improve their chemical and mechanical 
stability. Consequently, SF nanofibers have been widely used as drug 
carriers [24, 25] and membranes for guided tissue regeneration/guided 
bone regeneration (GTR/GBR) [26, 27]. 
The release of biomolecules from SF nanofibers is based on diffusion. 
Consequently, control over the rate of drug delivery is poor due to a lack of 
interaction between biomolecules and SF [25]. Therefore, we hypothesized 
that enrichment of electrospun SF membranes with additional drug carriers 
will improve the suitability of SF nanofibers for drug delivery.
Charged gelatin nanospheres (GNs) are promising candidates in view of their 
excellent bioactivity, tunable biodegradability and charge, non-toxicity and 
cost-effectiveness [28-30].  Positively charged gelatin type A nanospheres 
(GANs) and negatively charged gelatin type B nanospheres (GBNs) have 
been developed previously [28, 29]. These nanospheres were shown to 
facilitate sustained delivery of macromolecules such as growth factors [31] 
and nucleic acid [32]. Additionally, the GNs were capable of delivering small 
molecules including vancomycin and colistin in a controlled manner [30, 
33]. These beneficial features of GNs are attributed to strong molecular 
interactions between biomolecules and GNs, i.e., polyion complexation, 
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hydrophobic and electrostatic interactions [29, 30]. Consequently, GNs are 
superior drug carriers compared to other nanostructured delivery vehicles 
that rely on release by diffusion. Therefore, we aimed to incorporate 
oppositely charged GNs into the SF nanofibers as an effective strategy to 
provide additional controlled drug delivery performance of electrospun SF 
nanofibers. 
To this end, we dispersed vancomycin-loaded GNs into an aqueous SF 
solution and fabricated SF nanofibers embedded with GNs by using a 
colloid-electrospinning technique [34]. To monitor the distribution of GANs 
and GBNs inside the nanofibers, we labeled GANs and GBNs with blue and 
far-red fluorescent dyes, respectively. Thereafter, we used single or co-axial 
nozzle electrospinning to adjust the amount of oppositely charged GANs 
and GBNs inside the SF nanofibers and to organize the spatial distribution 
of GNs. Subsequently, we studied the in vitro release kinetics of vancomycin 
from the nanofibrous SF/GN membranes and examined the antibacterial 
effect of these membranes against Staphylococcus aureus (S. aureus) by 
using a zone of inhibition test.  Finally, we evaluated the cytotoxicity of the 
membranes using lactate dehydrogenase (LDH) activity assay, and cultured 
periodontal ligament (PDL) cells on the membranes containing different 
amounts of GNs to evaluate the cytocompatibility of these membranes. 
2 Materials and Methods
2.1 Materials
Silk cocoons were provided by Dr Aichun Zhao (State Key Laboratory of 
Silkworm Genome Biology, Southwest University, Chongqing, P.R. China). 
Poly(ethylene oxide) (PEO) (molecular weight = 900 kDa),  gelatin type A 
(from porcine skin, 300 Bloom, isoelectric point (IEP) ≈9) and gelatin type 
B (from bovine skin, 225 bloom, isoelectric point (IEP) ≈ 5) were purchased 
from Sigma-Aldrich (Zwijndrecht, the Netherlands). Glutaraldehyde (25 wt% 
in water) was purchased from Acros Organics (Geel, Belgium). DyLight™ 
405 and 650 NHS Esters were purchased from ThermoFisher Scientific 
(Bleiswijk, the Netherlands). All other chemicals were purchased from 
Sigma-Aldrich (Zwijndrecht, the Netherlands).
2.2 Extraction of silk fibroin from silk cocoons
SF was extracted from silk cocoons according to a previously reported 
protocol [20]. Briefly, 5 g of silk cocoons was boiled in a 0.02 N Na2CO3 
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solution for 30 min to remove sericin proteins. After boiling, the silk material 
was rinsed in cold deionized water for 20 min with three repetitions and 
then dried at ambient temperature for 24 h. The dried silk materials was 
then dissolved in a 9.3 M LiBr (Sigma-Aldrich, Zwijndrecht, the Netherlands) 
solution at 60 °C for 4 h. Thereafter, the SF solution was dialyzed in 
deionized water with a Slide-A-Lyzer™ dialysis cassette (3.5 K, Thermo 
Fisher Scientific, Rockford, USA) for 48 h with six times changes of water, 
followed by centrifugation twice at 5,000 rpm for 20 min to remove the 
impurities. The SF solution was stored at 4 °C for further experiments.
2.3 Preparation of gelatin nanospheres
GANs and GBNs were prepared using a two-step desolvation method 
[31]. Briefly, 1.25 g gelatin was dissolved in 25 ml deionized water at 50 
°C to form a 5 w/v% solution. The high molecular weight gelatin in the 
solution was then precipitated by adding 25 ml acetone. The supernatant 
was discarded afterwards, and 25 ml deionized water was added to re-
dissolve the precipitated gelatin at 50 °C. The pH of the gelatin solution 
was then adjusted to 2.5 using hydrochloric acid solution. After that, 
75 ml acetone for gelatin A or 80 ml for gelatin B was added dropwise 
to the gelatin solution (~ 4 ml/min) under vigorous stirring to form GNs. 
Subsequently, the GNs were stabilized by adding glutaraldehyde into the 
suspension yielding molar ratios between glutaraldehyde and amines (as 
present in gelatin) of 1:1 for GANs (i.e., 132 μl of glutaraldehyde per gram 
of gelatin A ) and 4:1 for GBNs (i.e., 592 μl of glutaraldehyde per gram of 
gelatin B). After 16 h of cross-linking, 100 ml of 100 mM guanidine and 
105 ml of 100 mM glycine solution for gelatin A and B, respectively, was 
added to block the unreacted aldehyde groups. The suspension was then 
subjected to three cycles of centrifugation at 5000 rpm for 60 min and re-
suspension in deionized water by vortexing, followed by adjusting the pH 
of the nanosphere suspension to 7.0. The suspension was stored at 4 °C 
for further use.
2.4 Fluorescent labeling of gelatin nanospheres
GANs and GBNs were fluorescently labeled with DyLight™ 405 ester in 
blue and 650 NHS Esters in far-red, respectively, according to a standard 
protocol (ThermoFisher Scientific, Bleiswijk, the Netherlands). In brief, 200 
mg of GNs were dispersed in 20 ml of phosphate buffered saline (PBS). The 
pH of the GNs suspension was then adjusted to 7.2 by using 1M sodium 
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hydroxide solution. Thereafter, 25 μg of NHS esters were dissolved in 200 
μl of N,N dimethylformamide (Serva Electrophoresis GmbH, Heidelberg, 
Germany), and the solution was then added dropwise into the GNs 
suspensions under magnetic stirring at 400 rpm. After 1 h of reaction, the 
suspension was subjected to two cycles of centrifugation (5000 rpm for 60 
min) and re-suspension in deionized water by vortexing. The suspension 
was stored at 4 °C until further use.
2.5 Characterization of gelatin nanospheres
The size and size distribution of GNs (either with or without conjugated 
fluorescent dyes) were measured in 5 mM HEPES buffer at pH 7.0 in swollen 
state by using dynamic light scattering (DLS, Zetasizer Nano-S, Malvern 
Instruments Ltd., Worcestershire, United Kingdom). The ζ-potential of the 
GNs was examined by laser Doppler electrophoresis using a Zetasizer 
Nano-Z (Malvern Instruments Ltd., Worcestershire, United Kingdom) in the 
same HEPES buffer.
2.6 Electrospinning nanofibers containing gelatin nanospheres
2.6.1 Single nozzle electrospinning
To assist the water phase electrospinning of SF, 75 mg of PEO was dissolved 
in 3 ml of SF solution (7.5 wt%) under magnetic stirring at 120 rpm to form a 
standard batch of SF/PEO (75/25 w/w) solution. Different amounts of GBNs 
were then added into the SF/PEO solution under magnetic stirring to form 
a colloid suspension. The composition of SF/PEO/GBN colloid suspensions 
used for electrospinning is listed in Table 1. 
Group SF solution (mg/ml)
SF solution 
(ml)
PEO 
(mg)
SF/PEO/GBN 
(wt/wt)
1 75 3 75 9/3/0
2  75 3 75 9/3/0.9
3 75 3 75 9/3/3
4 75 3 75 9/3/6
Table1. Composition of antibiotic-free suspensions
For visualization of the distribution of GNs inside the nanofibers, NHS-Ester 
labeled GNs were added into the SF/PEO solution (Group 1 in Table 1) 
under magnetic stirring at 120 rpm (Figure 1, a). The weight ratios of GANs/
GBNs were varied from 75/25, 50/50 to 25/75. The weight ratio of SF/PEO/
GN was fixed at 9/3/0.45 for all the experimental groups. This ratio allowed 
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Figure 1. Schematic diagrams of the preparation of silk fibroin (SF)/poly(ethylene oxide) (PEO)/
gelatin nanosphere (GN) nanofibers by using colloid electrospinning with single (a) or co-axial (b) 
nozzles.
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Group SF/PEO/GBN (wt/wt)
GBN 
(mg)
Vancomycin 
(mg)
Vancomycin/GBN 
(wt %)
Drug/polymer 
(wt %)
V-Control 9/3/0 — 1.5 — 0.50
20 wt% GBNs 9/3/3 75 1.5 2 0.40
33 wt% GBNs 9/3/6 150 1.5 1 0.33
Table 2. Composition of vancomycin-containing suspensions
for facile monitoring of the spatial distribution of GNs inside the nanofibers 
using confocal microscopy. 
For the vancomycin-loaded groups (Table 2), vancomycin was first loaded 
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onto GBNs by mixing aqueous vancomycin solutions with GBNs suspensions 
at different vancomycin/GBN weight ratios. The vancomycin/GBN mixture 
was kept at 4 °C overnight to allow for complete absorption of vancomycin 
into GBNs.  Thereafter, this mixture was added to the silk/PEO solution to 
form the colloidal suspensions for electrospinning.
The electrospinning process was performed using a commercially available 
electrospinning set-up (Esprayer ES-2000S, Fuence Co., Ltd, Tokyo, 
Japan) with optimized conditions (Figure 1). Briefly, the prepared colloid 
suspensions were ejected at a flow rate of 20 μl/min at a voltage of 22 - 
28 kV. The distance between the spinneret and collector was fixed at 20 
cm. The obtained electrospun nanofibers were collected on an aluminum 
foil. After electrospinning, the fibrous membranes of approximately 
200 μm thick were cross-linked by water annealing overnight to induce 
β-sheet formation followed by drying at room temperature. Thereafter, the 
electrospun membranes were punched into discs with a diameter of 11.5 
mm. The samples were stored in a desiccator at room temperature until 
further use. 
2.6.2 Core-shell electrospinning
The suspension containing fluorescently labeled GANs or GBNs was added 
into the standard batch of SF/PEO solution (Group 1, Table 1) under 
magnetic stirring at 120 rpm to form a colloidal suspension. The weight 
ratio of SF/PEO/GN was kept at 9/3/0.45. Co-axial electrospinning was 
conducted in an electrospinning set-up as described previously [35] with 
minor modifications. The core-shell spinneret contained a Teflon chamber 
for the shell solution and metal chamber for the core solution. The inner 
metal chamber was connected to a 21 G needle (with inner and outer 
diameters of 0.514 and 0.820 mm, respectively) while the inner diameter 
of the shell outlet was 2 mm. A high voltage (15-18 kV) was applied onto 
the inner metal chamber. Colloidal suspensions containing GANs or GBNs 
were used as core or shell feeds, respectively (Figure 1b). These core and 
shell feeds were ejected at different flow rates controlled by syringe pumps 
(BD Scientific Inc., USA). The distance between the spinneret and collector 
was fixed at 20 cm. The obtained electrospun nanofibers were collected 
on an aluminum foil or a glass slide for further characterization. Detailed 
information on the core-shell electrospinning parameters are listed in 
Table 3. 
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2.7 Characterization of the nanofibers 
2.7.1 Microscopy
The morphology of the electrospun nanofibers was observed by scanning 
electron microscopy (SEM, JEOL 6301) at an acceleration voltage of 10 
kV with gold sputtered on the sample surfaces. The distribution of the 
GNs inside the nanofibers was examined using confocal laser scanning 
microscopy (CLSM, Olympus FV1000, Zoeterwoude, the Netherlands). 
2.7.2 FT-IR analysis
Electrospun membranes (Group 1 in Table 1) before and after cross-
linking were used for FT-IR analysis. The contribution of the different SF 
conformations to the amide I region was determined by Fourier self-
deconvolution and subsequent curve fitting according to a previously 
reported method [36]. In brief, the absorbance of each membrane was 
measured with 400 scans at a resolution of 4 cm-1 at wavenumbers 
ranging from 400 to 4000 cm-1 on an attenuated total reflectance infrared 
spectroscopy (ATR-IR, UATR two, PerkinElmer, the Netherlands). Thereafter, 
the second derivative was applied to the original spectra in the amide I 
region to check the peak positions in cm-1. The Fourier self-deconvolution 
was then performed using the PerkinElmer software. The parameters of 
deconvolution were selected based on the resolution and peak positions 
corresponding to the positions of the minima in the second derivative of the 
initial spectra. Subsequently, curve fitting was applied to the deconvoluted 
spectra with Gaussian line shape profiles to measure the relative areas of 
the amide I components. 
Group GAN suspension
GBN
suspension
SF/PEO/GBN 
(wt/wt)
Core feeding 
rate (ml/h)
shell feeding 
rate (ml/h)
Core/shell 
ratio (wt/wt)
1 Core Shell 9/3/0.45 0.4 2 1/5
2 Core Shell 9/3/0.45 0.6 1.8 1/3
3 Core Shell 9/3/0.45 1.2 1.2 1/1
4 Core Shell 9/3/0.45 1.6 0.8 1/0.5
5 Shell Core 9/3/0.45 2.0 0.4 5/1
6 Shell Core 9/3/0.45 1.8 0.6 3/1
7 Shell Core 9/3/0.45 1.2 1.2 1/1
8 Shell Core 9/3/0.45 0.8 1.6 0.5/1
Table 3. Composition of suspensions containing fluorescently labeled GNs for core-shell  elec-
trospinning
Chapter 5
110
2.8 Vancomycin release and detection
Vancomycin loaded membranes (Table 2) were used for the release study. 
The nanofibrous membrane discs weighed 10 mg and were placed into a 
1.5 ml Eppendorf® tube (n = 5) containing 1 ml PBS. The tubes were then 
incubated at 37 °C and gently shaken at 90 rpm. At each predetermined 
time point, 900 μl supernatant was collected and refreshed with PBS. The 
collected supernatant was stored at 4 °C for further analysis.
The concentration of vancomycin was detected by reverse-phase high 
performance liquid chromatography (RP-HPLC) according to a previously 
reported method [30]. A Hitachi HPLC machine was used in the present 
study. This HPLC system consisted of a Hitachi L-2130 pump, a Hitachi 
L-2400 UV detector, a Hitachi L-2200 autosampler and a LiChrospher® 
RP-18 endcapped HPLC column (125 mm × 4 mm, particle size 5 μm). 
The mobile phase consisted of ammonia phosphate buffer (50 mM, pH 
3 adjusted with H3PO4) and acetonitrile at a volume ratio of 90/10. The 
injection volume was 30 μl with a flow rate of 1 ml/min. The concentration 
of vancomycin was quantified at 196 nm using a standard calibration curve 
in the concentration range between 0.2 and 25 μg/ml.
2.9 Cytotoxicity
The electrospun membranes were sterilized under UV light for one hour and 
the cytotoxicity of the sterilized membranes was evaluated by a LDH activity 
assay following a standard protocol (ThermoFisher Scientific, Bleiswijk, the 
Netherlands). Briefly, human foreskin fibroblasts (HFFs, isolated from the 
foreskin specimens of a healthy donor by following the national guidelines 
for working with human materials) were cultured in αMEM medium 
(Gibco, Invitrogen Corp., Paisley, Scotland). The cells were trypsinized and 
reseeded onto a 48-well plate containing electrospun membrane discs at a 
seeding density of 2 × 104 cells/cm2 (Table 2, n = 5). Wells containing only 
culture medium and wells containing 2 v/v% Triton - X100 were used as 
low and high controls, respectively. Thermanox™ coverslips (ThermoFisher 
Scientific, Bleiswijk, the Netherlands) and 10% DMSO were used as positive 
and negative controls, respectively. After 24 h of incubation, a 100 µl aliquot 
of metabolized medium was transferred into a 96-well plate in duplicate, 
followed by addition of 100 µl of the freshly prepared reaction medium. The 
mixture was incubated at room temperature for 30 min. The cytotoxicity of 
the electrospun membranes was determined by measuring the activity of 
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the LDH released from the cytosol of damaged cells. The absorbance of 
the suspension was measured at a wavelength of 590 nm in a Bio-Tek® 
FL600 microplate fluorescence reader (Biotek, VT, USA). The cytotoxicity 
was calculated according to the following equation: 
                                        (experimental value-low control)
               Cytotoxicity=                                                            × 100%
                                              (high control-low control)  
2.10 Antibacterial effect
The antibacterial effect of the electrospun membranes (Table 2) was 
determined by a zone of inhibition test against S. aureus (ATCC® 25923TM, 
Manassas, USA) [18]. In brief, the isolated bacterial colonies were 
dispersed in sterile saline (0.85% NaCl w/v in water) to reach the density 
of a McFarland 0.5 standard. After dispersion, the bacterial suspension 
was diluted to a concentration of approximately 3 × 107 colony-forming 
units (CFU) per ml. Thereafter, the bacteria were inoculated by spreading 
the bacteria suspension evenly over the entire surface of an agar plate 
with a sterile cotton swab, followed by placing the electrospun membrane 
discs (n = 4) on the Muller Hinton agar plate. The radius of the zone of 
inhibition was measured from the centre point of the disc to the border 
of the inhibition zone after incubation at 36 °C for 20 h. The results were 
listed as the diameter of the inhibition zone. 
2.11 Periodontal ligament cells growth on the electrospun silk 
fibroin membranes
For the evaluation of the cytocompatibility of the SF membranes for later 
use in GTR/GBR applications, PDL cells were cultured on the electrospun 
SF membranes (Table 2). PDL cells were isolated from healthy donors with 
informed consent and cultured in Dulbecco's modified eagle medium 
(DMEM, Gibco, Invitrogen Corp., Paisley, Scotland) supplemented with 
10% fetal bovine serine and 1% penicillin/ streptomycin. The cells were 
trypsinized and reseeded onto a 48-well plate containing electrospun 
membrane discs at 2 × 104 cells/cm2 (Table 2, n = 5). The Thermanox™ 
coverslips (ThermoFisher Scientific, Bleiswijk, the Netherlands) was used as 
positive control. 
2.11.1 Live/Dead assay
The viability of PDL cells growing on the electrospun SF membranes at 
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24 h was determined by using the LIVE/DEAD® Viability/Cytotoxicity 
Kit (ThermoFisher Scientific, Bleiswijk, the Netherlands) following the 
manufacturer’s standard protocol. Briefly, the LIVE/DEAD® reagent stock 
solutions were removed from the freezer and warmed to room temperature. 
Thereafter, calcein AM and ethidium homodimer-1 (EthD-1) stock solutions 
were diluted in the DMEM culture medium at a final concentration of 2 
μM and 4 μM for calcein AM and EthD-1, respectively. Subsequently, 300 
μl of the staining solution was directly added onto the membranes. After 
30 min of incubation at 20-25°C, the membranes were washed with PBS 
and then placed on the microscope slides. Image acquisition of the PDL 
cells was performed by using CLSM (Olympus FV1000, Olympus FV1000, 
Zoeterwoude, the Netherland) with a 20× objective. 
2.11.2 Cell morphology
The morphology of the PDL cells cultured on the SF membranes was 
examined with SEM (Zeiss Sigma-300, Germany). In brief, PDL cells were 
washed with PBS and then fixed with 2 wt% glutaraldehyde in 0.1 M 
sodium-cacodylate solution for 20 min. After fixation, the PDL cells were 
washed with 0.1 M sodium-cacodylate solution for 5 min. Subsequently, 
the PDL cells were dehydrated in a graded series of ethanol (70, 80, 90 and 
96% ethanol for 5 min each, and then 100 % ethanol and 100 % water-free 
ethanol for 10 min each), followed by adding enough tetramethylsilane on 
top of samples and dried in fume hood. The samples were sputter-coated 
with 10 nm chromium and then examined under SEM.
2.12 Statistics
Statistical analyses were conducted using GraphPad Prism and all results 
were reported as mean ± standard deviation. Differences among groups 
were analyzed by one-way analysis of variance (ANOVA) followed by a Tukey 
post hoc test, and a p-value of < 0.05 was considered as a statistically 
significant difference.
3 Results 
3.1 Characterization of the electrospun fibrous membranes
Fluorescently labeled GANs and GBNs with size of approximately 400 
and 600 nm in swollen state, respectively, were prepared (Table S1). No 
significant difference in size was observed for the nanospheres before and 
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after conjugation of fluorescent dye (Table S1). Uniform and defect-free SF 
nanofibers containing negatively charged GBNs with a size of approximately 
600 nm (Table S1) in swollen state were prepared successfully (Figure 2, a-c; 
Figure 3, c and d). Although the nanofibers became less uniform in size with 
increasing amount of GBNs (Figure 2), defect-free fibers were obtained up to 
a GBNs content of 33 wt% at an SF/PEO/GBN weight ratio of 9/3/6 (Figure 2, 
d). Besides GBNs, GANs were also incorporated into the nanofibers (Figure 
3, a-b) to form a nano-in-nano fibrous composite. The distribution of the 
GANs and GBNs inside the SF nanofibers was homogeneous (Figure 3). At 
an SF/PEO/GBN weight ratio of 9/3/0.45, individual GBNs were uniformly 
arranged along the nanofibers (Figure 3, c-d).
To check the efficiency of water annealing on the SF electrospun fibrous 
membranes, we used FT-IR analysis to examine these membranes (Group 
1, Table 1) before and after water annealing. After water annealing, 
extensive strong β-sheet formation was observed as reflected by a stretch 
vibration at 1625 cm-1 [36] (Figure 4, a). Weak β-sheet formation was 
observed as indicated by a stretch vibration at 1697 cm-1 [36] (Figure 4, a). 
In the spectra of uncross-linked membranes, however, we only observed a 
stretch vibration at 1646 cm-1 attributing to the random coil conformation 
[36] (Figure 4, a and d). To investigate the conformational changes of SF 
in more detail, Fourier self-deconvolution to the original spectra were 
Figure 2. Scanning electronic micrographs of electrospun nanofibers containing gelatin B nano-
spheres (GBNs) at SF/PEO/GBN weight ratios of 9/3/0 (a), 9/3/0.9 (b), 9/3/3 (c) and 9/3/6 (d). Scale 
bars represent 4 µm.
a b c d
Figure 3. Confocal laser scanning micrographs of nanofibers containing gelatin A nanospheres 
(labeled blue, a-b) or gelatin B nanospheres (labeled red, c-d) at an SF/PEO/GN weight ratio of 
9/3/0.45. Figure (b) and (d) are magnified pictures from the framed areas in (a) and (c), respec-
tively. Scale bars represent 10 µm in (a) and (c) and 1 µm in (b) and (d).
a b c d
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performed, followed by curve fitting using Gaussian line shape profiles 
(Figure4, b-c). The conformation of approximately 50.01% of the silk fibroin 
was strong intermolecular β-sheet, which was induced from random coils 
and intramolecular β-sheet by cross-linking (Figure 4, b-d). In addition, 
around 3.39% of silk fibroin was induced to weak β-sheet (Figure 4, b-d).
Figure 4. FT-IR analysis of SF/PEO nanofibers before and after water annealing. Original FT-IR 
absorbance spectra of the amide I region between 1720 and 1580 cm-1 (a). Fractions distribution 
(blue dashed lines) of different SF conformations in the amide I region before (b) and after (c) 
cross-linking, red dashed lines are the fitted curve. Contribution of different conformations of silk 
fibroin (d).
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3.2 Spatial distribution of gelatin nanospheres: single-nozzle 
electrospinning
SF nanofibers containing oppositely charged GANs and GBNs (Table S1) 
were fabricated by a simple single-nozzle electrospinning technique (Figure 
5, g-i). To explore the possibility to control the distribution of oppositely 
charged GANs and GBNs inside electrospun SF membranes, GANs and 
GBNs were added into the SF/PEO solution at different weight ratios. The 
distribution of GANs (Figure 5, a-c) and GBNs (Figure 5, d-f) inside the 
nanofibers was clearly homogeneous, while the amount of GANs or GBNs 
inside the nanofibers correlated with their initial amount in the SF/PEO/GN 
colloidal suspensions (Figure 5, a-f). At a GAN/GBN weight ratio of 50/50, an 
equal distribution of GANs and GBNs was observed without overlap of the 
nanospheres (Figure 5, h). 
This excellent control over the spatial distribution of GANs and GBNs was, 
however, only possible at low amounts of GANs and GBNs in the SF/PEO/
GN colloidal suspensions. By increasing the amount of GNs to a SF/PEO/
GAN/GBN weight ratio of 9/3/3/3, flocculation was observed with obvious 
phase separation (arrow in Figure S1) which hindered electrospinning. 
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3.3 Spatial organization of gelatin nanospheres: core-shell 
electrospinning
Figure 5. Confocal laser scanning micrographs of single-nozzle electrospinning of SF nanofibers 
containing both gelatin A and B nanospheres (GANs and GBNs) at an SF/PEO/GN weight ratio of 
9/3/0.45. The weight ratios of GAN/GBN are 25/75 (a, d and g), 50/50 (b, e and h) and 75/25 (c, 
f and i). GANs are labeled blue (a-c) and GBNs are labeled red (d-f). Scale bars represent 10 µm.
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Figure 6. Confocal laser scanning micrographs of core-shell electrospinning of SF nanofibers con-
taining gelatin A and B nanospheres (GANs and GBNs) at an SF/PEO/GN weight ratio of 9/3/0.45. 
The shell (GBNs solution)/core (GANs solution) feeding rate was 5/1 (a, e and i), 3/1 (b, f and j), 
1/1 (c, g and k) and 0.5/1 (d, h and i), respectively. GANs are labeled blue (a-d) and GBNs are 
labeled red (e-h). Scale bars represent 10 µm.
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To prepare the SF nanofibers with high amounts of GANs and GBNs, we 
used a core-shell electrospinning technique. The electrospinning process 
was stable up to an SF/PEO/GN weight ratio of 9/3/3 (20 wt% of GNs to 
polymer). The distribution of these high amounts of GANs and GBNs in the 
nanofibers could, however, not be monitored using CLSM. Therefore, we 
fixed the SF/PEO/GN weight ratio at 9/3/0.45 when electrospinning colloidal 
suspensions containing GANs or GBNs as core or shell solutions to allow 
for CLSM observation. SF nanofibers containing both GANs and GBNs were 
obtained using core-shell electrospinning with GANs and GBNs as core and 
shell suspensions, respectively (Figure 6). The amount of GANs and GBNs 
inside the nanofibers was correlated to the feeding ratio between core 
and shell suspensions (Figure 6, a-h). Identical results were obtained when 
using colloid suspensions containing GANs and GBNs as shell and core 
suspensions, respectively (Figure S2).
3.4 Release of vancomycin from electrospun silk fibroin 
nanofibrous membranes 
To test our hypothesis that the incorporation of GNs into the nanofibers 
would improve the release kinetics of biomolecules, vancomycin-loaded 
GBNs were electrospun into the SF nanofibers and monitored the release 
kinetics of vancomycin by means of 
HPLC. Burst release of vancomycin 
was observed on the first day for 
both samples with and without 
the presence of GBNs (Figure 7, 
a). In contrast, sustained release 
of vancomycin was observed for 
more than 14 days for membranes 
containing GBNs (Figure 7, b). The 
released amounts of vancomycin 
from membranes containing 20 wt% 
vs. 33 wt% of GBNs were statistically 
insignificant (Figure 7, b). Figure 7. Cumulative release of vancomycin 
from silk fibroin nanofibers containing vancomycin without GBNs (Control), vancomycin with 20 
and 33 wt% of GBNs until 1 day (a) and from day 2 to day 14 (b).
3.5 Cytotoxicity
The cytotoxicity of the electrospun SF nanofibrous membranes was 
Electrospun Silk/Gelatin Nanospheres Nanofibrous Delivery System
117
5
determined by a LDH activity 
assay as shown in Figure 8. These 
results indicated that none of the 
electrospun SF membranes was 
cytotoxic. No significant differences 
were observed among the various 
electrospun membranes. 
3.6 Antibacterial effect
A zone of inhibition test was used to 
determine the antibacterial effects 
of the various SF nanofibrous 
membranes. An obvious inhibition 
zone was observed for all the 
membranes loaded with vancomycin 
(Figure 9, b-d). The zones of inhibition were significantly different for 
membrane samples with or without the presence of GBNs (Figure 9, e). The 
diameter of the inhibition zone was correlated to the weight percentage of 
vancomycin loaded inside the membranes (Table 2; Figure 9, e). 
Figure 8. Cytotoxicity of silk fibroin nano-
fibrous membranes containing different 
amounts of gelatin B nanospheres (GBNs) 
loaded with vancomycin. * p < 0.05, *** p 
< 0.001.
Figure 9. Zone of inhibition test against Staphylococcus aureus. Optical images of the inhibition 
zones surrounding electrospun silk fibroin membranes containing neither gelatin B nanospheres 
(GBNs) nor vancomycin (a, control), membranes containing only vancomycin (b, V-control), 
membranes containing 20 (c) and 33 wt% (d) of GBNs loaded with vancomycin.
a b c d e
3.7 Viability of periodontal ligament cells on silk fibroin 
nanofibrous membranes
To explore the potential of the SF nanofibrous membranes for GBR/
GTR applications, PDL cells were cultured on the membranes containing 
different amounts of GBNs. A live/dead assay was performed to evaluate 
the viabilities of the PDL cells, which revealed that the majority of the 
cells were alive on all membranes (Figure 10, a-c, live cells were stained 
green while dead cells were stained red). Spreading of the PDL cells on 
the membranes containing GBNs was clearly observed using electron 
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microscopy (Figure 10, b-c), while spherical cell clusters were observed 
on membranes without GBNs (Figure 10, a). Additionally, the mechanical 
integrity and fibrous structure of the membranes were retained after 48 h 
of cell culture (Figure 10, d-f). SEM characterization of the cell attachment 
also confirmed that PDL cells adhered and spread only on membranes 
containing GBNs after 48 h of cell culture (Figure 10, e-f).
Discussion
The aim of present study was to develop an electrospun nanofibrous SF-
based drug delivery system for the controlled release of biomolecules. 
To this end, GNs were added into SF/PEO solutions to form colloidal 
suspensions for electrospinning. Defect-free nanofibers containing GNs 
were successfully prepared (Figure 2 and 3) with a GNs content of up to 
33 wt% (Figure 2, d). This result demonstrated that electrospinning is a 
powerful method to prepare nano-in-nano structures [34, 37]. 
Prior to colloidal electrospinning, GNs were dispersed into aqueous SF 
solutions as vehicles for drug delivery while the SF solution was used as 
fiber-forming template [34]. Inflammable and toxic organic solvents were 
not used, which is in line with the concept of green electrospinning [38, 
Figure 10. Confocal laser scanning micrographs (a-c) and scanning electron micrographs (d-f) of 
periodontal ligament cells cultured on membranes without GBNs (Control, a, d), with 20 (b, e) 
and 33 wt% (c, f) of GBNs. Viabilities of PDL cells were evaluated by live/dead staining after 24 h 
culture (a-c) where live and dead cells were stained green and red, respectively. The morphology 
of the PDL cells was examined after 48 h culture (d-f). Scale bars represent 100 µm in (a-c) and 
20 µm in (d-f).
d
24h
48h
e f
Control 20 wt% GBNs 33 wt% GBNs
a b c
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39]. At low amounts of GNs in the colloidal suspension, the GNs could be 
dispersed without substantial aggregation (Figure 3). Uniform and defect-
free fibers were obtained with SF/PEO/GNs weight ratios equal to or lower 
than 9/3/3 (Figure 2, b-c). With increasing the amount of GNs to SF/PEO/
GNs weight ratio of 9/3/6, fibers became less uniform (Figure 2, d) which 
may be caused by the aggregation of GNs. 
After electrospinning, water annealing was used to induce cross-linking by 
β-sheet formation [36] inside the nanofibers to ensure both mechanical and 
chemical stability of the nanofibrous membranes. This process effectively 
induced the conformation change of the silk fibroin with 30.31% of strong 
β-sheets formation (Figure 4, b-d) from random coils and weak β-sheets. 
The mechanical integrity of the nanofibrous membranes was conserved 
after water annealing (Figure S3), and this integrity was also maintained 
after the membranes were placed into the PBS medium for 14 days of 
release of loaded drugs (Figure S4). 
Using the electrospinning technique as presented herein, oppositely 
charged GANs and GBNs were incorporated into SF nanofibers by means 
of single-nozzle without any substantial aggregation (Figure 5). In addition, 
this technique allowed control over the spatial distribution of the GNs in 
a straightforward manner. The distribution of GANs and GBNs inside the 
nanofibers was fine-tuned by adjusting the weight ratio between GANs and 
GBNs (Figure 5). Single-nozzle electrospinning was, however, not suitable for 
solutions containing high amounts of oppositely charged GANs and GBNs 
due to agglomeration of GANs and GBNs (Figure S1). This problem was 
overcome by using a co-axial electrospinning method, which guaranteed 
that agglomeration of GNs could be avoided since suspensions containing 
GANs and GBNs were only mixed at the tip of the nozzle. By adjusting the 
feeding ratios between core and shell suspensions, the distribution of 
GANs and GBNs could be easily manipulated in an efficient way (Figure 6). 
These results indicated that the colloidal electrospinning technique was a 
straightforward and effective strategy to confine GNs drug carriers at the 
nanoscale in nanofibrous membranes. 
Although SF nanofibers have been widely used as drug delivery vehicles 
for e.g., GTR/GBR [26, 27], the release of biomolecules from these carriers/
membranes is generally based on diffusion and consequently difficult to 
control due to a lack of interaction between the biomolecules and SF [25]. 
Herein, we hypothesized that this problem could be solved by incorporating 
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GNs as drug delivery vehicles into SF nanofibers. 
To test our hypothesis, we electrospun SF nanofibrous membranes 
containing vancomycin-loaded GBNs by means of colloidal electrospinning 
(Table 2). Release of vancomycin from nanofibrous membranes containing 
GBNs was more sustained after the initial burst release compared to 
GBNs-free membranes (Figure 7). These results indicated that the GBNs 
were capable of prolonging the release of vancomycin due to the formation 
of interactions between vancomycin and GBNs as observed previously 
[30]. Nevertheless, only limited amounts of vancomycin can be bound 
onto GBNs to achieve a sustained release without any burst [30]. The 
amount of vancomycin loading in the present study (Table 2) surpassed 
the vancomycin-binding capability of GBNs, which in turn induced the 
burst release of vancomycin in the first day. To investigate the influence of 
the amount of GBNs on the release of vancomycin, we incorporated the 
same amount of vancomycin into the membranes with different amount 
of GBNs (Table 2). The release of vancomycin from membranes containing 
different amounts of GBNs was, however, statistically insignificant. This 
may be caused by the dissolution of PEO from the fibers. With more GBNs 
inside the nanofibers, the PEO was dissolved faster (Figure S4, d-f) since 
the SF/PEO layer was thinner as compared to nanofibers containing less 
GBNs. The disappearance of PEO in turn accelerated the exposure of 
GBNs to the medium, which resulted in the acceleration of vancomycin 
release. Consequently, the capability of the GBNs for the sustained release 
of vancomycin was comprised by the fast dissolution of PEO from the 
nanofibers. 
The cytotoxicity test confirmed the excellent cytocompatibility of the 
vancomycin-loaded SF nanofibrous membranes (Figure 8). Additionally, the 
antibacterial efficacy of these membranes was confirmed since the release 
of vancomycin led to distinct inhibition zones (Figure 9, b-e). The diameter 
of the inhibition zone was correlated to the amount of the vancomycin 
released from the nanofibrous membranes (Figure 7, a; Figure 9, e). The 
amount of burst release of vancomycin in the first day decreased in the 
same order as the original weight percentage of vancomycin relative to the 
polymer content, i.e., V-control > 20 wt% GBNs > 33 wt% GBNs was in the 
same decreasing order (Figure 7, a; Table 2). 
The cytocompatibility of the SF nanofibrous membranes was confirmed by 
direct culture of PDL cells onto the membranes. Most PDL cells were alive 
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after 24 h of cell culture on these membranes (Figure 10, a-c). In addition, 
the PDL cells attached and spread only on the membranes containing 
GBNs (Figure 10, b-c and e-f), which confirmed the added value of the 
incorporation of GBNs into the nanofibers. The GBNs contain cell recognition 
sites such as Arg-Gly-Asp (RGD) peptide sequences which modulate cell 
adhesion [28]. Upon dissolution of the PEO from the nanofibers, the GBNs 
became exposed and presented cell binding sites, thereby facilitating the 
attachment and spreading of the PDL cells. 
Conclusion
Novel silk fibroin nanofibrous membranes containing gelatin nanospheres 
with a nano-in-nano structure were successfully fabricated. Both 
oppositely charged gelatin A and B nanospheres were incorporated into 
the nanofibers. The distribution of gelatin A and B nanospheres could 
be fine-tuned at the nanoscale by adjustment of either the weight ratio 
between the nanospheres by using single nozzle electrospinning, or the 
relative feeding rate of core and shell solutions by using co-axial nozzle 
electrospinning. A more sustained release of vancomycin was achieved 
from membranes containing gelatin B nanospheres inside the nanofibrous 
membranes as compared to the nanosphere-free membranes. These 
membranes were highly cytocompatible and exhibited antibacterial effects 
against Staphylococcus aureus. Additionally, these membranes supported 
the attachment and spreading of periodontal ligament cells. These results 
indicate that the nano-in-nano fibrous silk fibroin membranes containing 
gelatin nanospheres are promising candidates to control the release of 
(multiple) bioactive molecules.
Acknowledgement
Jiankang Song was financially supported by the Chinese Scholarship Council 
under foundation number 201206150058. The authors would like to thank 
Carla J.M. Bartels for her help with the antibacterial test, Dr. Luis Cordero 
for his help with surface roughness characterization.
 
Chapter 5
122
References
1. Ji, W., et al., Local delivery of small and large biomolecules in craniomaxillofacial bone. Adv 
Drug Deliv Rev, 2012. 64(12): p. 1152-64.
2. Kim, Y.-H. and Y. Tabata, Dual-controlled release system of drugs for bone regeneration. 
Adv Drug Deliv Rev, 2015. 94: p. 28-40.
3. Pérez, R.A., et al., Naturally and synthetic smart composite biomaterials for tissue 
regeneration. Adv Drug Deliv Rev, 2013. 65(4): p. 471-496.
4. Stebbins, N.D., M.A. Ouimet, and K.E. Uhrich, Antibiotic-containing polymers for localized, 
sustained drug delivery. Adv Drug Deliv Rev, 2014. 78: p. 77-87.
5. Xiong, M.-H., et al., Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev, 
2014. 78: p. 63-76.
6. Bongio, M., et al., Development of bone substitute materials: from 'biocompatible' to 
'instructive'. J Mater Chem, 2010. 20(40): p. 8747-8759.
7. Mottaghitalab, F., et al., Silk fibroin nanoparticle as a novel drug delivery system. J Control 
Release, 2015. 206: p. 161-76.
8. Mallick, S. and J.S. Choi, Liposomes: versatile and biocompatible nanovesicles for efficient 
biomolecules delivery. J Nanosci Nanotechnol, 2014. 14(1): p. 755-65.
9. Monteiro, N., et al., Liposomes in tissue engineering and regenerative medicine. J R Soc 
Interface, 2014. 11(101): p. 20140459.
10. Silva, A.C., et al., Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, 
Microemulsions and Dendrimers. Curr Pharm Biotechnol, 2015. 16(11): p. 955-65.
11. Brunetti, V., L.M. Bouchet, and M.C. Strumia, Nanoparticle-cored dendrimers: functional 
hybrid nanocomposites as a new platform for drug delivery systems. Nanoscale, 2015. 
7(9): p. 3808-16.
12. Wang, H., et al., Stimuli-responsive dendrimers in drug delivery. Biomater Sci, 2016. 4(3): 
p. 375-90.
13. Cho, H., J. Gao, and G.S. Kwon, PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for 
drug delivery. J Control Release, 2015.
14. De Jong, W.H. and P.J. Borm, Drug delivery and nanoparticles:applications and hazards. 
Int J Nanomedicine, 2008. 3(2): p. 133-49.
15. Wilczewska, A.Z., et al., Nanoparticles as drug delivery systems. Pharmacol Rep, 2012. 
64(5): p. 1020-37.
16. Hu, X., et al., Electrospinning of polymeric nanofibers for drug delivery applications. J 
Control Release, 2014. 185: p. 12-21.
17. Chou, S.F., D. Carson, and K.A. Woodrow, Current strategies for sustaining drug release 
from electrospun nanofibers. J Control Release, 2015. 220(Pt B): p. 584-91.
18. Song, J., et al., Antibacterial effects of electrospun chitosan/poly(ethylene oxide) 
nanofibrous membranes loaded with chlorhexidine and silver. Nanomedicine, 2016.
19. Vepari, C. and D.L. Kaplan, Silk as a Biomaterial. Prog Polym Sci, 2007. 32(8-9): p. 991-
1007.
20. Rockwood, D.N., et al., Materials fabrication from Bombyx mori silk fibroin. Nat Protoc, 
2011. 6(10): p. 1612-31.
21. Hopkins, A.M., et al., Silk Hydrogels as Soft Substrates for Neural Tissue Engineering. Adv 
Funct Mater, 2013. 23(41): p. 5140-5149.
22. Pritchard, E.M., et al., Antibiotic-Releasing Silk Biomaterials for Infection Prevention and 
Electrospun Silk/Gelatin Nanospheres Nanofibrous Delivery System
123
5
Treatment. Adv Funct Mater, 2013. 23(7): p. 854-861.
23. Han, H., et al., Silk Biomaterials with Vascularization Capacity. Advanced Functional 
Materials, 2016. 26(3): p. 421-432.
24. Wenk, E., H.P. Merkle, and L. Meinel, Silk fibroin as a vehicle for drug delivery applications. 
J Control Release, 2011. 150(2): p. 128-141.
25. Yucel, T., M.L. Lovett, and D.L. Kaplan, Silk-based biomaterials for sustained drug delivery. 
J Control Release, 2014. 190: p. 381-397.
26. Kim, K.-H., et al., Biological efficacy of silk fibroin nanofiber membranes for guided bone 
regeneration. J Biotechnol, 2005. 120(3): p. 327-339.
27. Lu, S., et al., A novel silk fibroin nanofibrous membrane for guided bone regeneration: a 
study in rat calvarial defects. Am J Transl Res, 2015. 7(11): p. 2244-2253.
28. Wang, H., et al., Oppositely charged gelatin nanospheres as building blocks for injectable 
and biodegradable gels. Adv Mater, 2011. 23(12): p. H119-24.
29. Song, J. and S.C. Leeuwenburgh, Sustained delivery of biomolecules from gelatin carriers 
for applications in bone regeneration. Ther Deliv, 2014. 5(8): p. 943-58.
30. Song, J., et al., Influence of the Molecular Weight and Charge of Antibiotics on Their 
Release Kinetics From Gelatin Nanospheres. Macromol Biosci, 2015. 15(7): p. 901-11.
31. van der Stok, J., et al., Enhanced bone regeneration of cortical segmental bone defects 
using porous titanium scaffolds incorporated with colloidal gelatin gels for time- and 
dose-controlled delivery of dual growth factors. Tissue Eng Part A, 2013. 19(23-24): p. 
2605-14.
32. Ishikawa, H., et al., Gelatin nanospheres incorporating siRNA for controlled intracellular 
release. Biomaterials, 2012. 33(35): p. 9097-104.
33. Song, J., et al., Electrophoretic deposition of chitosan coatings modified with gelatin 
nanospheres to tune the release of antibiotics. ACS Appl Mater Interfaces, 2016.
34. Crespy, D., K. Friedemann, and A.M. Popa, Colloid-electrospinning: fabrication of 
multicompartment nanofibers by the electrospinning of organic or/and inorganic 
dispersions and emulsions. Macromol Rapid Commun, 2012. 33(23): p. 1978-95.
35. Yang, F., J.G.C. Wolke, and J.A. Jansen, Biomimetic calcium phosphate coating on 
electrospun poly(ε-caprolactone) scaffolds for bone tissue engineering. Chem Eng J, 
2008. 137(1): p. 154-161.
36. Hu, X., D. Kaplan, and P. Cebe, Determining Beta-Sheet Crystallinity in Fibrous Proteins 
by Thermal Analysis and Infrared Spectroscopy. Macromolecules, 2006. 39(18): p. 6161-
6170.
37. Zhang, C.-L. and S.-H. Yu, Nanoparticles meet electrospinning: recent advances and 
future prospects. Chem Soc Rev, 2014. 43(13): p. 4423-4448.
38. Sun, J., et al., Nanofibers by green electrospinning of aqueous suspensions of 
biodegradable block copolyesters for applications in medicine, pharmacy and agriculture. 
Macromol Rapid Commun, 2010. 31(23): p. 2077-83.
39. Agarwal, S. and A. Greiner, On the way to clean and safe electrospinning—green 
electrospinning: emulsion and suspension electrospinning. Polym Adv Technol, 2011. 
22(3): p. 372-378.
Chapter 5
124
Supplementary information
Table S1. Parameters of gelatin nanospheres in the swollen state
Parameters
Gelatin A Gelatin B
No dye NHS-405 labeled   No dye NHS-650 labeled
Particle size (nm) 400 ± 5 390 ± 2 613 ± 7 619 ± 4
ζ-potential (mV) 11.80 ± 0.49 -1.67 ± 0.08 -24.40 ± 0.30 -20.70 ± 0.50
Figure S1. Optical images of silk fibroin (SF)/gelatin nanospheres (GANs and GBNs) colloid sus-
pensions at SF/PEO/GBNs of 9/3/6 (a) and SF/PEO/GANs/GBNs of 9/3/3/3. Arrow indicates the 
phase separation between silk fibroin and gelatin nanospheres.
a b
Figure S2. Confocal laser scanning micrographs of core-shell electrospinning of silk fibroin nano-
fibers containing gelatin A and B nanospheres (GANs and GBNs, in shell and core, respectively) at 
silk fibroin:PEO:gelatin nanospheres weight ratio of 9:3:0.45 with core:shell feeding rate of 1:5 
(a, e and i), 1:3 (b, f and j), 1:1 (c, g and k) and 0.5:1 (d, h and i), respectively. GANs are labeled 
blue (a, b, c and d) and GBNs are labeled red (e, f, g and h). Scale bars represent 10 µm.
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Figure S3. Scanning electronic micrographs of electrospun silk fibroin (SF) nanofibers without 
gelatin B nanospheres after water annealing.
4 μm
Figure S4. Scanning electronic micrographs of cross-linked electrospun silk fibroin (SF) nanofibers 
without GBNs (a, d), with 20 (b, e) and 33 wt% (c, f) of GBNs after 14 days of vancomycin release 
in PBS. Scale bars represent 4 µm in (a-c) and 800 nm in (d-f). 
a b c
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1 Introduction
Gelatin and gelatin-based materials have been widely used in the field 
of regenerative medicine due to their biodegradability, biocompatibility, 
and cost-effectiveness [1-4]. Gelatin nanospheres (GNs) are particularly 
interesting in view of their advantageous features for regenerative medicine 
and drug delivery [5-7].
First of all, the charged nature of GNs renders them suitable for controlled 
delivery of oppositely charged bioactive macromolecules such as growth 
factors [5, 8, 9] and nucleic acids [10, 11]. Beside macromolecules, GNs 
were shown to facilitate delivery of small biomolecules such as vancomycin 
and colistin in a sustained manner resulting from the formation of 
electrostatic and hydrophobic bonds between GNs and the specific drugs 
[12]. Moreover, the degradation profile of GNs can be easily fine-tuned 
by simple adjustment of the cross-linking density during their preparation 
[5, 9, 12, 13]. Furthermore, GNs can be chemically modified using various 
functional groups such as targeting-ligands owing to their proteinaceous 
nature. This modification provides the possibility for targeted delivery of 
biomolecules [6, 14]. 
The clinical applicability of GNs is, however, debated due to the potentially 
harmful effects of GNs related to the animal origin of gelatin [6, 15]. 
Although gelatin has been clinically applied as a plasma expander for 
several decades, retrospective analyses from observational studies found 
that the use of gelatin was associated with an increased renal impairment 
for patients with severe sepsis [16]. Therefore, preclinical evaluation of GNs 
in animal models is crucial before the clinical translation of GNs can be 
considered. 
Although in vivo studies regarding the use of GNs for bone tissue 
regeneration have been reported previously [8, 9], real-time tracking of the 
GNs inside animals and monitoring of the host response to GNs is not 
yet possible. A clear understanding of the spatial distribution of GNs upon 
injection into various types of tissues is of critical importance since this 
distribution determines the final clinical applicability of the GNs. Currently, 
no suitable animal model which would allow combined real-time tracking of 
GNs and monitoring of the host response to GNs is available. 
Because of their tractable genetic and embryologic characteristics [17], 
zebrafish (Danio rerio) have been used since the 1970s as a powerful 
Chapter 6
130
model in biomedical research for drug screening [18-20], translational 
neuroscience [21, 22], physiological analysis [23, 24], infection biology [25] 
as well as evaluation of nanocarriers for drug delivery [26, 27]. The zebrafish 
embryo has fully functional organs and a strong physiological and genetic 
homology to mammals [17, 22] e.g. with respective to their innate immune 
system which is mainly comprised of neutrophils and macrophages at 3 d 
post fertilization [28]. These unique characteristics enable the evaluation 
of GNs with zebrafish embryo alternatives instead of mammalian models, 
which is in line with ethical requirements related to reducing, replacing or 
refining animal experiments [18]. In addition, the high fecundity, external 
fertilization and rapid development of zebrafish embryos render them cost- 
and space-effective for in vivo research [22, 29], and even allows medium to 
high throughput analyses [25, 30]. Moreover, transgenic zebrafish lines that 
express green fluorescent proteins (GFP) under control of a macrophage-
specific promoter (e.g., the macrophage expressed gene 1 (mpeg1) 
promoter [31]) allow the in vivo real-time visualization and detailed analysis 
of macrophage responses to GNs in transparent zebrafish embryos until 7 
d post fertilization [32]. Consequently, the zebrafish embryo holds strong 
promise as animal model for the in vivo evaluation of GNs. 
The aim of this study was to perform a preclinical real-time evaluation of 
GNs in a transgenic zebrafish model with GFP-expressing macrophages. To 
this end, we labeled GNs fluorescently with a far-red dye to allow for their 
visualization within the zebrafish embryo. Subsequently, we injected the 
labeled GNs suspension into either the blood stream or muscle tissue of 
3-day-old zebrafish embryos by micro-injection. We hypothesized that this 
model would allow for real-time visualization of the distribution of GNs inside 
the zebrafish and monitoring of the interactions between macrophages 
and GNs by using confocal laser scanning microscopy (CLSM). 
2 Materials and Methods
2.1 Materials 
Gelatin type B (from bovine skin, 225 bloom, isoelectric point (IEP) ~ 
5) was purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
Glutaraldehyde (25 wt% solution in water) was purchased from Acros 
Organics (Geel, Belgium). DyLight™ 650 NHS Esters were purchased from 
ThermoFisher Scientific (Bleiswijk, the Netherlands). All other chemicals 
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were purchased from Sigma-Aldrich. The zebrafish embryo medium (E3 
medium) was home made. 
2.2 Preparation of gelatin nanospheres
GNs were prepared by a two-step desolvation method [12]. Briefly, 1.25 g of 
gelatin was added to 25 ml deionized water to form a 5 w/v% solution at 50 °C 
under magnetic stirring. Twentyfive ml of acetone was subsequently added 
to precipitate the high molecular weight gelatin chains. After precipitation, 
the supernatant was discarded and the gelatin was re-dissolved in water 
at 50 °C. Thereafter, the pH value of the gelatin solution was adjusted to 
2.5, followed by addition of 80 ml of acetone at a constant rate of 4 ml/min 
under a stirring speed of 1200 rpm to form GNs. Subsequently, the GNs 
were cross-linked by addition of 740 μl of 25 wt% glutaraldehyde. After 16 h 
of reaction, the cross-linking process was stopped by adding 105 ml of 100 
mM glycine solution. The suspension was centrifuged subsequently at 5000 
rpm for 60 min and re-suspended in deionized water by vortexing. After 3 
cycles of washing, the GNs suspension was stored at 4 °C until further use.
2.3 Fluorescent labeling of gelatin nanospheres
To trace the GNs inside the zebrafish, the GNs were fluorescently labeled 
with a far-red dye by DyLight™ 650 NHS esters according to a standard 
protocol (ThermoFisher Scientific, Bleiswijk, the Netherlands). Briefly, 200 
mg of GNs were dispersed in 20 ml of phosphate buffered saline (PBS), 
followed by adjustment of the pH of the GNs suspension to 7.2 using 1M 
sodium hydroxide solution. Thereafter, 50 μg of NHS ester were dissolved 
in 200 μl of N,N-dimethylformamide (Serva Electrophoresis GmbH, 
Heidelberg, Germany). The NHS ester solution was then added dropwise 
to the GNs suspension under magnetic stirring at 400 rpm. After one hour 
of reaction, the suspension was centrifuged at 5000 rpm for 60 min and 
re-suspended in deionized water by vortexing. The suspension was stored 
at 4 °C until further use. 
2.4 Characterizations of gelatin nanospheres
The morphology of the GNs before and after fluorescent labeling was 
characterized by scanning electron microscopy (SEM, LEO 435 VP Zeiss, 
Germany). The size and size distribution of GNs in swollen state before 
and after fluorescent labeling were measured in HEPES (5 mM, pH 7.0) and 
PBS (154 mM, pH 7.4) by means of dynamic light scattering (DLS, Zetasizer 
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Nano-S, Malvern Instruments Ltd., Worcestershire, United Kingdom). The 
ζ-potential of GNs was examined by laser Doppler electrophoresis with 
a Zetasizer Nano-Z (Malvern Instruments Ltd., Worcestershire, United 
Kingdom) in the same HEPES and PBS buffer. 
2.5 Zebrafish husbandry
The zebrafish embryos used in this study were produced by the transgenic 
line Mpeg1:Kaede. Macrophages of these embryos are fluorescent due to 
the expression of GFP. The embryos were maintained in E3 medium and 
kept in an incubator (VWR Incu-line, Amsterdam, the Netherlands) at 28.5 
°C. E3 medium was refreshed and dead embryos were removed every day. 
All experiments with zebrafish embryos were conducted in agreement with 
the local animal welfare regulations (European Union Council Guidelines 
86/609/EU).
2.6 Micro-injection of the gelatin nanospheres
Fluorescently labeled GNs were suspended in deionized water at a 
concentration of 18 mg/ml for the micro-injection into zebrafish embryos. 
The GNs suspension was vortexed for 1 min before administration to 
zebrafish embryos. The zebrafish embryos with fluorescent macrophages 
were first selected using a fluorescent stereo microscope (Leica M205 
FA, Eindhoven, the Netherlands). These embryos were subsequently 
anesthetized with 0.03% tricaine (buffered 3 aminobenzoic acid ethyl ester, 
Sigma-Aldrich, Zwijndrecht, the Netherlands) and aligned in the U-shape 
grooves in an agarose plate casted with a specific mold. GNs were injected 
into either the blood stream via the duct of curvier or the tail muscle tissue 
of mpeg 1:Kaede zebrafish embryos at 3 d post fertilization using a glass 
capillary (Harvard Apparatus, Holliston, MA). The outer diameter of the 
openings of all glass capillaries was adjusted to a size of approximately 15 
μm under the light microscope (Leica M50, Eindhoven, the Netherlands), 
leading to an injection volume of approximately 3 nl of the GNs suspension. 
The same volume of nanosphere-free PBS was injected into muscle tissue 
as control. Injections were performed with an Eppendorf FemtoJet. A light 
microscope was used to monitor the injection procedure. 
2.7 Confocal imaging of the gelatin nanospheres and 
macrophages
To observe the distribution of GNs and the response of macrophages to 
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the GNs in the zebrafish embryos, we used CLSM (Leica DMI6000 inverted 
microscope, mounted with the Leica TCS SP8 SMD, Eindhoven, the 
Netherlands) to monitor the GNs and fluorescently labeled macrophages 
after 3 h and 24 h post injection. For imaging, the zebrafish embryos were 
first anesthetized with 0.03% tricaine (Sigma-Aldrich, Zwijndrecht, the 
Netherlands). Subsequently, they were placed in a glass-bottom culture 
dish (35 mm, MatTek Corporation, Ashland, USA) filled with low melting 
point agarose. After hardening of the agarose, E3 medium was added to 
cover the agarose with the embryo entirely and a water lens was used for 
visualization. 
Since the fluorescent Kaede protein expressed in macrophages of this 
zebrafish line was reported to undergo an irreversible photoconversion 
from green to red fluorescence upon UV illumination (350 - 400 nm) [33, 
34]. We used a filter at wavelength of 504-555nm to observe macrophages 
and a filter at wavelength of 659-764 nm to observe GNs. By using these 
two filters, the color conversion of the Kaede protein did not impede 
visualization of the macrophages in the zebrafish since no far-red signals 
was observed at the injection site (Figure S1, d and f).
2.8 In vitro macrophage culture studies 
THP-1 derived macrophages were cultured in the presence of GNs to 
monitor the in vitro cellular internalization of GNs. Briefly, THP-1 human 
monocytic cells were cultured in RPMI 1640 medium (Gibco™, Fisher 
Scientific, Paisley, Scotland) supplemented with 10% fetal bovine serum, 
100 U/ml penicillin and 100 μg/mL streptomycin at 37 °C in a 5% CO2 and 
95% air environment. The cells were seeded on Thermanox coverslips 
(ThermoFisher Scientific, Bleiswijk, the Netherlands) at a cell density of 2.5 × 
105 cells/cm2. Phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich, Saint 
Louis, USA) was then added at a final concentration of 50 ng/ml to generate 
macrophages. After 48 h of culture, fluorescently labeled GNs were added 
to the medium (at a concentration of 180 μg/ml). Macrophages were further 
incubated with the GNs for 5 h and 24 h. After incubation, Cell-Tracker™ 
CMFDA green (ThermoFisher Scientific, Bleiswijk, the Netherlands), staining 
the cell cytoplasm, was added at a concentration of 10 μM. After 30 min 
of incubation, the cells were washed 3 times with PBS and fixed with 4% 
paraformaldehyde. Thereafter, DNA/nuclei of these cells were stained 
with 4',6-diamidin-2-phenylindol (DAPI, Roche Applied Science, Mannheim, 
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Germany) and the cells were mounted with ProLong® Diamond Antifade 
Mountant (ThermoFisher Scientific, Bleiswijk, the Netherlands) for imaging. 
3 Results
3.1 Characterization of fluorescently labeled gelatin 
nanospheres
Fluorescent labeling of GNs did 
not affect the morphology of the 
nanospheres (Figure 1), while their 
size in swollen state in PBS buffer 
increased slightly from 329 to 387 
nm (Table 1). The average size of the 
fluorescently labeled GNs in swollen 
state in HEPES and PBS buffers 
was approximately 566 and 387 nm, respectively. The GNs became less 
negatively charged in PBS buffer of high ionic strength buffer compared to 
HEPES buffer of much lower ionic strength. The lower nanosphere size in 
PBS buffer was attributed to screening of the repulsive negative charges 
between the nanospheres.
3.2 In vivo distribution of and macrophage response to gelatin 
nanospheres after intravenous injection
Around 3 nl of the aqueous suspension containing fluorescently labeled 
GNs (Figure 1 and Table 1) were successfully injected intravenously (Figure 
2, a-d) into zebrafish embryos at 3 d post fertilization. Three hours after 
intravenous injection, the GNs were spread throughout the large blood 
vessels (Figure 2, a and d, yellow arrow in d) and small blood vessels of the 
embryos (Figure 2, d, white arrows). These GNs were observed as separate 
aggregated clusters (Figure 2, c), whereas individual GNs could not be 
observed due to the limited resolution of the CLSM. 
Three hours after intravenous injection, the macrophages were mainly 
Figure 1. Scanning electronic micrograph of 
gelatin nanospheres before (a) and after (b) 
fluorescent labeling with a far-red dye. Scale 
bars represent 500 nm. 
a b
Table 1. Parameters of gelatin nanospheres in the swollen state
Parameters
No dye NHS-650 labeled
PBS (154 mM, pH 7.4)   HEPES buffer (5 mM, pH 7) PBS (154 mM, pH 7.4)
Particle size (nm) 329 ± 5 566 ± 6 387 ± 7
ζ-potential (mV) -6.63 ± 0.86 -25.00 ± 0.50 -6.55 ± 0.20
Injection of Gelatin Nanospheres into Zebrafish
135
6
present in the blood vessels (Figure 2, c and f), whereas macrophages 
were hardly observed in muscle tissue of embryos (Figure 2, e and f). Co-
localization of GNs and macrophages was clearly observed within the blood 
circulation 24 h after injection (Figure 3, a-c and f, white arrows in b-c), 
when the majority of the macrophages was observed in close proximity to 
the GNs (Figure 3, d-f).
Figure 2. Macrophages (green) were observed mainly in the blood stream 3 h after intravenous 
injection of the gelatin nanospheres (GNs, red). (a) Lateral view of the entire embryo. (b-c) Lateral 
views of the selected areas from (a). (d-f) Top view of 3D reconstruction of the distribution of GNs 
and macrophages. Yellow and white arrows in (d) indicate the big and small blood vessels, respec-
tively. Scale bars represent 500 μm in (a, d-f) and 100 μm in (b-c). Different zebrafish embryos 
with the same treatment were used for (a-c) and (d-f). 
b c
a
b
c
e Macrophages
d Gelatin nanospheres
f Merged
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3.3 In vivo distribution of and macrophage response to gelatin 
nanospheres after intramuscular injection
Approximately 3 nl of fluorescently labeled GNs (Figure 1 and Table 1) were 
injected intramuscularly (Figure 4, a-c). In contrast to intravenous injection 
of GNs, the GNs remained cohesive and confined within muscle tissue 3 h 
after intramuscular injection (Figure 4, d). The nanospheres were distributed 
throughout the muscle tissue near the injection site, as reflected by the 
Figure 3. Co-localization of gelatin nanospheres (GNs, red) and macrophages (green) can be ob-
served 24 h after intravenous injection. (a) Lateral view of the embryo. (b-c) Lateral views of the 
selected areas from (a). Arrows indicate the co-localization of GNs and macrophages. (d-f) Top 
view of 3D reconstruction of the distribution of GNs and macrophages. Scale bars represent 100 
μm in (a), 50 μm in (b-c) and 500 μm in (d-f).
b c
a
b
c
b
b c
c
e Macrophages
d Gelatin nanospheres
f Merged
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stripe pattern of the muscle tissue (Figure 4, a-d). The original cohesive 
mass of GNs was disintegrated into separate clusters of GNs 24 h after 
intramuscular injection (Figure 5, a-d).
Macrophages were attracted to the injection site 3 h after intramuscular 
injection, while more macrophages were observed in muscle tissue of 
zebrafish upon intramuscular injection of GNs (Figure 4, e -f) as compared 
to injection of nanosphere-free PBS control (Figure S1, e-f). More 
macrophages were observed at the injection site 24 h after intramuscular 
injection compared to 3 h after injection (Figure 4, e-f; Figure 5, e-f). GNs and 
macrophages clearly co-localized in the zebrafish 24 h after intramuscular 
injection of GNs (Figure 5, a-c, white arrows in b-c). Moreover, the GNs were 
intimately surrounded by macrophages (Figure 5, f), which might suggest 
that GNs were occasionally internalized by macrophages (Figure 5, g, white 
arrow).
3.4 In vitro macrophage culture studies
To study the interactions between GNs and macrophages in more detail, 
Figure 4. Abundant macrophages (green) were observed at the injection depot of gelatin nano-
spheres (GNs, red) 3 h after intramuscular injection. (a) Lateral view of the entire embryo. (b-c) 
Lateral views of the selected areas from (a). (d-f) Top view of 3D reconstruction of the distribution 
of gelatin nanospheres (red) and macrophages (green). Scale bars represent 500 μm in (a) and 
100 μm in (b-f).
b c
a
b
c
e Macrophagesd Gelatin nanospheres f Merged
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we cultured human macrophages derived from the monocytic cell line 
THP-1 in the presence of fluorescently labeled GNs to allow imaging using 
CLSM. The nuclei and cytoplasm of the macrophages were stained blue 
Figure 5. Gelatin nanosphers (GNs, red) co-localized with macrophages (green) 24 h after in-
tramuscular injection of GNs. (a) Lateral view of the embryo. (b-c) Lateral views of the selected 
areas from (a). Arrows indicate the co-localization of GNs and macrophages. (d-f) Top view of 3D 
reconstruction of the distribution of GNs and macrophages. (g) Higher magnification of selected 
area in (f) where the white arrow indicates that GNs were intimately surrounded by macrophages. 
Scale bars represent 100 μm in (a, d-f), 50 μm in (b-c) and 20 μm in (g).
a
cb c
b
e Macrophagesd Gelatin nanospheres f Merged g
Figure 6. Cellular internalization of gelatin nanospheres (GNs) by THP-1 macrophages after 5h 
(a-d) and 24 h (e-h) of macrophage culture in the presence of GNs. Scale bars represent 20 μm. 
Nuclei of the cells were stained with DAPI/blue (a and e), cytoplasm was stained with Cell-Track-
er™ CMFDA/green (b and f) and GNs were labeled with far-red dye/red (c and g).
5h
24h
Merged
d
Cytoplasm
b
GNs
c
Nuclei
a
e f g h
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(Figure 6, a and e) and green (Figure 6, b and f), respectively. GNs labeled 
with a far-red fluorescent dye were observed clearly as well (Figure 6, c 
and g). Internalization of GNs into the macrophages was confirmed after 
5h (Figure 6, a-d; video S1) and 24h of macrophage culture (Figure 6, e-h; 
video S2).
4 Discussion
The aim of the present study was to monitor the spatial distribution as 
well as macrophage response to GNs in a zebrafish model. Although 
the suitability of GNs for application in regenerative medicine has been 
confirmed in various animal models [8, 9], tracking the fate of GNs in these 
animal models is not yet possible. Monitoring the spatial distribution of 
GNs and the associated immune response in vivo is, however, prerequisite 
for the clinical translation of GNs. By using transgenic zebrafish embryo 
model, we were able to image the spatial distribution of GNs in real-time 
in a living vertebrate using a relatively simple and straightforward method. 
In addition, we were able to monitor the response of macrophages to the 
injected GNs by using zebrafish macrophages expressing green fluorescent 
proteins. 
Upon injection of artificial particulate material in vivo, the response of 
the material to biological environment is determined by a plethora of 
factors including blood circulation, ionic strength and protein adsorption. 
Accordingly, the immune response to the presence of foreign body 
material in zebrafish is initiated via its innate immune system. This immune 
system is highly comparable to the one of mammals [28, 35, 36] and 
mainly comprised of the two major types of innate immune cells, i.e., 
neutrophils and macrophages, which are already present and functional at 
3 d post fertilization [28]. Neutrophils respond first, and macrophages are 
subsequently recruited to phagocytose pathogens and tissue debris [28, 
37]. Macrophages have been shown to play a central role in this immune 
reaction [38, 39]. Therefore, we used transgenic zebrafish expressing GFP 
in macrophages to study the response of macrophages to injected GNs.
In the present study, the GNs were spread throughout the blood vessels 
3 h after intravenous injection (Figure 2, a and d) caused by blood 
circulation, whereas GNs were largely confined at the intramuscular depot 
following intramuscular injection. The individual GNs agglomerated in the 
blood stream 3 h after intravenous injection (Figure 2, c-d), whereas the 
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nanospheres were not agglomerated before tissue injection as confirmed 
by reproducible size measurements using DLS of about 566 ± 6 nm in 
5 mM HEPES buffer (Figure 1 and Table 1). This agglomeration may be 
caused by the high ionic strength of the blood, which screens the repulsive 
interactions between the negatively charged GNs [5]. This charge screening 
was confirmed by the decreased charge of the GNs in PBS buffer (which 
has an ionic strength comparable to blood, Table 1). A similar phenomenon 
was observed 24 h after intramuscular injection. Although the majority of 
the GNs remained cohesive and confined in the muscle tissue close to the 
injection site (Figure 5, d and f), the original bulk of the GNs disintegrated 
into separate clusters (Figure 4, a and d; Figure 5, a and d). In addition to 
the ionic strength, adsorption of proteins onto the negatively charged GNs 
might also have contributed to the agglomeration of GNs in vivo. Although 
the exact mechanism behind agglomeration and disintegration of GNs 
remains to be elucidated, our observations confirmed that the zebrafish 
model is suitable for the real-time monitoring of the spatial distribution of 
the GNs in vivo, which will be highly instrumental for further research on 
the therapeutic efficacy of GNs as carriers for local drug delivery. 
Three hours after intravenous or intramuscular injection of GNs, the 
macrophages were observed close proximity to the GNs in the blood 
stream or at the injection sites (Figure 2, c and f; Figure 4, c and f). Over 
time, an increasing number of macrophages was observed 24 h after 
injection (Figure 3, f; Figure 5, f), which may be caused by chemotaxis as 
reported previously [27, 40]. Consequently, macrophages surrounded 
the GNs, resulting into co-localization of GNs and macrophages 24 h after 
injection of GNs in the blood (Figure 3, a-c and f) or muscle tissue (Figure 5, 
a-c and f-g). Nevertheless, internalization of the GNs by macrophages could 
not be confirmed unambiguously using CLSM to observe the zebrafish. 
Therefore, macrophage culture studies were performed to study if GNs 
could be internalized in vitro.
Internalization of GNs by macrophages was indeed observed in vitro upon 
culture of THP-1-derived macrophages in the presence of fluorescently 
labeled GNs. We found that the GNs can be internalized by macrophages 
after 5 h of macrophage culture (Figure 6, a-d; video S1), while a much 
larger number of GNs was observed inside the macrophages after 24h of 
culture (Figure 6, e-h). This internalization of GNs by macrophages suggests 
that GNs can be used for local delivery of antibacterial agents to combat 
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macrophage-associated intracellular infections. 
5 Conclusion
A novel in vivo method was developed for the biological evaluation of 
gelatin nanospheres using transgenic zebrafish expressing GFP-labeled 
macrophages. Upon intravenous or intramuscular injection of the 
fluorescently labeled gelatin nanospheres into zebrafish embryos, the 
real-time spatial distribution of gelatin nanospheres as well as interaction 
between gelatin nanospheres and macrophages could be studied using 
confocal laser scanning microscopy. 
The method presented herein provides a valuable tool for the biological 
evaluation of gelatin nanospheres, which can be useful for investigation on 
the effect of local delivery of biomolecules from gelatin nanospheres. 
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Supplementary information
Figure S1. Distribution of macrophages (green) in zebrafish embryos 3 h after intramuscular in-
jection of 3 nl of nanosphere-free PBS. (a) Lateral view of the embryo. (b-c) Lateral views of the 
selected areas from (a). (d-f) Top view of 3D reconstruction of the distribution of macrophages. 
Scale bars represent 100 μm in (a, d-f) and 50 μm in (b-c). Autofluorescence caused by pigments 
(a and d-f, white arrows) of the zebrafish embryos appeared as yellow (f, white arrows) upon 
merging of far-red and green channels. The results in this figure confirmed that the color con-
version of the Kaede protein did not impede visualization of the macrophages in the zebrafish.
d Far-red channel Merged
b
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1 Introduction
Percutaneous medical devices, such as external fixation devices, urinary 
catheters, peritoneal dialysis catheters, bone-anchored hearing aids, voice 
prostheses and intravenous catheters for haemodialysis, have become 
indispensible in clinical practice [1-3]. These external devices, however, 
are particularly susceptible to bacterial infections due to their penetration 
through the skin, the body’s primary defence to infection. The open space 
created around the implant provides an entrance for bacteria migrating into 
the body and subsequently colonizing on the implanted medical devices 
followed by formation of a biofilm [4, 5]. Within the biofilm, organisms are 
protected from a matrix consists of self-produced extracellular polymeric 
substances, which enables the bacteria less susceptible to host defense 
mechanisms and to the treatment of antibiotics [2, 5]. Consequently, 
the development of such infections may results into life-threatening 
complications, which yields high morbidity and mortality rates, and high 
costs to the health care system [6]. Although decades of research, including 
hospital and patient hygiene measures and development of antimicrobial 
coatings, has been done, no ubiquitously accepted clinical solution to 
address the problem of percutaneous device associated infections (PDAIs) 
has been forwarded. 
Instead of treating the PDAIs, development of methods or techniques 
to prevent PDAIs is of enormous value. Recently, the use of an effective 
chlorhexidine (CHX)-impregnated dressing at the exit-site of catheters with 
weekly replacement was reported [7]. This dressing had high efficiency 
both in reducing colonization of bacteria on the catheter and in reduction 
of catheter-related bloodstream or central nervous system infections. 
Therefore, the development of active antibacterial dressing, which can 
deliver antimicrobial agents locally in a sustained manner, can be an 
efficient approach for the prevention of PDAIs. 
Antimicrobial agents involve both antibiotics and antiseptics [8], which 
are chemical substances that prevent the growth and development of 
the microorganisms. Nevertheless, compared with antiseptics, antibiotics 
are only effective against bacteria and have a higher risk to develop 
antibacterial resistance [9, 10]. In fact, drug-resistant pathogens are 
emerging dramatically, leading to strongly increased global healthcare cost 
[11, 12]. Unfortunately, the development rate of antimicrobial resistance 
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exceeds the development rate of new drugs by far [12]. Furthermore, 
clinical therapy based on single drug is often not sufficiently effective 
to counteract infections, which has stimulated the development of 
combinatorial multidrug approaches to combat infections more effectively 
[12-14]. To this end, combination of antiseptics can be an effect method to 
kill bacteria without inducing antibacterial resistance. 
Among the various types of antiseptics, silver nanoparticles (AgNPs) are 
particularly attractive thanks to their broad-spectrum antibacterial activity. 
As a consequence, AgNPs have been widely used in various medical 
products [15, 16]. More recently, it has been demonstrated that silver 
ions (Ag+) are the active bactericidal agent that is released from AgNPs, 
and the antibacterial activity of AgNPs could be controlled by modulating 
Ag+ release through manipulation of oxygen availability, particle size as 
well as shape of AgNPs [17]. Besides AgNPs, CHX is another commonly 
used antiseptic, which has both bacteriostatic and bactericidal properties 
against gram positive and negative bacteria [18]. Recent studies showed 
that the combination of CHX with silver reduced the incidence of catheter 
infections and prolonged the antibacterial efficacy against a wide range of 
clinically significant potential pathogens [19, 20]. 
To achieve the dual delivery of Ag+ and CHX, a suitable drug carrier is 
required for the fabrication of antibacterial dressing. More recently, chitosan 
and chitosan-based nanofibrous matrices have gained interest due to their 
large specific surface area, high drug encapsulation efficiency, superior 
biocompatibility, and ease of processing by using the electrospinning 
technique [21-23]. Furthermore, chitosan is a stabilizing material that 
can protect AgNPs from oxidization [24], while chitosan itself has intrinsic 
antibacterial properties [23, 25]. 
Based on the aforementioned, the objective of this work was to develop 
a chitosan-based nanofibrous antibacterial dressing containing AgNPs for 
the dual release of Ag+ and CHX. We hypothesized that the most effective 
approach to prevent PDAIs would involve fast release of CHX to achieve a 
powerful initial bactericidal effect and avoid the development of bacterial 
resistance, followed by a sustained release of Ag+ to prevent any latent 
bacterial infections. To this end, we electrospun chitosan/poly(ethylene 
oxide) (PEO) in acetic acid solution containing silver nitrate (AgNO3) to obtain 
uniform and defect-free nanofibres embedding AgNPs. Additionally, we 
post-loaded CHX onto the nanofibrous membrane by a diffusion method 
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and then investigated the release of CHX and Ag+ in deionized water. 
Finally, we examined the antibacterial effect of the membranes loaded with 
different amount of CHX and AgNO3 and the long-term antibacterial effect 
of the membrane loaded with 5 wt% of AgNO3 using the zone of inhibition 
test against Staphylococcus aureus (S. aureus), which is one of the most 
common pathogens associated with PDAIs [1].
2 Methods
2.1 Electrospinning of nanofibres containing AgNPs
Chitosan (degree of deacetylation = 90%, molecular weight = 200-400 kDa, 
Heppe Medical Chitosan) and PEO (molecular weight = 900 kDa, Sigma-
Aldrich®) were mixed at a weight ratio of 75:25 and dissolved in 35 v/v% 
acetic acid solution to form a 3 w/v% polymer solution. Subsequently, 
0.1, 1 and 5 wt% (to polymer) of AgNO3 (Boom BV, The Netherlands) were 
added and the mixture was stirred overnight before electrospinning. The 
electrospinning setup was described previously [26]. The electrospinning 
process was conducted at 27 kV and the polymer solution was ejected 
at a flow rate of 4 ml/h controlled by a syringe pump (BD scientific Inc., 
USA), while the distance between the spinneret and collector was fixed at 
15 cm. The electrospun membranes were then punched into discs with 
a diameter of 11-12 mm, a surface area of approximately 1 cm2 and a 
thickness of approximately 135 µm. The punched discs were cross-linked 
by glutaraldehyde (25 wt% in water) vapour for 2 h and then left in a fume 
hood overnight to remove the residual glutaraldehyde. Thereafter, the 
samples were stored in a desiccator at room temperature for further use. 
2.2 Characterization of electrospun fibres 
The electrospun discs were sputtered coated with gold (approximately 10 
nm in thickness) to make the nanofibres conductive and the morphology of 
the discs were observed by scanning electron microscopy (SEM, JEOL 6301) 
at an accelerating voltage of 10 kV. Diameter distributions of the fibres 
were determined from the SEM micrographs obtained at random locations 
using the software Image J (National Institutes of Health, Bethesda, USA). 
One hundred fibres per membrane were analyzed. The formation of AgNPs 
was examined by transmission electronic microscopy (TEM, JEOL 1010) and 
TEM-energy dispersive X-ray spectroscopy (TEM-EDX, JEOL 2100 TEM with 
a Bruker Quantax EDX detector). To investigate the distribution of AgNPs 
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inside the fibres, cross-sectional samples of the fibres were prepared by 
embedding of the fibres in Epofix™ cold-setting embedding resin (Struers, 
The Netherlands) followed by microtome cutting. The cross-sectional 
samples were then mounted on 200-mesh carbon-coated copper grids 
(Agar Scientific, United Kingdom) before TEM observation.  
2.3 Drug loading and release 
A diffusional post-loading method was used to load CHX (chlorhexidine-
digluconate, Sigma-Aldrich®) onto cross-linked nanofibrous discs. Briefly, 5 
µl of CHX solution in deionized water containing 20, 60 or 100 µg of CHX 
was dripped on each membrane disc. This volume of CHX solution was 
selected to allow for total adsorption of the drug solution in the membranes 
according to our water adsorption test. The membranes were then freeze 
dried for later use. 
Nine groups of loaded membranes were used for the release study of Ag+ 
and CHX (Table 1, group 2-10). Each piece of membrane disc was placed 
into a 1.5 ml Eppendorf® tube (n = 5) containing 1 ml deionized water. 
The tubes were then incubated at 37 °C with gentle agitation. At each 
predetermined time point, 900 μl supernatant was collected for further 
analysis and then 900 μl of deionized water was added.
Group Amount of AgNO3 (wt% to polymer)
Amount of chlorhexidine
(μg per membrane)
1 — —
2 0.1 —
3 1 —
4 5 —
5 — 20
6 — 60
7 — 100
8 0.1 60
9 1 60
10 5 60
Table1. Experimental groups
CHX in supernatant was detected by reverse phase high performance 
liquid chromatography (RP-HPLC) using a Hitachi HPLC machine, which 
consists of a Hitachi L-2130 pump, a Hitachi L-2400 UV detector and a 
Hitachi L-2200 auto sampler. The specimens were analyzed by a previously 
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described method [27] with some modifications. Briefly, the mobile phase 
consisted of acetonitrile/water (40:60, v/v, containing 0.1 v/v% trifluoroacetic 
acid and 0.1 v/v% triethylamine) which was eluted through a LiChrospher® 
RP-18 endcapped HPLC column (125 mm × 4 mm, particle size 5 μm) 
at a flow rate of 1 ml/min. Fifty microliter of collected supernatant was 
injected and the effluent was monitored at 260 nm. A standard calibration 
curve was prepared from CHX solution with concentrations ranging from 
0.2 to 100 μg/ml. The Ag+ content was determined by using inductively 
coupled plasma mass spectroscopy (ICP-MS, Thermo Scientific, X series I). 
The collected supernatant was diluted 20 times in 1 wt% nitric acid for 
ICP-MS analysis of silver. A standard calibration curve was prepared with 
concentrations of Ag+ ranging from 8 to 1000 ng/ml.  
2.4 Cytotoxicity
The alamarBlue® Cell Viability Assay was used to evaluate the cytotoxicity 
of the membranes. All groups of membranes listed in Table 1 (n = 3) were 
immersed in 2.5 ml αMEM cell culture medium supplemented with 10% 
Fetal Bovine Serum (FBS, Sigma F7524, Taukirchen, Germany) and 1% 
Penicillin/Streptomycin (Gibco, Invitrogen Corp., Paisley, Scotland) for 24 h 
to obtain the release medium. Human Foreskin Fibroblasts (HFFs, isolated 
from foreskin specimens from a healthy donor by following national 
guidelines for working with human materials) were cultured in αMEM 
medium. The cells were trypsinized and reseeded onto a 24-well plate 
with a cell density of 50.000 cells per well. After 24 h, the culture medium 
was replaced with 1 ml of the release medium. Fresh culture medium 
and 5% DMSO were used as positive and negative control, respectively. 
Additionally, a series of CHX solution from 0.2 to100 µg/ml and Ag+ from 
0.2 to 50 µg/ml were prepared in fresh medium and tested simultaneously. 
After 20 h, the culture medium was refreshed with 1 ml culture medium 
containing 10 v/v% alamarBlue dye. After 4 h of incubation, a 200 µl aliquot 
of metabolized medium from each well was transferred into a 96-well plate 
in duplicate and the absorbance was measured with emission wavelength 
of 530 nm and excitation wavelength of 590 nm in a Bio-Tek® FL600 
microplate fluorescence reader.  
2.5 Antibacterial effect
The antibacterial effect of the membranes against S. aureus (ATCC® 
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25923TM, Manassas, USA) was examined by a zone of inhibition test 
[28] recommended by the European Society of Clinical Microbiology and 
Infectious Disease, with the EUCAST (European Committee on Antimicrobial 
Susceptibility Testing) standard tablets containing 30 µg of cefoxitin as the 
positive control. In brief, the bacterial suspensions for inoculations were 
firstly prepared by dispersing the isolated bacterial colonies in sterile saline 
(0.85% NaCl w/v in water) at a density of a McFarland 0.5 standard. The 
bacterial suspension was then diluted to a concentration of approximately 
6 × 107 colony-forming units (CFU) per ml and spread evenly over the entire 
surface of an agar plate by using a sterile cotton swab. The electrospun 
discs were then placed on the agar plate. After incubation at 35 °C for 20 h, 
the diameter of the inhibition zone was measured from the centre point of 
the disk to the border of the inhibition zone. 
The zone of inhibition test was also used to examine the long-term 
antibacterial effect of the membrane. Membranes containing 5 wt% AgNO3 
were first incubated with in deionized water under the same conditions as 
described in section 2.3. The membranes were collected at day 1, 2, 3 and 
4 (n = 3) and used for the zone of inhibition test as described above.
2.6 Statistics
Statistical analyses were conducted using GraphPad Prism and all results 
were reported as mean ± standard deviation. Differences among groups 
were analyzed by one way analysis of variance followed by a Tukey post-
hoc test, and a p-value of < 0.05 was considered as a statistically significant 
difference.
Figure 1. Scanning electron micrographs and fibre diameter distributions of chitosan/PEO  nano-
fibrous membranes containing 0 (A and E), 0.1 (B and F), 1 (C and G) and 5 wt% (D and H) of 
AgNO3, with average size of 97 ± 20 nm (E), 99 ± 21 nm (F), 120 ± 26 nm (G) and 121 ± 25 
nm (H), respectively.
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3 Results
3.1 Characterization of the electrospun fibrous membranes
Chitosan/PEO nanofibrous membranes containing 0, 0.1, 1 and 5 wt% 
of AgNO3 were successfully prepared. The nanofibres were uniform and 
defect-free (Figure 1 A to D), with an average size of approximately 100 nm. 
Differences in size distributions of the fibres containing different amount of 
AgNO3 were statistically insignificant. 
The in-situ formation of AgNPs inside the nanofibres was confirmed by 
TEM (Figure 2). Electron-dense nanoparticles of approximately 4 nm were 
detectable when AgNO3 levels 
were equal or higher than 1 wt% 
(Figure 2C), and the number of 
these nanoparticles increased with 
increasing amount of AgNO3 (Figure 
2D). Moreover, the distribution of 
the particles throughout the fibres 
was shown to be homogeneous 
by means of TEM analysis of the 
fibre cross-sections (Figure 2 E and 
F). Elemental analysis of the fibres 
using TEM-EDX confirmed that 
these nanoparticles were composed 
of silver, and the homogeneous 
distribution of silver inside the 
organic matrix of the nanofibres 
could be clearly demonstrated by 
means of elemental mapping (Figure 
3). Furthermore, it was shown that 
the AgNPs were formed prior to 
electrospinning (Figure S1).
Figure 2. Transmission electron micrographs 
of chitosan/PEO nanofibres containing 0 (A), 
0.1 (B), 1 (C) and 5 wt% (D) of AgNO3, and 
transmission electron micrographs of the 
cross-section of nanofibres with 0.1 (E) and 5 
wt% (F) of AgNO3. 
Figure 3. Transmission electron micrograph 
(A) combined elemental mapping using en-
ergy dispersive X-ray spectroscopy (B) of chi-
tosan/PEO nanofibres containing 5 wt% of 
AgNO3. Distribution of silver and carbon is 
shown in red and green, respectively.
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3.2 Release of chlorhexidine and Ag+
Significantly different release profiles 
were observed for CHX and Ag+. 
A burst-type release pattern was 
observed for CHX, irrespective of the 
amount of CHX or AgNO3 loaded on 
each membrane (Figure 4A and 4B). 
In contrast, Ag+ was released in a 
sustained manner for more than 28 
days for the membranes containing 
different amount of AgNO3, 
irrespective of the presence of CHX 
(Figure 4C). Moreover, the Ag+ was 
released relatively fast during the 
first 4 days followed by slow release 
during the following time period. 
After 28 days of release, AgNPs were 
hardly observed anymore inside the 
nanofibres (Figure S2).
3.3 Cytotoxicity 
To examine the cytotoxicicy of the membranes loaded with different amount 
of CHX and AgNO3, we immersed the membranes in cell culture medium 
for 24h, and subsequently collected the release medium and tested the 
cytotoxicity of the release medium. Significant cytotoxicity was observed 
for membranes containing ≥ 60 µg CHX (Figure 5A), and no cytotoxicity was 
observed for membranes loaded with 20 µg CHX or those with AgNO3. To 
Figure 4. Release kinetics of chlorhexidine 
(CHX) (A and B) and Ag+ (C) from chitosan/
PEO nanofibrous membranes. 
Figure 5. Cytotoxicity analysis. (A) Cytotoxicity of chitosan/PEO nanofibres membrane loaded 
with different amount of AgNO3 and chlorhexidine (CHX); (B) Cytotoxicity of cell culture medium 
containing AgNO3 and CHX dissolved at various concentrations.
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examine and compare the cytotoxic level of Ag+ and CHX, a serial dilution 
of AgNO3 and CHX in cell culture medium was tested. It was shown that 
Ag+ had no cytotoxic effect at concentrations of AgNO3 up to the highest 
concentration tested (50 µg/ml). However, obvious cytotoxicity of CHX was 
observed when the concentration of CHX was higher than 25 µg/ml. 
3.4 Antibacterial effect
A zone of inhibition test against S. aureus was used to examine the 
antibacterial effects of the membranes loaded with different amount of 
AgNO3 and CHX (Figure 6). Membranes were surrounded by an obvious 
inhibition zone when the amount of incorporated AgNO3 was increased to 
1 wt% (Figure 6C) and a significantly larger zone of inhibition was observed 
for samples containing 5 wt% AgNO3 as compared to the samples containing 
0.1 and 1 wt% AgNO3 (Figure 6E). Both membranes loaded with 20 µg CHX 
(Figure S3) and 60 µg CHX (Figure 6F) induced the formation of distinct 
inhibition zones. However, the zones of inhibition for membranes loaded 
with 60 µg CHX and different amounts of AgNO3 were of similar diameter 
(Figure 6F to 6J). Moreover, all membranes loaded with 5 wt% AgNO3 
had obvious comparable antibacterial effects (Figure 6K to 6N) against S. 
Figure 6. Zone of inhibition test against Staphylococcus aureus. Optical photos of membranes 
loaded with 0 (A), 0.1 (B), 1 (C) and 5 wt% AgNO3 (D) and the diameter of the zone of inhibition 
of these membranes (E), P < 0.0001; membranes loaded with both 60 µg CHX and 0 (F), 0.1 (G), 
1 (H) and 5 wt% AgNO3 (I) and the diameter of the zone of inhibition of these membranes (J); 
membranes loaded with 5 wt% AgNO3 after 1 d (K), 2 d (L), 3 d (M) and 4 d (N) release of Ag
+ 
and the diameter of the zone of inhibition of these membranes (O). Dark lines (E, J, O) indicate 
the original diameter of the discs.
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aureus after release of silver for different periods (Figure 6O). Although the 
differences in the diameter of zone of inhibition were statistically different 
between day 0, 1 and 4, the average diameter of the inhibition zone of 
these three groups differed less than 1 mm. It is noted that the diameter of 
the membranes is different from the size of the EUCAST standard control 
samples [28], the results in this study were not compared with the EUCAST 
standard control. 
4 Discussion
The aim of this study was to develop an antibacterial dressing with local 
dual delivery of antiseptics, i.e. Ag+ and CHX, for the prevention of PDAIs. To 
this end, defect-free chitosan/PEO nanofibres containing homogeneously 
dispersed AgNPs were successfully prepared. 
The traditional method for the fabrication of chitosan/AgNPs nanofibres 
involves a two-step process to prepare the solution for electrospinning, 
in which the chitosan/AgNPs complex was prepared prior to mixing 
with chitosan and/or polymer solutions for electrospinning [29-33]. This 
method, however, involves the use of toxic reductive chemical agents 
and complicates the dispersion of chitosan/AgNPs complexes in the 
viscous electrospinning solution. Although reductive reagents were not 
used by Wang et al. [34], UV irradiation was introduced to induce the 
formation of AgNPs after preparation of the solution. Herein, we have 
developed a novel and simple one-step electrospinning method, in which 
the electrospinning solution containing AgNPs was prepared by simple 
dissolution of chitosan and PEO into acetic acid solution containing AgNO3, 
without adding any reductive reagent. The in-situ formation of AgNPs prior 
to electrospinning was confirmed by investigating the electrospinning 
solution using TEM (Figure S1). Chitosan is a natural antioxidant and the 
reducing power of chitosan has been confirmed previously [35]. In this 
study, we proved that the reducing power of chitosan was strong enough 
to reduce Ag+ into neutral Ag without the addition of reductive reagents or 
UV irradiation. Furthermore, the AgNPs were distributed homogeneously 
without aggregation throughout the nanofibres, as confirmed by the TEM 
micrographs (Figure 2 and 3). These results indicated that the novel one-
step method used in this study is efficient and effective for the preparation 
of chitosan-based nanofibres containing AgNPs. 
To improve the chemical and mechanical stability of chitosan, the 
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nanofibrous membranes were cross-linked by glutaraldehyde vapour. Two 
possible mechanisms have been suggessted for this cross-linking process: 
glutaraldehyde reacts with chitosan either through Shiff base formation 
which results into imine-type functionality or through Michel-type adducts 
with terminal aldehydes which leads to the formation of carbonyl groups 
[36]. After cross-linking, the dissolution of the nanofibres was avoided 
when contacting with neutral or basic aqueous solutions. 
We hypothesized that the ideal dual release profile would correspond to 
an initial burst release of a drug to efficiently kill the invaded bacteria but 
not toxic to the surrounding host cells, followed by a sustained release 
of a drug at a concentration sufficient to kill any latent bacteria [12]. In 
this study, CHX was loaded onto the membrane through a diffusional post-
loading method, and 70 to 85 % of CHX was released within 2 days (Figure 
4A and 4B). There were no strong interactions between CHX and nanofibres 
since only burst-type release of CHX was observed (Figure 4A). Besides, 
silver had no influence on the release of CHX since the release profiles of 
CHX from nanofibrous membranes containing different amounts of AgNO3 
(Figure 4B) or vice versa (Figure 4C) were identical. On the other hand, 
sustained release of Ag+ for more than 28 days was achieved. AgNPs were 
oxidized upon contact with water resulting into subsequent release of Ag+ 
from the nanofibrous membranes. This process was shown to be time- and 
oxygen-dependent [17]. AgNPs were depleted almost completely after 28 
days release (Figure S2), which indicated that all the AgNPs were oxidized 
and released as silver ions. The differences of the release kinetics between 
CHX and Ag+ were induced by the release mechanisms of these two 
antibacterial drugs from the nanofibrous membranes. CHX was released 
from the membranes mainly through a diffusion-based manner since no 
strong interactions existed between CHX and nanofibres, while Ag+ were 
released from the matrices via the oxidization of AgNPs, which was time- 
and oxygen-dependent [17]. Compared to recent studies [31, 32, 34] 
using chitosan nanofibres containing AgNPs for antibacterial applications, 
which obtained only 3 to 7 days of release of Ag+, we were able to obtain 
sustained release of Ag+ during significantly longer periods. 
The cytotoxicity test showed that CHX was the main toxicant and toxicity of 
CHX appeared to be dose-dependent (Figure 5A), which was in agreement 
with other studies [37, 38]. Therefore, it is of critical importance to find the 
toxic level of CHX for practical applications. To characterize the toxicity of 
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CHX in more detail, we tested the cell viability as a function of CHX dose and 
found that the threshold level for cytotoxicity of CHX was 25 µg/ml in the 
current study (Figure 5B). In comparison, although AgNPs were reported 
previously to be toxic even at low concentrations [39], they had no obvious 
cytotoxic effect upon incorporation into the nanofibrous membranes 
(Figure 5A), while dissolved AgNO3 was not toxic up to a concentration of 
50 µg/ml (Figure 5B). 
According to the cytotoxicity results, several groups were selected for 
the zone of inhibition test against S. aureus to examine the antibacterial 
effectiveness of the antiseptics loaded membranes. Membranes loaded 
with 20 µg CHX killed S. aureus effectively (Figure S3) and the membranes 
killed S. aureus effectively when the amount of incorporated AgNO3 was 1 
wt% or higher. The killing effectiveness increased with increasing AgNO3 
content (Figure 6D and 6E). Moreover, the long-term antibacterial test 
showed that membranes containing 5 wt% AgNO3 could kill bacteria 
effectively and constantly for more than 4 days (Figure 6K to 6O). However, 
when the amount of loaded CHX was increased to 60 µg, the antibacterial 
effect of the membrane was dominated by CHX since there were no 
significant differences among groups loaded with 60 µg CHX and with or 
without AgNO3 (Figure 6F to 6J). This result may be related to the release 
kinetic of CHX from the nanofibrous membranes. Large amount of CHX 
was released in the first 6h and killed the surrounded bacteria, which 
dominated the antibacterial effect. 
5 Conclusion
A novel one-step electrospinning method was successfully developed 
for the preparation of chitosan/PEO nanofibrous antibacterial dressing 
containing silver nanoparticles that facilitate local and dual delivery of 
two antiseptics, i.e. chlorhexidine and silver ions, at the site of infection 
for the prevention of percutaneous device associated infections. The in-
situ formation of silver nanoparticles was confirmed by TEM-EDX and the 
silver nanoparticles were distributed homogeneously throughout the 
nanofibres. Chlorhexidine was released in a burst-type manner within 2 
days, while silver ions were released in a sustained manner for more than 
28 days were observed. Silver nanoparticles had no cytotoxicity in our 
experimental conditions while chlorhexidine was toxic when the loaded 
amount was higher than 25 µg per membrane. The membranes exhibited 
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obvious antibacterial effect upon loading with either chlorhexidine (20 µg 
or more per membrane) or silver nitrate¬ (1 and 5 wt% to polymer) and 
long-term antibacterial effects were observed for membranes containing 
5 wt% silver nitrate¬¬. Consequently, chitosan/PEO/silver nanoparticles 
nanofibrous membranes can be used as a local/topical alternative for 
the prevention of S. aureus associated percutaneous devices associated 
infections.
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Supplementary information
Figure S1. Transmission electron micrograph of chitosan/poly (ethylene oxide) solution containing 
5 wt% AgNO3 prior to electrospinning.
Figure S2. Cross-sectional transmission electron micrograph of chitosan/poly (ethylene oxide) 
nanofibre initially loaded 5 wt% AgNO3 after 28 days of Ag+ release.
Figure S3. Optical photo of zone of inhibition test against Staphylococcus aureus for membranes 
loaded with 20 µg CHX.
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1 Summary
Bone infections are a major problem in clinical healthcare since the 
treatment of these infections is associated with huge medical cost and 
severe clinical complications. Traditional treatment modalities focus on 
systemic administration of antibiotics, which may result into systemic 
toxicity, antibiotic resistance and recurrence of infections. A powerful 
strategy to address these problems involves local and sustained delivery of 
antibacterial drugs to treat and/or prevent infections. Therefore, this PhD 
thesis has focused on the development of various nanostructured drug 
delivery systems for the local and sustained delivery of antibacterial drugs. 
To this end, a general introduction on bone infections as well as a brief 
description of the objectives of this thesis was provided in Chapter 1. 
Since gelatin-based materials have been widely used for the delivery of 
biomolecules, Chapter 2 provided an overview of the use of various types of 
gelatin carriers for application in bone regeneration, with specific emphasis 
on the relationship between carrier properties and delivery characteristics. 
Generally, biomolecules can bind to gelatin matrices through the formation 
of polyion complexes with gelatin macromolecules following diffusional 
post-loading, thereby retaining their biological activity. Upon enzymatic 
degradation of gelatin carriers, the loaded biomolecules are released at 
rates which can be precisely tuned by adjusting the cross-linking density of 
gelatin. This mechanism has been confirmed for large biomolecules such 
as growth factors and nucleic acids, but it is unknown yet if small molecules 
such as antibiotics can also be bound to gelatin matrices. To facilitate clinical 
translation and commercialization of gelatin-based carriers for applications 
in regenerative medicine, carrier manufacturing should be upscaled under 
good manufacturing practice conditions, while proper preclinical animal 
models should be selected to correlate the physicochemical properties of 
the gelatin carriers with the in vivo release kinetics of loaded biomolecules.
The possibility to use gelatin nanospheres as carriers for the sustained 
delivery of antibiotics was studied in Chapter 3. In more detail, this chapter 
investigated the relationship between the physicochemical characteristics 
of selected antibiotics and the kinetics of their release from gelatin 
nanospheres. We found that the release of antibiotics loaded onto GNs by 
simple post-loading depended strongly on the physicochemical properties 
of the selected antibiotics. Antibiotics of high molecular weight (colistin and 
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vancomycin) were released in a sustained manner for more than 14 days, 
whereas antibiotics of low molecular weight (gentamicin and moxifloxacin) 
were released in a burst-type manner. The interactions between antibiotics 
and gelatin carriers were mainly dominated by i) strong electrostatic forces 
for colistin, ii) strong hydrophobic and electrostatic forces for vancomycin, 
iii) weak electrostatic and hydrophobic forces for gentamicin, and iv) weak 
hydrophobic forces for moxifloxacin. The release kinetics of these four 
selected antibiotics strongly correlated to the binding affinity of antibiotics 
to gelatin carriers, which decreased in the order colistin (high molecular 
weight and charge) > vancomycin (high molecular weight and neutral) > 
gentamicin (low molecular weight and charge) > moxifloxacin (low molecular 
weight and neutral).
Various drug-loaded coatings have been applied onto orthopedic and dental 
implants to prevent infections. Control over the release of antibacterial 
drugs from these coatings is, however, still a challenge. To overcome 
this problem, Chapter 4 focused on the deposition of implant coatings 
composed of a chitosan matrix containing gelatin nanospheres loaded 
with antibiotics onto stainless steel plates by means of the electrophoretic 
deposition technique. The coatings adhered tightly to the stainless steel 
substrates, while gelatin nanospheres were distributed homogeneously 
throughout the chitosan matrix of the coatings. The surface roughness and 
hydrophobicity of the coatings was fine-tuned by adjustment of the weight 
ratio between gelatin nanospheres and chitosan in the suspensions. 
Vancomycin and moxifloxacin were released in a sustained vs. burst-type 
manner, respectively, while the coatings were highly cytocompatible and 
exhibited antibacterial efficacy. These results suggest that the antibacterial 
capacity of metallic implants can be tuned by orthogonal control over 
the release of (multiple) antibiotics from electrophoretically deposited 
chitosan-gelatin nanospheres coatings, which offers a new strategy to 
prevent implant-associated infections.
In Chapter 5 we showed that gelatin nanospheres can also be used 
to modulate the biological and antibacterial properties of fibrous 
membranes. Specifically, fibrous silk fibroin membranes were studied 
since these nanofibers have been widely studied for drug delivery 
purposes. Nevertheless, control over the release of biomolecules from this 
type of nanofibers is generally poor due to a lack of interaction between 
biomolecules and silk fibroin. To combat this problem, we incorporated 
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oppositely charged gelatin A and B nanospheres into the silk fibroin 
nanofibers by using the electrospinning technique. Novel silk fibroin 
nanofibrous membranes containing gelatin nanospheres with a nano-
in-nano structure were successfully fabricated. Both oppositely charged 
gelatin A and B nanospheres were incorporated into the nanofibers. 
The distribution of gelatin A and B nanospheres could be fine-tuned at 
the nanoscale by adjustment of either the weight ratio between the 
nanospheres (using single nozzle electrospinning) or the relative feeding 
rate of core and shell solutions by using co-axial nozzle electrospinning. 
A more sustained release of vancomycin was achieved from membranes 
containing gelatin B nanospheres as compared to nanosphere-free 
membranes. Gelatin-modified membranes were highly cytocompatible 
and exhibited antibacterial efficacy against Staphylococcus aureus. 
Additionally, these membranes supported the attachment and spreading 
of periodontal ligament cells. These results indicate that the nano-in-
nano fibrous silk fibroin membranes containing gelatin nanospheres are 
promising candidates for controlled delivery of (multiple) biomolecules.
The suitability of gelatin nanospheres for local delivery of biomolecules has 
been confirmed in various preclinical studies. Traditional animal models 
are, however, not suitable for real-time tracking of gelatin nanospheres and 
monitoring of the immune response to gelatin nanospheres. Therefore, 
we have evaluated a novel in vivo method in Chapter 6 to monitor the 
spatial distribution of and immune response to gelatin nanospheres by 
using a transgenic zebrafish embryo model with fluorescently labeled 
macrophages. Upon intravenous or intramuscular injection of the 
fluorescently labeled gelatin nanospheres into zebrafish embryos, the 
spatial distribution of gelatin nanospheres as well as the interaction 
between gelatin nanospheres and macrophages could be monitored real-
time using confocal laser scanning microscopy. This method could become 
a valuable new tool for biological assessment of gelatin nanospheres and 
the application of gelatin nanospheres for local delivery of various bioactive 
molecules.
A specific type of infection relates to the use of percutaneous devices. 
To prevent these infections, antimicrobial dressings can be a promising 
treatment strategy. However, the use of antibiotics is associated with 
development of antibacterial resistance, while single drug therapy is often 
not sufficiently effective to counteract infections. Therefore, we proposed 
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dual release of antiseptics (such as chlorhexidine, CHX) and silver as an 
effective strategy to combat percutaneous device-associated infections. 
In Chapter 7, we prepared electrospun chitosan/poly(ethylene oxide) 
(PEO) nanofibrous membranes containing silver nanoparticles as an 
implantable delivery vehicle for the dual and local release of CHX and 
silver ions. The in-situ formation of silver nanoparticles was confirmed 
by transmission electron microscopy combined with energy dispersive 
X-ray spectroscopy, which indicated that the silver nanoparticles were 
distributed homogeneously throughout the nanofibers. CHX was released 
in a burst-type manner within 2 days, while silver ions were released in 
a sustained manner for more than 28 days. Silver nanoparticles did not 
cause any cytotoxicity under the current experimental conditions while 
CHX was toxic when the membranes were loaded with more than 25 µg 
of CHX. The membranes exhibited obvious antibacterial efficacy upon 
loading with CHX (20 µg or more per membrane) and/or silver nitrate (1 
and 5 wt% to polymer). Long-term antibacterial effect up to 4 days was 
observed for membranes containing 5 wt% of silver nitrate. In summary, 
it was concluded that chitosan/PEO nanofibrous membranes containing 
silver nanoparticles and CHX can be used as a local drug delivery device to 
prevent infections caused by percutaneous devices.
2 Closing remarks and future perspective
This thesis described the development of various nanostructured 
antibacterial drug delivery systems to treat and/or prevent infections. 
These nanosphere- and nanofiber-based systems were shown to facilitate 
local and sustained delivery of antibiotics and antiseptics to kill bacteria. 
As a result, these antibacterial delivery systems are suitable to treat and/
or prevent bone infections, as evidenced by our positive in vitro results. 
However, several challenges remain to be addressed in future studies. 
First, the exact amount of antibacterial drugs needs to be determined 
before clinical translation of these delivery systems can be considered. 
Ideally, an initial burst release of a high amount of antibacterial drugs 
(to kill invaded bacteria) should be followed by a sustained release of 
antibacterial drugs (to prevent latent infections) [1, 2]. At the sustained 
release stage, the concentration of released antibacterial drugs should be 
higher than the minimal inhibition concentration or minimal bactericidal 
concentration (MIC or MBC) for specific bacteria. In vitro models need to be 
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developed which can mimic the in vivo conditions for bacterial growth to 
study the effects of antibacterial drug treatment and optimize the in vitro 
drug dosage and release kinetics. Subsequently, the release kinetics and 
therapeutic efficacy of the antibacterial effect should be studied in suitable 
animal models of infection to further optimize the delivery systems. 
Second, treatment of infection using antibiotics may result into the 
development of antibacterial resistance. Unfortunately, the development 
rate of antibacterial resistance exceeds the development rate of new drugs 
by far [1]. Consequently, antibacterial drug delivery systems need to be 
developed that allow local release of alternative antibacterial agents such 
as antiseptics and antimicrobial peptides (AMPs) which have less possibility 
to induce antibacterial resistance [2-4]. Although nanofibrous membranes 
loaded with antiseptics (chlorhexidine and silver) were successfully 
developed in Chapter 7, only burst-type release of chlorhexidine was 
observed due to a lack of interaction between chlorhexidine and chitosan, 
while potential side effects of silver delivery are still debated [5, 6]. 
Therefore, delivery of positively charged AMPs from negatively charged 
gelatin nanospheres can be a solution to increase the mutual interaction 
between drugs and carriers as well as reduce toxicity. 
AMPs are endogenous polypeptides produced by a wide variety of 
organisms as an essential component of their innate immune response 
to protect a host from pathogenic microbes [4, 7, 8]. These AMPs can be 
found among all classes of life ranging from prokaryotes to humans [7]. 
Generally, AMPs have less than 100 amino acids residues with an overall 
net charge of + 2 to + 9 caused by charged lysine and arginine residues [4, 
8]. Moreover, AMPs can be active against both Gram-positive and Gram-
negative bacteria, yeast and some viruses [3]. Positively charged AMPs 
of molecular weight higher than 2 kDa are hypothesized to form polyion 
complex with negatively charged gelatin nanospheres through electrostatic 
and hydrophobic interactions. Consequently, the possibility of using gelatin 
nanospheres for the sustained delivery of AMPs can be investigated in the 
future to overcome issues related to antibacterial resistance. 
Third, intracellular infections especially intracellular infections induced by 
medical devices are typically highly persistent infections which are difficult 
to treat. These bacteria exhibit reduced susceptibility to antibiotics and 
may develop intracellular persistence. The capability of the delivery systems 
developed in this thesis to target intracellular infections was not yet studied. 
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In Chapter 6, by culturing THP-1-derived macrophages in the presence of 
gelatin nanospheres, we confirmed that the gelatin nanospheres can be 
internalized by macrophages. Therefore, future studies should focus on the 
possibility to use gelatin nanospheres to combat intracellular infections. To 
this end, the transgenic zebrafish model as developed in Chapter 6 could 
be used to study intracellular delivery of antibacterial agents from gelatin 
nanospheres in vivo by using fluorescently labeled macrophages, gelatin 
nanospheres and antibacterial agents.
Summary, Closing Remarks and Future Perspectives
175
8
References
1. Brooks, B.D. and A.E. Brooks, Therapeutic strategies to combat antibiotic resistance. Adv 
Drug Deliv Rev, 2014. 78: p. 14-27.
2. Song, J., et al., Antibacterial effects of electrospun chitosan/poly(ethylene oxide) 
nanofibrous membranes loaded with chlorhexidine and silver. Nanomedicine, 2016. 
12(5): p. 1357-64.
3. Kang, S.J., et al., Antimicrobial peptides: therapeutic potentials. Expert Rev Anti Infect 
Ther, 2014. 12(12): p. 1477-86.
4. Seo, M.D., et al., Antimicrobial peptides for therapeutic applications: a review. Molecules, 
2012. 17(10): p. 12276-86.
5. Greulich, C., et al., The toxic effect of silver ions and silver nanoparticles towards bacteria 
and human cells occurs in the same concentration range. RSC Adv, 2012. 2(17): p. 6981-
6987.
6. Hadrup, N. and H.R. Lam, Oral toxicity of silver ions, silver nanoparticles and colloidal 
silver--a review. Regul Toxicol Pharmacol, 2014. 68(1): p. 1-7.
7. Giuliani, A., G. Pirri, and S.F. Nicoletto, Antimicrobial peptides: an overview of a promising 
class of therapeutics. Cent Eur J Biol, 2007. 2(1): p. 1-33.
8. Pushpanathan, M., P. Gunasekaran, and J. Rajendhran, Antimicrobial peptides: versatile 
biological properties. Int J Pept, 2013. 2013: p. 675391.

Samenvatting, slotopmerkingen en 
toekomstperspectieven
Chapter 9

Samenvatting, Slotopmerkingen en Toekomstperspectieven
179
9
1 Samenvatting
Botinfecties zijn een groot probleem in de klinische zorg omdat de 
behandeling van deze infecties gepaard gaat met enorme medische 
kosten en ernstige klinische complicaties. Traditionele behandelingen 
tegen botinfecties gaan uit van systemische toediening van antibiotica, 
wat kan leiden tot systemische toxiciteit, resistentie tegen antibiotica 
en terugkeer van infecties. Een alternatieve strategie behelst lokale 
en langdurige afgifte van antibacteriële middelen waarmee infecties 
behandeld dan wel voorkomen kunnen worden. Dit proefschrift borduurt 
voort op dit concept door een bijdrage te leveren aan de ontwikkeling van 
diverse nanogestructureerde dragersystemen ten behoeve van lokale en 
langdurige afgifte van antibacteriële middelen.
Na een algemene inleiding over botinfecties werden in Hoofdstuk 1 
de doelstellingen van dit proefschrift beschreven. Aangezien gelatine-
gebaseerde materialen op grote schaal toegepast worden om biomoleculen 
af te geven, werd in Hoofdstuk 2 het gebruik van verschillende soorten 
gelatine dragermaterialen ten behoeve van de regeneratie van botweefsel 
beschreven. Daarbij lag de nadruk op de relatie tussen de eigenschappen 
van de dragermaterialen en het afgifteprofiel van de diverse biomoleculen. 
In het algemeen kunnen biomoleculen aan gelatine matrices binden door 
zogenaamde polyion complexen met gelatine macromoleculen te vormen 
waardoor hun biologische activiteit behouden blijft. Doordat gelatine 
enzymatisch degradeert kunnen de geladen biomoleculen vrijkomen met 
een snelheid die afhankelijk is van de crosslink-dichtheid van gelatine. Dit 
mechanisme is bevestigd voor grote biomoleculen zoals groeifactoren 
en nucleïnezuren, maar het is nog onbekend of kleine moleculen zoals 
antibiotica eveneens binden aan gelatine matrices. Om de klinische vertaling 
en commercialisering van gelatine-gebaseerde dragers voor toepassingen 
in de regeneratieve geneeskunde mogelijk te maken, zal de productie van 
dragermaterialen moeten worden opgeschaald onder GMP condities. 
Daarnaast dienen geschikte preklinische diermodellen ontwikkeld te 
worden om de fysisch-chemische eigenschappen van de gelatine dragers 
te kunnen correleren met de in vivo afgifte van biomoleculen.
De mogelijkheid om gelatine nanosferen als dragers te gebruiken voor 
de langdurige afgifte van antibiotica is onderzocht in Hoofdstuk 3. Dit 
hoofdstuk richtte zich met name op de relatie tussen de fysisch-chemische 
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eigenschappen en afgiftekinetiek van enkele veelgebruikte antibiotica. 
Hierbij bleek dat de afgifte van antibiotica vanuit gelatine nanosferen 
sterk afhing van de fysisch-chemische eigenschappen van de specifieke 
antibiotica. Antibiotica met een hoog molecuulgewicht (colistine en 
vancomycine) werden langdurig afgegeven gedurende 14 dagen, terwijl 
antibiotica met een laag molecuulgewicht (gentamicine en moxifloxacine) 
veel sneller en abrupter werden afgegeven. De interacties tussen antibiotica 
en gelatine nanosferen werden bepaald door i) sterke elektrostatische 
krachten voor colistine, ii) sterke hydrofobe en elektrostatische krachten 
voor vancomycine, iii) zwakke elektrostatische en hydrofobe krachten voor 
gentamicine, en iv) zwakke hydrofobe krachten voor moxifloxacine. De 
afgiftekinetiek van deze vier specifieke antibiotica bleek sterk te correleren 
met de affiniteit van antibiotica aan gelatine die afnam in de volgorde 
colistine (hoog molecuulgewicht en sterke lading) > vancomycine (hoog 
molecuulgewicht en neutrale lading) >  gentamicine (laag molecuulgewicht 
en zwakke lading ) > moxifloxacine (laag molecuulgewicht en neutrale 
lading).
Diverse deklagen zijn na belading met geneesmiddelen aangebracht 
op orthopedische en tandheelkundige implantaten ter voorkoming 
van infecties. Het blijft echter een uitdaging om de afgiftekinetiek van 
antibacteriële geneesmiddelen uit deze deklagen te kunnen gecontroleerd 
te laten plaatsvinden. Dientengevolge richtte Hoofdstuk 4 zich op het 
aanbrengen van deklagen bestaande uit een chitosan matrix en met 
antibiotica (vancomycine en moxifloxacine) beladen gelatine nanosferen 
op roestvast stalen implantaten met behulp van de elektroforetische 
depositietechniek. De deklagen hechtten stevig aan de roestvrij stalen 
substraten, en de gelatine nanosferen waren homogeen verspreid door de 
chitosan matrix van de deklagen. De oppervlakteruwheid en hydrofobiciteit 
van de deklagen kon worden beïnvloed door de gewichtsverhouding 
tussen gelatine en chitosan in de suspensies te variëren. Vancomycine 
en moxifloxacine werden afgegeven in een langdurige respectievelijk 
kortdurige wijze. De deklagen waren cytocompatibel en vertoonden 
antibacteriële activiteit. Deze resultaten suggereren dat de antibacteriële 
capaciteit van metallische implantaten kan worden gemodificeerd door 
controle over de afgifte van (meerdere) antibiotica uit elektroforetisch 
aangebrachte chitosan-gelatine deklagen. Deze nieuwe methode vormt 
daarmee een nieuwe strategie voor de bestrijding van implantatie-
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geassocieerde infecties.
In Hoofdstuk 5 hebben we aangetoond dat gelatine nanosferen 
eveneens kunnen worden gebruikt om de biologische en antibacteriële 
eigenschappen van vezelige membranen te modificeren. Hiertoe werden 
nanovezelmembranen op basis van zijde geselecteerd omdat dit type 
vezels veelvuldig is onderzocht ten behoeve van gecontroleerde afgifte van 
geneesmiddelen. Ondanks deze populariteit  is de controle over de afgifte 
van biomoleculen vanuit zijde nanovezels matig, wat te wijten valt aan een 
gebrek aan interactie tussen biomoleculen en de zijde dragermaterialen. 
Om dit probleem op te lossen, werden gelatine nanosferen in de 
zijdemembranen aangebracht met behulp van de electrospinning 
techniek. Zowel positief geladen gelatine A als negatief geladen gelatine 
B nanosferen werden met succes ingebouwd in de zijde nanovezels. De 
verdeling van gelatine A en B nanosferen kon op nanoschaal worden 
ingesteld door de gewichtsverhouding tussen de beide typen nanosferen 
of de relatieve toevoersnelheid te variëren. De afgifte van vancomycine was 
langduriger vanuit membranen beladen met gelatine B nanosferen ten 
opzichte van membranen zonder ingebouwde nanosferen. De gelatine-
gemodificeerde zijdemembranen waren cytocompatibel en vertoonden 
antibacteriële werkzaamheid tegen Staphylococcus aureus bacteriën. 
Bovendien ondersteunden deze membranen de hechting en spreiding 
van parodontale ligamentcellen. Deze resultaten bewijzen dat de “nano-in-
nano” nanovezelmembranen veelbelovende eigenschappen bezitten voor 
het bewerkstelligen van gereguleerde afgifte van (meerdere) biomoleculen.
De geschiktheid van gelatine nanosferen voor lokale afgifte van biomoleculen 
is in verschillende preklinische studies bevestigd. Traditionele diermodellen 
zijn echter niet geschikt voor real-time tracking van gelatine nanosferen en 
het monitoren van de immuunrespons op gelatine nanosferen. Daarom 
hebben we in Hoofdstuk 6 een nieuwe in vivo methode onderzocht om 
de ruimtelijke verdeling van en immuunrespons op gelatine nanosferen 
te monitoren in transgene zebravisembryo’s met fluorescent gelabelde 
macrofagen. Na intraveneuze of intramusculaire injectie van fluorescent 
gelabelde gelatine nanosferen in zebravisembryo's kon de ruimtelijke 
verdeling van gelatine nanosferen en de interactie tussen gelatine 
nanosferen en macrofagen real-time worden gevolgd met behulp van 
confocale laser scanning microscopie. Deze methode kan een waardevol 
hulpmiddel vormen bij de biologische evaluatie van gelatine nanosferen 
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ten behoeve van lokale afgifte van bioactieve moleculen.
Het gebruik van percutane medische devices kan eveneens tot infectie 
leiden. Om dit type infecties te voorkomen, kunnen antimicrobiële 
dressings worden ingezet. Het gebruik van antibiotica leidt echter tot 
de ontwikkeling van antibacteriële resistentie, terwijl de toediening van 
slechts één medicijn vaak niet voldoende effectief is om infecties te 
bestrijden. Daarom hebben wij in deze studie de gelijktijdige afgifte van 
zowel een ontsmettingsmiddel (chloorhexidine, CHX) en antibacterieel 
zilver als een mogelijke strategie om infecties rondom percutane devices 
te bestrijden. In Hoofdstuk 7 zijn chitosan / poly (ethyleen oxide) (PEO) 
nanovezelmembranen gesynthetiseerd die zilver nanodeeltjes bevatten 
om daarmee lokale afgifte van zowel CHX en zilverionen te bewerkstelligen. 
De in-situ vorming van zilver nanodeeltjes werd bevestigd door transmissie 
elektronenmicroscopie gecombineerd met energie dispersieve 
röntgenspectroscopie, waaruit bleek dat de zilver nanodeeltjes homogeen 
door de nanovezels verspreid waren. CHX werd kortstondig afgegeven 
binnen 2 dagen , terwijl zilverionen langduriger werden afgegeven 
gedurende meer dan 28 dagen. Zilver nanodeeltjes veroorzaakten geen 
cytotoxiciteit onder de huidige experimentele, terwijl CHX toxisch werd 
wanneer de membranen beladen waren met meer dan 25 μg CHX. De 
membranen vertoonden antibacteriële effectiviteit bij belading met CHX 
(20 of meer μg per membraan) en / of zilvernitraat (1 en 5 gewichtsprocent 
ten opzichte van chitosan). Membranen die 5 gewichtsprocent zilvernitraat 
bevatten, vertoonden langdurige antibacteriële effectiviteit tot 4 dagen. 
Samenvattend kon uit deze studie worden geconcludeerd dat chitosan / 
PEO nanovezel membranen zeer bruikbaar zijn voor de lokale afgifte van 
medicijnen tegen infecties die veroorzaakt zijn door percutane devices.
2  Slotopmerkingen en toekomstperspectieven
Dit proefschrift beschrijft de ontwikkeling van diverse nanogestructureerde 
dragermaterialen voor de lokale afgifte van antibacteriële middelen ter 
voorkoming en / of behandeling van infecties. Deze op nanosferen en / of 
nanovezels gebaseerde systemen bleken geschikt te zijn voor de lokale en 
langdurige afgifte van antibiotica en ontsmettingsmiddelen. Dientengevolge 
kunnen deze systemen ingezet worden bij de bestrijding van botinfecties, 
zoals blijkt uit onze positieve in vitro resultaten. Hiertoe dienen echter nog 
diverse uitdagingen worden overwonnen.
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Ten eerste dient de vereiste dosering van de antibacteriële geneesmiddelen 
vastgesteld te worden voordat klinische translatie van de afgiftesystemen 
kan worden overwogen. Idealiter zou een initiële kortstondige afgifte 
van een grote dosering antibacteriële geneesmiddelen (ter bestrijding 
van binnengedrongen bacteriën) gevolgd dienen te worden door een 
langdurige afgifte van antibacteriële geneesmiddelen (om latente infecties 
te bestrijden) [1, 2]. Tijdens deze tweede, langdurige fase van de afgifte 
dient de concentratie van afgegeven antibacteriële geneesmiddelen hoger 
te zijn dan de minimale bactericidale concentratie (MIC of MBC) die voor de 
desbetreffende bacteriën geldt. In vitro modellen moeten worden ontwikkeld 
die de in vivo omstandigheden voor bacteriële groei zoveel mogelijk 
nabootsen om de effecten van antibacteriële geneesmiddelbehandeling 
te kunnen bestuderen, waarmee de in vitro dosering en afgiftekinetiek 
van deze geneesmiddelen geoptimaliseerd kan worden. Vervolgens dient 
de afgiftekinetiek en therapeutische werkzaamheid van de antibacteriële 
middelen bestudeerd te worden in geschikte diermodellen voor infectie 
om de uiteindelijke afgiftesystemen verder te kunnen optimaliseren.
Ten tweede kan de behandeling van infectie met behulp van antibiotica 
leiden tot de ontwikkeling van antibacteriële resistentie. Helaas is de 
ontwikkelingssnelheid van antibacteriële resistentie veel hoger dan de 
ontwikkelingssnelheid van nieuwe geneesmiddelen [1]. Derhalve dienen 
afgiftesystemen ontwikkeld te worden die lokale afgifte van alternatieve 
antibacteriële middelen zoals antiseptica en antimicrobiële peptiden 
(AMPs) mogelijk maken, aangezien dergelijke middelen minder snel tot 
antibacteriële resistentie leiden [2-4]. Hoewel nanovezel membranen 
beladen met antiseptica (chloorhexidine en zilver) met succes in Hoofdstuk 
7 zijn ontwikkeld, blijft de kortstondige afgifte van chloorhexidine - 
veroorzaakt door een gebrek aan interactie tussen chloorhexidine en 
chitosan - een probleem. Daarnaast kunnen mogelijke bijwerkingen van 
zilver niet uitgesloten worden [5,6]. Afgifte van positief geladen AMPs uit 
negatief geladen gelatine nanosferen zou een mogelijke oplossing kunnen 
zijn om de affiniteit tussen geneesmiddelen en dragermaterialen te 
versterken en de toxiciteit te verminderen.
AMPs zijn endogene polypeptiden die geproduceerd worden door een 
grote verscheidenheid aan organismen als een essentieel onderdeel van 
hun aangeboren immuunsysteem ter bescherming tegen pathogene 
micro-organismen [4, 7, 8]. Deze peptiden komen voor in alle klassen 
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van leven variërend van prokaryoten tot de mens [7]. AMPs bestaan 
gewoonlijk uit minder dan 100 aminozuurresiduen en dragen een totale 
nettolading van + 2 tot + 9 als gevolg van positief geladen lysine en arginine 
residuen [4, 8]. Bovendien zijn AMPs tegen zowel Gram-positieve als Gram-
negatieve bacteriën, gisten en sommige virussen [3]. Positief geladen 
AMPs met een molecuulgewicht hoger dan 2 kDa zouden wellicht polyion 
complexen kunnen vormen met negatief geladen gelatine nanosferen 
dankzij elektrostatische en hydrofobe interacties. Dientengevolge kan de 
mogelijkheid worden onderzocht om gelatine nanosferen te gebruiken 
voor de langdurige afgifte van AMPs om uitdagingen met betrekking tot 
antibacteriële weerstand te overwinnen.
Ten derde zijn intracellulaire infecties – en dan met name intracellulaire 
infecties veroorzaakt door medische devices – gewoonlijk zeer hardnekkige 
infecties die moeilijk te behandelen zijn. Deze bacteriën vertonen een 
verminderde gevoeligheid voor antibiotica en kunnen intracellulaire 
persistentie ontwikkelen. De mogelijkheid om de afgiftesystemen zoals 
ontwikkeld in dit proefschrift in te zetten tegen intracellulaire infecties is 
echter nog niet eerder onderzocht. In Hoofdstuk 6 is middels in vitro studies 
aangetoond dat gelatine nanosferen kunnen worden geïnternaliseerd 
door in THP-1 afgeleide macrofagen. Toekomstige studies dienen zich 
te richten op de mogelijkheid om intracellulaire infecties te bestrijden 
met gebruikmaking van gelatine nanosferen. Hiertoe kan het transgene 
zebravismodel worden gebruikt zoals ontwikkeld in Hoofdstuk 6. Dit model 
kan worden ingezet om in vivo intracellulaire afgifte van antibiotica uit 
gelatine nanosferen te bestuderen door gebruik te maken van fluorescent 
gelabelde macrofagen, gelatine nanosferen en antibacteriële middelen.
Samenvatting, Slotopmerkingen en Toekomstperspectieven
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